<SEC-DOCUMENT>0001104659-25-091281.txt : 20250918
<SEC-HEADER>0001104659-25-091281.hdr.sgml : 20250918
<ACCEPTANCE-DATETIME>20250918162914
ACCESSION NUMBER:		0001104659-25-091281
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250915
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250918
DATE AS OF CHANGE:		20250918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				364787690
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38445
		FILM NUMBER:		251323809

	BUSINESS ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-944-6100

	MAIL ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC
		DATE OF NAME CHANGE:	20180517

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20140613
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2526455d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:hsdt="http://heliusmedical.com/20250915">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_hsdt_heliusmedical.com_20250915 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20250915_20250915 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001610853 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000005" name="dei:EntityCentralIndexKey">0001610853</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hsdt-20250915.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610853</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-15</xbrli:startDate>
        <xbrli:endDate>2025-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>



<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b>&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20250915__20250915_z1weKTxSWIYc"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b>&#8239;<b>of
the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):<span id="xdx_903_edei--DocumentPeriodEndDate_c20250915__20250915_zdPPcdtamhX7">
<ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">September 15, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="tm2526455d1_8kimg01.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-variant: small-caps"><b><span id="xdx_902_edei--EntityRegistrantName_c20250915__20250915_zACvPQ7R90c9"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000012" name="dei:EntityRegistrantName">HELIUS MEDICAL TECHNOLOGIES, INC.</ix:nonNumeric>
</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; width: 33%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20250915__20250915_zyC99ITOvESe"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; width: 34%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20250915__20250915_zwklujuITx39"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000014" name="dei:EntityFileNumber">001-38445</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; width: 33%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20250915__20250915_zx2xYCgvMan"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000015" name="dei:EntityTaxIdentificationNumber">36-4787690</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other
jurisdiction</b></p></td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"/><td style="padding: 0.25pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS Employer</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; text-align: center"><b>of incorporation)</b></td>
    <td style="padding: 0.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission
    File Number)</b></span></td>
    <td style="padding: 0.25pt; text-align: center"><b>Identification No.)</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20250915__20250915_zrXZRqaky3Z4"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000016" name="dei:EntityAddressAddressLine1">642 Newtown Yardley Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20250915__20250915_zH4JJWzQdbNk"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite
    100</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20250915__20250915_z267NlC43Bqj"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000018" name="dei:EntityAddressCityOrTown">Newtown</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20250915__20250915_zRkZH7blamWl"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000019" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span></b></p></td>
    <td style="padding: 0.25pt 0.25pt 0.25pt 7.45pt">&#160;</td>
    <td style="padding: 0.25pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20250915__20250915_zt3FnJ8YHgca"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000020" name="dei:EntityAddressPostalZipCode">18940</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0.25pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="padding: 0.25pt 0.25pt 0.25pt 7.45pt">&#160;</td>
    <td style="padding: 0.25pt; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,&#160;including
area code</b>: <b>(<span id="xdx_904_edei--CityAreaCode_c20250915__20250915_zCTdhwxf2t49"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000021" name="dei:CityAreaCode">215</ix:nonNumeric></span></b><b>) <span id="xdx_907_edei--LocalPhoneNumber_c20250915__20250915_zONDFF1yPAbf"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000022" name="dei:LocalPhoneNumber">944-6100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address,
if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20250915__20250915_z72qKw4tEbQ5"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Written communications pursuant to Rule&#160;425 under the Securities
Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20250915__20250915_zskcP9Yy7BE1"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange
Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementTenderOffer_c20250915__20250915_zqhBCILqKyta"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20250915__20250915_ziQd0UltLMOj"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading <br/>
Symbol(s)</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which&#8239;registered</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20250915__20250915_zgDB9o1qDjl6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000027" name="dei:Security12bTitle">Class&#160;A
    Common Stock, $0.001 par value</ix:nonNumeric></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_90F_edei--TradingSymbol_c20250915__20250915_z1v2Qd7Hdj15" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-15" id="Fact000028" name="dei:TradingSymbol">HSDT</ix:nonNumeric></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20250915__20250915_zdRpcLQsafq4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Emerging growth
company </span><span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20250915__20250915_zsdYKXF3b33f"><ix:nonNumeric contextRef="AsOf2025-09-15" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed, on September&#160;15,
2025, Helius Medical Technologies,&#160;Inc. (the &#8220;Company&#8221;) entered into subscription agreements (the &#8220;Cash Subscription
Agreements&#8221;) with certain accredited investors (the &#8220;Cash Purchasers&#8221;) pursuant to which the Company, in a private placement
(the &#8220;Cash Offering&#8221;), agreed to issue and sell to the Cash Purchasers an aggregate of (i)&#160;37,825,277 shares of Class&#160;A
common stock of the Company, par value $0.001 per share (the &#8220;Common Stock&#8221;) at an offering price of $6.881 per share, (ii)&#160;pre-funded
warrants (the &#8220;Cash Pre-Funded Warrants&#8221;) to purchase 25,121,713 shares of Common Stock at an offering price of $6.880 per
underlying share of Common Stock and (iii)&#160;stapled warrants (the &#8220;Cash Stapled Warrants&#8221;) to purchase 62,946,990 shares
of Common Stock at an exercise price of $10.134 per underlying share of Common Stock. In the Cash Offering, the Cash Purchasers had the
option to tender any of U.S. dollars, USDC or USDT (or a combination thereof) to the Company as consideration for the Cash Shares, Cash
Pre-Funded Warrants and Cash Stapled Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, on September&#160;15, 2025, the
Company entered into subscription agreements (the &#8220;Cryptocurrency Subscription Agreements,&#8221; and together with the Cash Subscription
Agreements, the &#8220;Subscription Agreements&#8221;) with certain accredited investors (the &#8220;Cryptocurrency Purchasers,&#8221;
and together with the Cash Purchasers, the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to sell and issue to the Cryptocurrency
Purchasers in a private placement (the &#8220;Cryptocurrency Offering,&#8221; and together with the Cash Offering, the &#8220;Offerings&#8221;)
an aggregate of (i)&#160;pre-funded warrants (the &#8220;Cryptocurrency Pre-Funded Warrants&#8221;) to purchase 10,994,199 shares of Common
Stock at an offering price of $6.880 and (ii)&#160;stapled warrants (the &#8220;Cryptocurrency Stapled Warrants&#8221; and together with
the Cryptocurrency Pre-Funded Warrants, the &#8220;Cryptocurrency Warrants&#8221;) to purchase 10,994,199 shares of Common Stock at an
exercise price of $10.134 per underlying Share of Common. In the Cryptocurrency Offering, the Cryptocurrency Purchasers had the option
to tender either Unlocked SOL tokens or Locked SOL tokens to the Company as consideration for the Cryptocurrency Pre-Funded Warrants and
the Cryptocurrency Stapled Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offerings closed on September&#160;18, 2025
(the &#8220;Closing&#8221;). The Offerings resulted in total gross proceeds of approximately $508.7 million before deducting estimated
placement agent fees and offering expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Offerings, the Company
agreed to file a registration statement with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) covering the resale of
the Cash Shares, Pre-Funded Warrant Shares and Stapled Warrant Shares. The Company has agreed to file such registration statement within
30 days of the closing of the Offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise of the Cryptocurrency Warrants is
subject to stockholder approval (&#8220;Stockholder Approval&#8221;) and such warrants will not be exercisable for Common Stock until
such Shareholder Approval is received. Pursuant to the Cryptocurrency Subscription Agreements, the Company will hold a special meeting
of stockholders to obtain Stockholder Approval as soon as practicable after the closing date of the Offerings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities sold in the Offerings were offered
and sold in reliance upon the exemption from the registration requirement of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), pursuant to Section&#160;4(a)(2)&#160;thereof and/or Rule&#160;506(b)&#160;of Regulation D promulgated thereunder, and applicable
state securities laws. The issuance of the securities sold in the Offerings have not been registered under the Securities Act and such
securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities
Act and any applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to use the net proceeds from
the Offerings to fund the acquisition of the native cryptocurrency of the Solana Foundation blockchain (&#8220;SOL&#8221;), through open
market purchases only and the establishment of the Company&#8217;s Solana treasury operations, as well as for working capital, general
corporate purposes and to pay all transaction fees and expenses related thereto. The Company will not use the net proceeds from the Offerings:
(a)&#160;for the redemption of any outstanding Common Stock or Common Stock equivalents of the Company, (b)&#160;for the settlement of
any outstanding litigation or (c)&#160;in violation of the Foreign Corrupt Practices Act of 1977, as amended or the Office of Foreign
Assets Control of the U.S. Treasury Department regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Cash Purchasers have agreed to not
to sell, transfer, pledge, hedge, or otherwise dispose of any Cash Securities until the resale registration statement is declared effective
(the &#8220;Effectiveness Date&#8221;), and with respect to 50% of the Cash Securities, until 30 calendar days following the Effectiveness
Date (the &#8220;PIPE Lock-Up Period&#8221;), except with the Company&#8217;s prior written consent and subject to certain customary exceptions.
Each of the Cryptocurrency Purchasers have agreed to not to sell, transfer, pledge, hedge, or otherwise dispose of any Cryptocurrency
Securities during the PIPE Lock-Up Period, except with the Company&#8217;s prior written consent and subject to certain customary exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&#160;15, 2025, the Company entered
into a Strategic Advisor Agreement (the &#8220;Strategic Advisor Agreement&#8221;) with Pantera Capital Management LP, a Delaware limited
partnership (&#8220;Pantera&#8221;) and Summer Wisdom Holdings Limited (&#8220;Summer&#8221; and with Pantera, the &#8220;Advisors&#8221;),
pursuant to which the Company engaged each of Pantera and Summer to provide strategic advice and guidance relating to the Company&#8217;s
business, operations, growth initiatives and industry trends in the crypto technology sector. In connection with the closing of the Offering,
on September&#160;18, 2025, the Company issued warrants to purchase 5,175,883 shares of Common Stock&#160;to Pantera (the &#8220;Pantera
Base Advisor Warrants&#8221;) and (ii)&#160;warrants to purchase 2,218,236 shares of Common Stock&#160;to Summer (the &#8220;Summer
Base Advisor Warrants&#8221; and together with the Pantera Base Advisor Warrants, the &#8220;Base Advisor Warrants&#8221;). Upon the
exercise of each Stapled Warrant, each of Pantera and Summer shall receive an additional grant of warrants to purchase an amount of shares
of Common Stock equal to their respective portion of 5% of the shares of Common Stock issued upon such exercise (the Performance Advisor
Warrants, and together with the Base Advisor Warrants, the &#8220;Advisor Warrants&#8221;). The exercise price per share of the Advisor
Warrants shall be equal to $0.001 per underlying share of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercise of the Advisor Warrants is subject
to stockholder approval and such warrants will not be exercisable for Common Stock until such stockholder approval is received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Strategic Advisor Warrants and underlying
shares of Comon Stock Shares are being offered in reliance upon the exemption from the registration requirements of the Securities Act,
pursuant to Section&#160;4(a)(2)&#160;thereof and/or Rule&#160;506(b)&#160;of Regulation D promulgated thereunder, and applicable state
securities laws. The issuance of the Strategic Advisor Warrants and the Strategic Advisor Warrant Shares have not been registered under
the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration
under the Securities Act and any applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Strategic Advisory Agreement,
Pantera agreed not to sell, transfer, pledge, hedge, or otherwise dispose of any shares underlying the Strategic Advisory Warrants for
180 days after the closing of the Offering (the &#8220;Advisor Lock-Up Period&#8221;), except (i)&#160;transfers to affiliates that agree
in writing to be bound by the remainder of the Advisor Lock-Up Period, or (ii)&#160;with the Company&#8217;s prior written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summaries of the Cash Pre-Funded
Warrants, Cryptocurrency Pre-Funded Warrants, the Cash Stapled Warrants, the Cryptocurrency Stapled Warrants, the Advisor Warrants, the
Cash Subscription Agreements, the Cryptocurrency Subscription Agreements, the PIPE Lock-Up Agreement, the Strategic Advisor Agreement
and do not purport to be complete and are qualified in their entirety by reference to the complete text of those agreements, which were
filed as Exhibits 4.1, 4.2, 4.3, 4.4, 4.5 and 10.1, 10.2, 10.3 and 10.4, respectively, to the Company&#8217;s Current Report on Form&#160;8-K,
previously filed with the SEC on September&#160;15, 2025 and are hereby incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Master Loan Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Agreements, the Company
has agreed to use the net proceeds from the sale of the Securities to the Purchasers in the Offerings to fund the acquisition of SOL,
and the establishment of a SOL treasury operation, as well as pay transaction fees and expenses, and for working capital and general corporate
purposes of the Company. To advance the Company&#8217;s planned SOL treasury operation, on September&#160;18, 2025, Marvel Operations
Corp., a Delaware limited liability company and wholly-owned subsidiary of the Company, entered into a Master Loan Agreement with a third-party
lender (the &#8220;Master Loan Agreement&#8221;) to provide a short term loan to make initial purchases of SOL. As of September&#160;18,
2025, Marvel Operations Corp., has no outstanding loans with the third-party lender under the Master Loan Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Master Loan Agreement
does not purport to be complete and is qualified in its entirety by the terms and conditions of the Master Loan Agreement, which is attached
hereto as Exhibit&#160;10.1 to this Current Report on Form&#160;8-K (this &#8220;Current Report&#8221;) and is incorporated herein by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The disclosure required by this Item is included
in Item 1.01 of this Current Report and is incorporated herein by reference. Based in part upon the representations of the Purchasers
in the Purchase Agreement, the offering and sale of the Shares, the Pre-Funded Warrant Shares, the Stapled Warrants and the Stapled Warrant
Shares, was made in reliance upon an exemption from registration under Section&#160;4(a)(2)&#160;of the Securities Act of 1933, as amended,
and/or Rule&#160;506(b)&#160;of Regulation D promulgated thereunder, and applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Director Appointment</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&#160;18, 2025, the Board of Directors
of the Company (the &#8220;Board&#8221;), pursuant to its powers under the Certificate of Incorporation, as amended, and the Second Amended
and Restated Bylaws of the Company, approved an increase in the size of the Board from six (6)&#160;to seven (7)&#160;directors and the
appointment of Joseph Chee as Executive Chairman of the Board to fill the vacancy created by such increase, which appointment became effective
on September&#160;18, 2025. Mr.&#160;Chee will serve for a one-year term until our 2026 annual meeting of stockholders and until his successor
is duly elected and qualified or until his earlier death, resignation or removal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&#160;Chee has served as the Founder and Chairman
of Summer Capital Limited. Summer Capital is an investment company dedicated to investing in early growth state companies in &#8220;new
economy&#8221; sectors such as fintech, blockchain infrastructure and application, consumption technology and healthcare. He has also
served as the Vice Chairman of AMINA Bank AG, a company focused on providing a bridge between traditional finance and digital assets while
operating as a FINMA-regulated cryptocurrency bank and offering services such as secure custody, crypto trading, staking, lending, asset
management and tokenized products to professional investors, corporations, family offices and institutions globally, since April&#160;2020.
In addition, Mr.&#160;Chee is the founder of Summer Healthcare Fund, L.P. since February&#160;2021 and Summer Everest Ecosystem Fund,
L.P. since September&#160;2023. Each are investment companies focused on healthcare and biotechnology and blockchain ecosystem and financial
technology, respectively. Prior to these positions, Mr.&#160;Chee was Head of Investment Banking and Head of Global Capital Markets, Asia
at UBS AG. From 2000 to 2017, Mr.&#160;Chee held a number of positions in UBS AG. Mr.&#160;Chee has earned a Doctorate degree in applied
finance from the University of Geneva, an Executive Master of Business Administration degree Tsinghua University, a Master of Business
Administration degree from New York University and a Bachelor&#8217;s degree in mechanical engineering from Stevens Institute of Technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has determined that Mr.&#160;Chee does
not satisfy the independence criteria set forth in the Nasdaq rules&#160;and is not &#8220;independent&#8221; for purposes of serving
on the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with Mr.&#160;Chee&#8217;s appointment
to the Board, the Company will enter into its standard form of indemnification agreement for directors and officers with Mr.&#160;Chee,
a copy of which is attached to this Current Report as Exhibit&#160;10.2. and is incorporated herein by reference. Pursuant to the terms
of the indemnification agreement, the Company may be required, among other things, to indemnify Mr.&#160;Chee for some expenses, including
attorneys&#8217; fees, judgments, fines and settlement amounts incurred by her in any action or proceeding arising out of her service
to the Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, upon the Closing, Mr.&#160;Chee and
the Company entered into an executive chairman agreement (the &#8220;Executive Chairman Agreement&#8221;). Pursuant to the terms of the
Executive Chairman Agreement, Mr.&#160;Chee will receive an equity award of restricted stock units (&#8220;RSUs&#8221;) equal to (i)&#160;1%
of the aggregate number of Common Stock and pre-funded warrants issued in the Offerings, plus (ii)&#160;0.5% of the aggregate number of
Common Stock underlying the stapled warrants issued in connection with the Offerings for his services related to the implementation of
the digital asset treasury for the Company. Further, following the closing of the Offerings and within 10 business days of the exercise
of a Cash Stapled Warrant issued to investors in the Offerings, the Company shall issue to Mr.&#160;Chee an additional RSU award equal
to 0.5% of the number of shares of the Company&#8217;s Common Stock issuable upon the exercise of the Cash Stapled Warrants. The vesting
of such RSU grants shall be subject to stockholder approval of an increase in the shares available under the Company&#8217;s 2022 Equity
Incentive Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary is qualified in its entirety
by reference to the full text of the Executive Chairman Agreement, a copy of which is filed as Exhibit&#160;10.3 to this Current Report
and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Indemnification Agreements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&#160;14, 2025, the Company entered
into amended and restated indemnification agreements with each of its directors and officers. Pursuant to the terms of the indemnification
agreement, the Company may be required, among other things, to indemnify each director and officer for some expenses, including attorneys&#8217;
fees, judgments, fines and settlement amounts incurred by such director or officer in any action or proceeding arising out of such director&#8217;s
or officer&#8217;s service to the Company, as applicable. The description of the indemnification agreement is qualified in its entirety
by the full text of the form of indemnification agreement, which is attached as Exhibit&#160;10.2 to this Current Report and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.03 Amendments to Articles of Incorporation
or Bylaws; Change in Fiscal Year.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously, disclosed, on May&#160;23, 2025,
at the special meeting of stockholders (the &#8220;Special Meeting&#8221;) of the Company, the Company&#8217;s stockholders approved a
proposal to amend the Company&#8217;s Certificate of Incorporation to increase the number of authorized shares of the Company&#8217;s
Common Stock to up to 800,000,000 shares, with such number to be determined at the Board&#8217;s discretion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&#160;12, 2025, the Board approved
an increase in the number of authorized shares of the Company&#8217;s Common Stock to 800,000,000 shares (the &#8220;Share Increase&#8221;).
On September&#160;15, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate
of Incorporation (the &#8220;Certificate of Amendment&#8221;) to effect the Share Increase, which became effective as of September&#160;15,
2025. A copy of the Certificate of Amendment is attached as Exhibit&#160;3.1 to this Current Report and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01. Regulation FD.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September&#160;18, 2025, the Company issued
a press release announcing the Closing and receipt of gross proceeds in excess of $500,0000,000, prior to deducting placement agent fees
and other offering expenses. A copy of the press release is attached as Exhibit&#160;99.1 to this Current Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 7.01 to this Current
Report, and in Exhibit&#160;99.1 furnished herewith, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of
the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section,
nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly
set forth by specific reference in such a filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Forward-Looking Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company&#8217;s existing
operations and the implementation of a SOL treasury strategy. Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially, and reported results should not be considered as an indication of future performance. Important
factors that may affect actual results or outcomes include, but are not limited to: the potential impact of market and other general economic
conditions; the ability of the Company to successfully execute its business plan, including the implementation of the SOL treasury strategy
and achieve the intended benefits thereof; the Company&#8217;s failure to manage growth effectively; the Company&#8217;s failure to fully
realize the anticipated benefits of the Offerings and use of proceeds therefrom; and other risks and uncertainties set forth in the Company&#8217;s
Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024 filed with the SEC on March&#160;23, 2025, and in the Company&#8217;s
subsequent filings with the SEC, including the supplemental risk factors filed with the Current Report on Form&#160;8-K filed on September&#160;15,
2025. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these forward-looking
statements, whether as a result of new information, future events, or otherwise, except as required by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company cautions investors not to place considerable
reliance on the forward-looking statements contained in this Current Report. Investors are encouraged to read the Company&#8217;s filings
with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in
this Current Report speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these
statements. The Company&#8217;s business is subject to substantial risks and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration to these risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>No Offer or Solicitation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of this Current Report nor the exhibits attached
hereto constitutes an offer to sell, or a solicitation of an offer to buy Common Stock or any other securities, nor shall there be any
sale of Common Stock or any other securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit<br/>
No.</span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2526455d1_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1 </span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2526455d1_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation of Helius Medical Technologies,&#160;Inc. </span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2526455d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1 </span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2526455d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Master Loan Agreement, dated as of September&#160;18, between Marvel Operations Corp. and the Lender (as defined therein)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2526455d1_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2526455d1_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of Indemnification Agreement</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2526455d1_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2526455d1_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Chairman Agreement, dated September&#160;18, 2025 between the Company and Joseph Chee.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2526455d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm2526455d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated September&#160;18, 2025</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: September&#160;18, 2025</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HELIUS MEDICAL TECHNOLOGIES,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Jeffrey S. Mathiesen </i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey S. Mathiesen</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer, Treasurer and Secretary </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLoVBdmjY4o4ZQwRX6uLUtyakVbdPsm/tNsQQ0gI955cISZiQ2tdIcN5VWRwxLqplEMo8IaM5orekWx3Mfhd4F1bx8q44fyBCXkGPbOYSnnxwmB9aYtlDOFiFi5ncg5RFPuZ70XQ6wmZmy7ROK0qUKaEnKlhjU5xN344qpYM1d0QdUK2mkwM0TQc5Q/IMJJwoJd6Ez8sZFkigslQgdgwPRvvSluHpichrbD2cXak/x18AQeUSo4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>tm2526455d1_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>HELIUS MEDICAL TECHNOLOGIES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Helius
Medical Technologies,&nbsp;Inc.</B></FONT><B>&nbsp;</B>(the &ldquo;<B><I>Corporation</I></B>&rdquo;), a corporation organized and existing
under and by&nbsp;virtue of the General Corporation Law of the State of Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;), does hereby certify
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-size: 10pt"><B>FIRST:</B></FONT>&nbsp;The
name of the Corporation is Helius Medical Technologies,&nbsp;Inc. and the date on which the Certificate&nbsp;of Incorporation of the Corporation
was originally filed with the Secretary of State of the State of Delaware was&nbsp;July&nbsp;18, 2018 (as previously corrected, the &ldquo;<B><I>Certificate
of Incorporation</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-size: 10pt"><B>SECOND:</B></FONT>&nbsp;The
Board of Directors of the Corporation has duly adopted resolutions proposing and declaring&nbsp;advisable that the Certificate of Incorporation
be amended as set forth herein and calling for the consideration and&nbsp;approval thereof at a meeting of the stockholders of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-size: 10pt"><B>THIRD:&nbsp;</B></FONT>The
Certificate of Incorporation is hereby amended by deleting the Paragraph A of ARTICLE&nbsp;IV in&nbsp;its entirety and inserting the following
in lieu thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white; color: #231f20">&ldquo;The
Company is authorized to issue two classes of stock to be designated, respectively, &ldquo;Class&nbsp;A Common Stock&rdquo; and &ldquo;Preferred
Stock.&rdquo; The total number of shares which the Company is authorized to issue is 810,000,000 shares, of which 800,000,000 shares shall
be Class&nbsp;A Common Stock (<B><I>&ldquo;Common Stock&rdquo;</I></B>), having a par value per share of $0.001, and 10,000,000 shares
shall be Preferred Stock, having a par value per share of $0.001.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-size: 10pt"><B>FOURTH:</B></FONT>&nbsp;Pursuant
to a resolution of the Board of Directors of the Corporation, this Certificate of Amendment&nbsp;to the Certificate of Incorporation was
submitted to the stockholders of the Corporation for their approval and was&nbsp;duly adopted in accordance with the provisions of Section&nbsp;242
of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-size: 10pt"><B>FIFTH:</B></FONT>&nbsp;This
Certificate of Amendment to the Certificate of Incorporation shall be effective as of 5:00&nbsp;p.m.&nbsp;Eastern time on September&nbsp;15,
2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, Helius Medical Technologies,&nbsp;Inc. has caused this Certificate of Amendment to be&nbsp;executed by its
duly authorized officer on this 15<SUP>th</SUP> day of&nbsp;September, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Helius Medical Technologies,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Jeffrey S. Mathiesen</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Jeffrey S. Mathiesen</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Financial Officer, Treasurer and Secretary</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tm2526455d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>MASTER LENDER AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Master Lender Agreement (&ldquo;<U>Agreement</U>&rdquo;)
is made on this __________________ (&ldquo;<U>Effective Date</U>&rdquo;) by and between FalconX Charlie,&nbsp;Inc, (&ldquo;<U>Lender</U>&rdquo;),
a corporation organized and existing under the laws of Delaware with its principal place of business at 1850 Gateway Drive, 6th floor
San Mateo CA, 94404 US and Marvel Operations Corp, (&ldquo;<U>Borrower</U>&rdquo;) a corporation residing and existing under the laws
of the State of Delaware with its principal place of business at 642 Newtown Yardley Road, Newtown, PA 18940.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender and Borrower are each individually, a &ldquo;<U>Party</U>,&rdquo;
and collectively the &ldquo;<U>Parties</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, subject to the terms and conditions
of this Agreement, Borrower may, from time to time, seek to initiate a transaction pursuant to which Lender, in its sole and absolute
discretion, will lend Digital Currency or U.S. Dollars (depending on the Loaned Asset specified on the Loan Term Sheet) to Borrower, and
Borrower will pay a Loan Fee and return an equivalent amount of such Digital Currency or U.S. Dollars to Lender upon the termination or
maturity of the Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, therefore, in consideration of the foregoing
and other good and valuable consideration, the receipt and sufficiency of which hereby acknowledged, the Borrower and the Lender hereby
agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>I.</B></TD><TD STYLE="text-align: justify"><B><U>Definitions</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Airdrop&rdquo; </I></B>means a distribution
of a new token or tokens resulting from the ownership of a preexisting token. For the purposes of Section&nbsp;V, an &ldquo;<B><I>Applicable
Airdrop</I></B>&rdquo; is an Airdrop for which the distribution of new tokens can be definitively calculated according to its distribution
method, such as a pro rata distribution based on the amount of the relevant Digital Currency held at a specified time. A &ldquo;<B><I>Non-Applicable
Airdrop</I></B>&rdquo; is an Airdrop for which the distribution of new tokens cannot be definitively calculated, such as a random distribution,
a distribution to every wallet of the relevant Digital Currency, or a distribution that depends on a wallet of the relevant Digital Currency
meeting a threshold requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Additional Collateral</I></B>&rdquo;
has the meaning set forth in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Authorized Agent</I></B>&rdquo; has
the meaning set forth in Exhibit&nbsp;A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Borrower</I></B>&rdquo; means Marvel
Operations Corp, a Delaware limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Borrower Email</I></B>&rdquo; means
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Business Day</I></B>&rdquo; means
a day on which banks are open for business, in New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Business Hours</I></B>&rdquo; means
between the hours of 8:00 am to 8:00 pm Eastern Standard Time on a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Call Option</I></B>&rdquo; means
Lender has the option to demand immediate payment of a portion or the entirety of the Loan Balance at any time, subject to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Close of Business&rdquo;</I></B>
means 8:00 pm Eastern Standard Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Collateral&rdquo; </I></B>is defined
as set forth in Section&nbsp;IV(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Collateral Ratio</B>&rdquo; is defined
as set forth in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Collateral Refund Rate</B>&rdquo; is
defined as set forth in Section&nbsp;IV(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Digital Currency</I></B>&rdquo; means
Bitcoin (BTC), Bitcoin Cash (BCH), Ether (ETH), Ether Classic (ETC), or Litecoin (LTC), or any digital currency that the Borrower and
Lender agree upon (as specified in the Loan Term Sheet).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Digital Currency Address</I></B>&rdquo;
means an identifier of alphanumeric characters that represents a digital identity or destination for a transfer of Digital Currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Early Termination Fee</I></B>&rdquo;
has the meaning ascribed to such term in Section&nbsp;III(e)&nbsp;herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>First Notification</I></B>&rdquo;
has the meaning ascribed to such term in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>First Notification Time Period</I></B>&rdquo;
has the meaning ascribed to such term in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Fixed Term Loan</I></B>&rdquo; means
a Loan with a pre-determined Maturity Date, where Borrower does not have a Prepayment Option and Lender does not have a Call Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Hard Fork&rdquo; </I></B>means a
permanent divergence in the blockchain (e.g., when non-upgraded nodes cannot validate blocks created by upgraded nodes that follow newer
consensus rules, or an airdrop or any other event which results in the creation of a new token).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Initial Collateral Ratio</I></B>&rdquo;
has the meaning ascribed to such term in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Late Fee</I></B>&rdquo; has the meaning
ascribed to such term in Section&nbsp;III(c)&nbsp;herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Lender</I></B>&rdquo; means FalconX
Charlie,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Lender Email</I></B>&rdquo; means:
if operations, <U>operations@falconx.io</U>; if invoicing/billing: <U>finance@falconx.io</U> with a copy to <U>operations@falconx.io</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loan</I></B>&rdquo; means a loan
of Digital Currency or U.S. Dollars made pursuant to and in accordance with this Agreement and a Loan Term Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loan Balance</I></B>&rdquo; means
the sum of all outstanding amounts of Loaned Assets, including New Tokens, Loan Fees, Late Fees, and any Earlier Termination Fee or Hard
Fork Fees for a particular Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loan Documents</I></B>&rdquo; means
this Master Lender Agreement and any and all Loan Term Sheets entered into between Lender and Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loan Effective Date</I></B>&rdquo;
means the date upon which a Loan is made, as specified in the Loan Term Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loan Fee</I></B>&rdquo; has the meaning
ascribed to such term in Section&nbsp;III(a)&nbsp;herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loan Term Sheet</I></B>&rdquo; means
the agreement between Lender and Borrower on the particular terms of an individual Loan. Such agreement shall be memorialized either (i)&nbsp;in
an agreement as set forth in Exhibit&nbsp;B, or (ii)&nbsp;through actions performed within Lender's platform constituting the approval
of individual loan terms and conditions, or (iii)&nbsp;in a form approved by Lender comparable therewith..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Loaned Assets</I></B>&rdquo; means
any Digital Currency or U.S. Dollar amount transferred in a Loan hereunder until such Digital Currency (or identical Digital Currency)
or U.S. Dollar amount is transferred back to Lender hereunder in accordance with the terms herein, except that, if any new or different
Digital Currency is created or split by a Hard Fork or other alteration in the underlying blockchain and meets the requirements set forth
in Section&nbsp;V of this Agreement, such new or different Digital Currency shall be deemed to become Loaned Assets in addition to the
former Digital Currency for which such exchange is made. For purposes of return of Loaned Assets by Borrower or purchase or sale of Digital
Currencies, such term shall include Digital Currency of the same quantity and type as the Digital Currency, as adjusted pursuant to the
preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Margin Call</I></B>&rdquo; has the
meaning ascribed to such term in Section&nbsp;IV(d)&nbsp;herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Margin Call Limit</I></B>&rdquo;
has the meaning ascribed to such term in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Margin Call Rate</I></B>&rdquo; has
the meaning ascribed to such term in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Maturity Date</I></B>&rdquo; means
the pre-determined future date upon which a Loan becomes due in full for whatever reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>New Tokens</I></B>&rdquo; has the
meaning ascribed to such term in Section&nbsp;V(c)&nbsp;herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Open Loan</I></B>&rdquo; means a
Loan without a Maturity Date where Borrower has a Prepayment Option and Lender has a Call Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Prepayment Option</I></B>&rdquo;
means the Borrower has the option to repay or return the Loaned Assets prior to the Maturity Date without incurring Early Termination
Fees, subject to this Agreement and in particular Section&nbsp;II(c)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Reference Exchange</I></B>&rdquo;
means Coinbase Pro or another exchange as mutually agreed to in writing by the Lender and the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Refunded Collateral</I></B>&rdquo;
has the meaning ascribed to such term in Section&nbsp;IV(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Request Day</I></B>&rdquo; has the
meaning ascribed to such term in Section&nbsp;II(b)&nbsp;herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Refund Limit</I></B>&rdquo; has the
meaning ascribed to such term in Section&nbsp;IV(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Second Notification</I></B>&rdquo;
has the meaning ascribed to such term in Section&nbsp;IV(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Securities</I></B>&rdquo; means any
tokenized assets agreed by the parties and specified in the Loan Term Sheet, including but not limited to (i)&nbsp;securities issued by,
or unconditionally guaranteed as to the timely payment of principal and interest by, the U.S. Department of Treasury, a U.S. government
agency or the European Central Bank and (ii)&nbsp;redeemable securities in a pooled investment fund issued and redeemed only on the basis
of the fund's net assets that are eligible under applicable regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Term</I></B>&rdquo; means the period
from the Loan Effective Date through Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Term Loan with Call Option</I></B>&rdquo;
means a Loan with a pre-determined Maturity Date where Lender has a Call Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Term Loan with Prepayment Option</I></B>&rdquo;
means a Loan with a pre-determined Maturity Date where Borrower has a Prepayment Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B><I>Termination Date</I></B>&rdquo; means
the date upon which a Loan is terminated or matures in accordance with the terms herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>II.</B></TD><TD><B><U>General Loan Terms.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD><U>Loans of Digital Currency or U.S. Dollars</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions hereof, Borrower
may, in its sole and absolute discretion, request from the Lender a Loan of a specified amount of Digital Currency or U.S. Dollars, and
Lender may, in its sole and absolute discretion, extend such Loan or decline to extend such Loan on terms and conditions acceptable to
Lender and as set forth in a corresponding Loan Term Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD><U>Loan Procedure</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time during the term of this Agreement,
during the hours of 8:00 am Eastern Standard Time to 8:00 pm Eastern Standard Time on a Business Day (the &ldquo;<U>Request Day</U>&rdquo;),
by email directed to Lender Email (or such other address as Lender may specify in writing), an Authorized Agent of Borrower may request
from Lender a Loan of a specific amount of Digital Currency or U.S. Dollars (a &ldquo;<U>Lending Request</U>&rdquo;). Provided Lender
receives such Lending Request prior to 3:00 pm Eastern Standard Time, Lender shall by email directed to Borrower Email (or such other
address as Borrower may specify in writing) to inform Borrower whether Lender agrees to make such a Loan. If Lender fails to accept a
Lending Request prior to Close of Business on the Request Day, such Lending Request shall be deemed to have been denied by Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of its Lending Request, Borrower shall provide the following
proposed terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">i.</TD><TD>whether U.S. Dollars or Digital Currency, and if Digital Currency, the type of Digital Currency being requested;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD>the amount of Digital Currency or U.S. Dollars being requested;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">iii.</TD><TD>whether the Loan is to be a Fixed Term Loan, a Term Loan with Prepayment Option, a Term Loan with a Call Option or an Open Loan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">iv.</TD><TD>the required Loan Effective Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">v.</TD><TD>the Collateral;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">vi.</TD><TD>the Initial Collateral Ratio;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">vii.</TD><TD>the Margin Call Limit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">viii.</TD><TD>the Refund Limit; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">ix.</TD><TD>the Maturity Date (for all Loans other than an Open Loan).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Lender agrees to make a Loan in accordance
with Borrower&rsquo;s proposed terms and the Borrower has delivered to and the Lender has received the Collateral required pursuant to
the terms herein, Lender shall commence transmission to either (x)&nbsp;the Borrower&rsquo;s Digital Currency Address the amount of Digital
Currency, or (y)&nbsp;Borrower&rsquo;s bank account by bank wire the amount of U.S. Dollars, as applicable, as such Digital Currency Address
or bank wire instruction is set forth in the Lending Request on or before Close of Business on the Request Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The specific and final terms of a Loan shall be
memorialized within the applicable Loan Term Sheet, which shall be delivered and executed after the final terms of a Loan are agreed to
and prior to the delivery of the Loaned Assets. In the event of a conflict of terms between this Master Lender Agreement and a Loan Term
Sheet, the terms in the Loan Term Sheet shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD><U>Loan Repayment Procedure</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">i.</TD><TD><U>Loan Repayment</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified in subsections (ii)&nbsp;and
(iii)&nbsp;below, upon the earlier of the Maturity Date, the Recall Delivery Day, or the Redelivery Day (as defined below) for a Loan
(the &ldquo;<U>Repayment Date</U>&rdquo;), Borrower shall repay the entirety of the Loan Balance to Lender by Close of Business on the
Repayment Date. If Lender has not provided to Borrower the Lender&rsquo;s Digital Currency Address (if the Loaned Assets is Digital Currency)
or the Lender&rsquo;s bank wire details (if the Loaned Asset is U.S. Dollars) for receiving the repayment of a Loan by Close of Business
on the day prior to the Repayment Date then such Loan will become an Open Loan on such Repayment Date and no additional Loan Fees shall
be accrued after the Maturity Date or the Redelivery Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD><U>Call Option</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Term Loans with a Call Option (or an Open
Loan), Lender may during Business Hours during any Business Day (the &ldquo;<U>Recall Request Day</U>&rdquo;) demand repayment of a portion
or the entirety of the Loan Balance (the &ldquo;<U>Recall Amount</U>&rdquo;). Within such request, Lender shall notify Borrower that it
is exercising its Call Option by email to Borrower&rsquo;s Email. Borrower will then have until Close of Business on the third (3rd) Business
Day after the Recall Request Day (each a &ldquo;<U>Recall Delivery Day</U>&rdquo;) to deliver the Recall Amount to the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a Call Option where Lender demands
repayment of only a portion of any given Loan, Borrower shall repay such portion of the Loan on the Recall Delivery Day and the remaining
portion of the Loan on the earlier of the Maturity Date or the subsequent Recall Delivery Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">iii.</TD><TD><U>Prepayment Option</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Open Loans and Term Loans with Prepayment Option, Borrower may
notify Lender during Business Hours of Borrower&rsquo;s intent to repay the Loan prior to the Maturity Date or a Recall Delivery Day,
as may be applicable, without being subject to Early Termination Fees as set forth in Section&nbsp;III(e)&nbsp;herein. Lender&rsquo;s
exercising of its Call Option shall also not be subject to Early Termination Fees as set forth in Section&nbsp;III(e). Borrower shall
provide such notice at least one Business Day prior to the date on which the Borrower will repay all or a portion of the Loan (the &ldquo;<U>Redelivery
Day</U>&rdquo;). Borrower&rsquo;s exercising of its Prepayment Option shall not relieve it of any of its obligations herein, including
without limitation its payment of outstanding Loan Fees and Late Fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event the Borrower repays only a portion of the Loan Balance,
Borrower shall repay the remaining portion of the Loan Balance on the earlier of the Maturity Date, Recall Delivery Day, or subsequent
Redelivery Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD><U>Termination of Loan</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Loan will terminate upon the earlier of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">i.</TD><TD>the Maturity Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD>the repayment of the Loan Balance by Borrower prior to the Maturity Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">iii.</TD><TD>the occurrence of an Event of Default as defined in Section&nbsp;VII; however, Lender shall have the right in its sole discretion
to waive any Event of Default upon terms and conditions acceptable to Lender in its sole discretion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">iv.</TD><TD>in the event any or all of the Loaned Assets becomes in Lender&rsquo;s sole discretion a risk of being: (1)&nbsp;considered a security,
swap, derivative, or other similarly-regulated financial instrument or asset by any regulatory authority, whether governmental, industrial,
or otherwise, or by any court of law or dispute resolution organization. arbitrator, or mediator; or (2)&nbsp;subject to future regulation
materially impacting this Agreement, the Loan, or Lender&rsquo;s business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in the forgoing shall cause, limit, or
otherwise affect the Term and termination of this Agreement except as specified in Section&nbsp;XXIV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a termination of a Loan, any Loaned
Assets shall be redelivered immediately and any fees or any amounts owing hereunder shall be payable immediately to the appropriate party
specified herein. Upon Lender&rsquo;s receipt of the Loaned Assets and all other amounts owing to it hereunder, the Lender shall deliver
the Collateral to the Borrower in accordance with Section&nbsp;IV(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify"><U>Redelivery in an Illiquid Market</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If (i)&nbsp;the seven-day average daily trading
volume across Coinbase Pro, Kraken and Bitstamp (collectively, the &ldquo;<U>Liquidity Exchanges</U>&rdquo;) for the applicable Digital
Currency (as measured against the 30-day average daily trading volume of the applicable Digital Currency on the Loan Effective Date) has
decreased by ninety percent (90%) or more or (ii)&nbsp;the Digital Currency ceases to be listed on any of the Liquidity Exchanges (the
duration of either event herein designated, the &ldquo;<U>Illiquid Period</U>&rdquo;), Borrower may repay the Loan in U.S. Dollars equal
to the volume-weighted average price of the Digital Currency on the Liquidity Exchanges (measured at 4:00 pm Eastern Standard Time) (the
 &ldquo;<U>Illiquid Market Spot Rate</U>&rdquo;) during the Illiquid Period, up to a maximum of 30 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If all of the Liquidity Exchanges limit or suspend
withdrawals or transactions in the Digital Currency on the Maturity Date, the Recall Delivery Day, or the Redelivery Day, whichever applicable,
the requirement for the Borrower to return the Digital Currency shall be temporarily suspended, without penalty or default, including
without limitation the incurring of additional Loan Fees, until such time that one of the Liquidity Exchanges allow the resumption of
withdrawals and transactions in the Digital Currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>III.</B></TD><TD><B><U>Loan Fees and Transaction Fees.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD><U>Loan Fee</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed, Borrower agrees to pay
Lender a financing fee on each Loan (the &ldquo;<U>Loan Fee</U>&rdquo;). When a Loan is executed, the Borrower will be responsible to
pay the Loan Fee as agreed to herein and annualized in the relevant Loan Term Sheet and subject to change if thereafter agreed by Borrower
and Lender. Except as Borrower and Lender may otherwise agree, Loan Fees shall accrue from and include the date on which the Loaned Assets
are transferred to Borrower to the date on which such Loaned Assets are repaid in their entirety to Lender in accordance with the terms
herein. For any Loan, the minimum Loan Fee shall be the Loan Fee that would accrue for one day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender shall calculate any Loan Fees owed on a
daily basis of a 365-day year for the actual number of days elapsed and provide Borrower with the calculation upon request. The Loan Fee
will be calculated off all outstanding portions of the Loaned Assets. The Loan Fee is payable monthly by Borrower in arrears.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender may adjust the Loan Fee by taking into
account any Minimum Fees paid by Borrower under any FalconX Direct Market Access User Agreement executed between the Borrower and the
Lender or its parent or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD><U>Origination Fee</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For certain Loans, Lender may charge Borrower
a fee (the &ldquo;<U>Origination Fee</U>&rdquo;) to be paid at the time the Collateral is delivered to Lender. If an Origination Fee applies
to a Loan, the Loan Term Sheet shall set forth the amount of the Origination Fee and whether the Origination Fee is to be paid in U.S.
Dollars or in a Digital Currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD><U>Late Fee</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For each calendar day in excess of the Maturity
Date or the Recall Delivery Day (whichever is applicable) in which Borrower has not returned the entirety of the Loaned Assets or failed
to timely pay any outstanding Loan Fee in accordance with the terms herein, Borrower shall incur an additional fee (the &ldquo;<U>Late
Fee</U>&rdquo;) equal to one percent (1%) (annualized, calculated daily) on all outstanding portions of the Loaned Assets and Loan Fees
which remain outstanding. If a Late Fee is imposed under this Section&nbsp;III(c)&nbsp;due to an event that would constitute an Event
of Default under Section&nbsp;VII, the imposition of a Late Fee by the Lender does not constitute a waiver of its right to declare an
Event of Default for the same event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD><U>Payment of Loan Fees and Late Fees</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed, any Loan Fee, Late Fee,
Early Termination Fee, Token Fee or any other amounts payable hereunder shall be paid by Borrower to Lender upon the earlier of (i)&nbsp;five
(5)&nbsp;Business Days after receipt of an invoice from Lender setting out the amounts of the outstanding fees or (ii)&nbsp;the termination
of all Loans hereunder (the &ldquo;<U>Payment Due Date</U>&rdquo;). An invoice for Loan Fees and any Late Fees (the &ldquo;<U>Invoice
Amount</U>&rdquo;) shall be sent out on the first Business Day of the month and shall include any Loan Fees, Late Fees, and Early Termination
Fees incurred and outstanding during the previous month. Borrower shall have up to five Business Days from the date of said Invoice to
pay the Invoice Amount. Failure of Lender to timely send an invoice in accordance with the preceding sentence shall not be considered
a default hereunder nor shall it relieve Borrower of its obligation to pay any Loan Fees, Late Fees, Early Termination Fees or any other
amounts owed herein nor negate any Event of Default resulting from Borrower&rsquo;s failure to timely pay such fees. The Loan Fee, Late
Fees, and Early Termination Fees shall be payable, unless otherwise agreed by the Borrower and Lender in the Loan Term Sheet, whether
U.S. Dollars or Digital Currency on the same blockchain and of the same type that was loaned by the Lender during the Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, in all cases, all
Loan Fees, Late Fees, and Early Termination Fees shall be payable by Borrower immediately upon the occurrence of an Event of Default hereunder
by Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e.</TD><TD><U>Early Termination Fees</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For Fixed Term Loans and Term Loans with Call Options, if Borrower
returns the Loaned Assets prior to the Maturity Date, Borrower shall pay to Lender a fee equal to twenty percent (20%) of the Loan Fee
that would have accrued from the date of the repayment until the Maturity Date of the Loan (the &ldquo;<U>Early Termination Fee</U>&rdquo;).
The Early Termination Fee is due and payable with the repayment of the Loaned Assets. The Early Termination Fee shall not apply if Borrower
returns the Loaned Assets to Lender in the event of a Hard Fork or if Lender moves up the Maturity Date to an earlier date by exercising
a Call Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">f.</TD><TD><U>Taxes and Fees</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither Borrower nor Lender shall have any liability
to the other party for any taxes due under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>IV.</B></TD><TD STYLE="text-align: justify"><B><U>Collateral Requirements</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify"><U>Collateral</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise agreed by the parties, or modified
in the Loan Term Sheet or as set forth below, Borrower shall provide, as security for its obligations under this Agreement, collateral
in an amount of U.S. Dollars, Digital Currency or Securities (such choice at the sole discretion of the Lender) to be determined and agreed
upon by the Borrower and Lender (&ldquo;<U>Collateral&rdquo;</U>) and memorialized using the Loan Term Sheet. Borrower shall, prior to
or concurrently with the transfer of the Loaned Assets to Borrower, but in no case later than the Close of Business on the day of such
transfer, transfer to Lender the agreed upon Collateral. Borrower, as security for the Obligations hereunder, hereby pledges with, assigns
to, and grants Lender a continuing first priority security interest in, and a lien upon, the Collateral, which shall attach upon the transfer
of the first Loaned Assets under this Agreement to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the avoidance of doubt, upon the repayment
of the Loaned Assets at the termination of a Loan, Lender shall return to Borrower the same amount and type of Collateral that was deposited,
net of any Additional Collateral or Margin Call adjustments. If a Hard Fork occurs, resulting in the creation of New Tokens while Lender
is holding such Digital Currency as Collateral and the New Token Criterion is satisfied, Lender shall return the New Tokens to Borrower
in addition to the Collateral and Additional Collateral upon the termination of a Loan. If a Hard Fork occurs resulting in the creation
of New Tokens and the New Token Criterion is not satisfied, Lender shall have no obligation to return any New Tokens to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify"><U>Use of Collateral</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding anything to the contrary in this
Agreement, the Collateral transferred by Borrower to Lender, as adjusted herein, shall be security for Borrower&rsquo;s obligations in
respect of such Loan and any other obligations it may have under the Loan Term Sheet, and any other obligations to FalconX and its affiliates
hereunder or in any other Agreement (collectively, the &ldquo;<U>Obligations</U>&rdquo;). Borrower, as security for the Obligations, hereby
pledges with, assigns to, and grants Lender a continuing first priority security interest in, and a lien upon, the Collateral, which shall
attach upon the transfer of the Loaned Assets by Lender to Borrower and which shall cease upon (i)&nbsp;the return of the Loaned Assets
by Borrower to Lender; and (ii)&nbsp;satisfaction of all Obligations by Borrower to Lender. During the term of the Loan, Borrower agrees
and affirms Lender&rsquo;s entitlement to and the exclusive use of the Collateral for the purpose of security for the loans that are borrowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower hereby covenants and agrees that any
Loaned Assets shall be used solely and exclusively to purchase Digital Currency through a transaction with a Lender affiliate pursuant
to a separate agreement between Borrower and such affiliate. Such Digital Currency shall be promptly transferred to, and settle in, a
digital currency address under the sole control of Lender. Upon such transfer, all such Digital Currency shall immediately constitute
Collateral for all of Borrower's Obligations under this Agreement and shall be subject to the continuing first priority security interest
granted to Lender in this Section&nbsp;IV hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify"><U>Loan and Collateral Transfer</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Lender transfers Loaned Assets to Borrower
and Borrower does not transfer Collateral to Lender as provided in Section&nbsp;IV(a), Lender shall have the absolute right to the return
of the Loaned Assets; and if Borrower transfers Collateral to Lender, as provided in Section&nbsp;IV(a), and Lender does not transfer
the Loaned Assets to Borrower, Borrower shall have the absolute right to the return of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify"><U>Margin Calls</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the term of such a Loan, the following
 &ldquo;<U>Collateral Ratio</U>&rdquo; shall be applied: A/B where A = [the total value of Collateral held with the Lender + the total
value of assets held with FalconX for trading on exchange, if any] and B = [the value of the Loaned Asset]. The Collateral Ratio shall
be measured against a threshold value specified in the applicable Loan Term Sheet (the &ldquo;<U>Margin Call Limit</U>&rdquo;). If the
Collateral Ratio drops below the Margin Call Limit, the Lender shall have the right to require the Borrower by way of a margin call (each
a &ldquo;<U>Margin Call</U>&rdquo;) to provide the Lender with additional Collateral (the &ldquo;<U>Additional Collateral</U>&rdquo;)
to cause the Collateral Ratio to be equal to the value listed in the Loan Term Sheet (the &ldquo;<U>Initial Collateral Ratio</U>&rdquo;).
The value of the Loaned Assets and the Collateral comprised of Digital Currency shall be measured on the spot rate published on the Reference
Exchange, or if the Collateral is comprised of Securities, based on the value of such Securities, as determined by Lender (such rate,
the &ldquo;Margin Call Rate&rdquo;). The Collateral shall always be valued in U.S. Dollars and shall be subject to a haircut or discount
determined at the sole discretion of the Lender (&ldquo;Collateral Haircut&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Lender requires Borrower to contribute Additional
Collateral, it shall send an email notification (the &ldquo;<U>First Notification</U>&rdquo;) to the Borrower at the email address indicated
in Section&nbsp;XIV (or such other address as the parties shall agree to in writing) that sets forth: (i)&nbsp;the value of the Loaned
Assets, (ii)&nbsp;the value of the Collateral, (iii)&nbsp;the Margin Call Rate, if applicable, and (iv)&nbsp;the amount of Additional
Collateral required based on the Collateral Ratio or, if applicable, the Margin Call Rate. Borrower shall have (A)&nbsp;twelve (12) hours
from the time Lender sends such First Notification (the &ldquo;<U>First Notification Time Period</U>&rdquo;), to (x)&nbsp;respond and
send payment to Lender in accordance with subsection (f)&nbsp;below, or (y)&nbsp;respond that the Required Collateral Ratio has once again
been obtained. If Lender agrees by email that Borrower&rsquo;s response according to (y)&nbsp;above is correct, then no other action is
required by Borrower. If Lender fails to agree by email with Borrower&rsquo;s response in accordance with (y)&nbsp;by Close of Business
that same day, such shall be deemed as Lender&rsquo;s rejection of Borrower&rsquo;s response and a re-statement of Lender&rsquo;s original
demand for Borrower to contribute Additional Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Borrower fails to respond to the First Notification
within the First Notification Time Period, or Lender rejects Borrower&rsquo;s response pursuant to (y)&nbsp;above and the Required Collateral
Ratio has not been obtained, Lender shall send a second email notification (the &ldquo;<U>Second Notification</U>&rdquo;) repeating the
information in provisions (i)&nbsp;&ndash; (iv)&nbsp;in the preceding paragraph. Borrower shall have twelve (12) hours from the time Lender
sends the Second Notification to respond according to (x)&nbsp;or (y)&nbsp;in the preceding paragraph, and Lender has the right to accept
or reject Borrower&rsquo;s response as stated above. Upon Lender's rejection of Borrower&rsquo;s response to the Second Notification,
whether affirmatively by email or by non-reply by the Close of Business that same day, Borrower shall make immediate payment of Additional
Collateral as set forth in Section&nbsp;IV(f)&nbsp;below. Failure to provide Additional Collateral, or failure by Borrower to respond
to either the First Notification or the Second Notification, shall give Lender the option to declare an Event of Default under Section&nbsp;VII
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding anything in this Section, the
value of the Collateral, which is subject to Collateral Haircut, <B>must at all times be above a threshold limit of 105%</B> of the value
of the Loaned Asset unless otherwise specified and agreed to by the Party&rsquo;s in the applicable Loan Term Sheet (the &ldquo;<U>Default
Limit</U>&rdquo;). If the Collateral drops below the Default Limit, the Lender shall have the option to declare an Event of Default under
Section&nbsp;VII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower acknowledges that its obligations under
this Section&nbsp;continue regardless of Lender&rsquo;s request for Additional Collateral and Borrower&rsquo;s acceptance or rejection
of the same. Borrower agrees that it is its responsibility to monitor its Collateral and to assure that it is equal to or higher than
the applicable Margin Call Limit and Default Limit. Borrower agrees that Lender may, automatically and without prior notice, liquidate
or otherwise convert the Collateral, in its sole judgment and discretion, determines that the amount of Collateral supporting the position
is insufficient to satisfy the Default Limit of 105% or otherwise specified in a Loan Term Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower acknowledges that its obligations hereunder,
including those in this Section&nbsp;IV, continue regardless of Lender&rsquo;s request for Additional Collateral and Borrower&rsquo;s
acceptance or rejection of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify"><U>Refund of Collateral</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If during the term of a Loan the Collateral Ratio
increases such that the Collateral Ratio is higher than the value specified in the Loan Term Sheet (the &ldquo;<U>Refund Limit</U>&rdquo;)
for a continuous period of thirty (30) days or more, the Borrower shall have the right to require the Lender to return an amount of Collateral
(the &ldquo;<U>Refunded Collateral</U>&rdquo;) such that the Collateral Ratio is equal to the Initial Collateral Ratio. The value of the
Loaned Assets and the Collateral comprised of Digital Currency shall be measured by the spot rate published on the Reference Exchange,
and the value of the Collateral comprised of Securities shall be based on the value of such Securities, as determined by the Lender (the
 &ldquo;<U>Collateral Refund Rate</U>&rdquo;). Lender shall deliver the Refunded Collateral to Borrower within two Business Days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">f.</TD><TD STYLE="text-align: justify"><U>Payment of Additional Collateral</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of the Additional Collateral shall be
made by bank wire to the account, or if applicable the Digital Currency Address, specified in the Loan Term Sheet or by a return of the
amount of Loaned Assets necessary to obtain the Required Collateral Ratio. For any return of Loaned Assets made in accordance with this
Section, Borrower is still responsible for payment of any Early Termination Fees that apply to the particular Loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">g.</TD><TD STYLE="text-align: justify"><U>Return of Collateral</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon Borrower&rsquo;s repayment of the Loan and
any other amounts owing hereunder and acceptance by Lender of the Loaned Assets into Lender&rsquo;s Digital Currency Address, with such
delivery being confirmed on the relevant Digital Currency blockchain ten times, Lender shall initiate the return of Collateral within
five Business Days to a bank account designated by Borrower or, where Digital Currency or Securities is Collateral, into an applicable
Digital Currency Address on the behalf of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>V.</B></TD><TD STYLE="text-align: justify"><B><U>Hard Fork</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD><U>Notification</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a public announcement of a future
Hard Fork or an Airdrop in the blockchain for any Loaned Assets or Collateral, Lender shall provide email notification to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD><U>No Immediate Termination of Loans Due to Hard Fork</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a Hard Fork in the blockchain
for any Loaned Assets or an Airdrop, any outstanding Loans will not be automatically terminated. Borrower and Lender may agree, regardless
of Loan type, either (i)&nbsp;to terminate the Loan without any penalties on an agreed upon date or (ii)&nbsp;for Lender to manage the
Hard Fork on the behalf of Borrower. If the Lender manages the Hard Fork on behalf of Borrower, Borrower shall return the Loaned Assets
to Lender two business days prior to the scheduled Hard Fork or Airdrop. Lender shall not be obligated to return any Collateral to the
Borrower during the period in which Lender manages the Loaned Assets on the behalf of Borrower. Lender shall fork the Loaned Assets, and
following the Hard Fork shall return to Borrower the Loaned Assets but not any New Tokens (as defined below). For any whole days in which
Lender manages the Loan Digital Currency pursuant to this section, the Loan Fee for those days shall not accrue. Nothing herein shall
relieve, waive, or otherwise satisfy Borrower&rsquo;s obligations hereunder, including without limitation, the return of the Loaned Assets
at the termination of the Loan and payment of accrued Loan Fees, which includes the per diem amounts for days on which Borrower transfers
Digital Currency to Lender and Lender transfers said Digital Currency back to Borrower pursuant to this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD><U>Lender&rsquo;s Right to New Tokens</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lender will receive the benefit and ownership
of any incremental tokens generated as a result of a Hard Fork in the Digital Currency protocol or an Applicable Airdrop (the &ldquo;<U>New
Tokens</U>&rdquo;) if any two of the following four conditions are met (the &ldquo;<U>New Token Criterion</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><I>Hash Power</I>: the average hash power mining the New Token on the 30th day following the occurrence
of the Hard Fork or Applicable Airdrop (calculated as a 30-day average on such date) is at least five percent (5%) of the hash power mining
the Loaned Assets on the day preceding the Hard Fork or Applicable Airdrop (calculated as a 3-day average of the 3 days preceding the
Hard Fork).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><I>Market Capitalization</I>: the average market capitalization of the New Token (defined as the total
value of all New Tokens) on the 30th day following the occurrence the Hard Fork or Applicable Airdrop (calculated as a 30-day average
on such date) is at least five percent (5%) of the average market capitalization of the Loaned Assets (defined as the total value of the
Loaned Assets) (calculated as a 30-day average on such date).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><I>24-Hour Trading Volume</I>: the average 24-hour trading volume of the New Token on the 30th day following
the occurrence the Hard Fork or Applicable Airdrop (calculated as a 30-day average on such date) is at least one percent (1%) of the average
24-hour trading volume of the Loaned Assets (calculated as a 30-day average on such date).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><I>Wallet Compatibility</I>: the New Token is supported by either BitGo wallets or Curv wallets within
30 days of the Hard Fork or Applicable Airdrop.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the above calculations, the source for the
relevant data on the Digital Currency hash power, market capitalization, and 24-Hour trading volume will be blockchain.info (or, if blockchain.info
does not provide the required information, bitinfocharts.com, and if neither provides the required information, the parties shall discuss
in good faith to mutually agree upon another data source) and the source for the hash power of the New Token will be bitinfocharts.com
(or, if bitinfocharts.com does not provide the required information, the parties shall discuss in good faith to mutually agree upon another
data source prior to the 30-day mark of the creation of the New Token).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Hard Fork or Applicable Airdrop meets the
criteria above, Borrower will have up to sixty (60) days from the Hard Fork or Applicable Airdrop to transfer the New Tokens to Lender.
If sending the New Tokens to Lender is burdensome, upon Lender&rsquo;s written agreement with Borrower, Borrower can reimburse Lender
for the value of the New Tokens by either (i)&nbsp;a one-time payment in the same Loaned Assets transferred as a part of the Loan reflecting
the amount of the New Tokens owed using the spot rate determined by Lender in its reasonable discretion at the time of said repayment,
or (ii)&nbsp;returning the borrowed Digital Currency so that Lender can manage the split of the underlying digital tokens as described
in Section&nbsp;IV(b)&nbsp;above. Alternatively, subject to Lender&rsquo;s written agreement, the parties may agree to other methods of
making Lender whole for Borrower&rsquo;s failure to transfer New Tokens to Lender. In all cases, Borrower will be solely responsible for
payment of additional costs incurred by any transfer method other than returning the New Tokens to Lender, including but not limited to
technical costs, third party fees, and tax obligations for the transaction, including but not limited to a tax gross-up payment. For the
avoidance of doubt, if Borrower returns a Loan to Lender prior to the 30<SUP>th</SUP> day following a Hard Fork, Borrower&rsquo;s obligations
under this Section&nbsp;V shall continue for any New Tokens that meet the criteria in this subsection (c)&nbsp;for such Loan on the 30<SUP>th</SUP>
day following the Hard Fork. Lender&rsquo;s rights to New Tokens as set forth in this Section&nbsp;shall survive the termination of the
relevant Loan, return of the Loaned Assets, and termination of this Agreement. If Borrower fails to transfer the New Tokens to Lender,
or provide alternative compensation to Lender as agreed to in accordance with this subsection, within sixty (60) days from the Hard Fork
or Applicable Airdrop, such failure will be considered an Event of Default in accordance with Section&nbsp;VII(b), and Borrower shall
incur an additional fee (the &ldquo;<U>Hard Fork Fee</U>&rdquo;) equal to ten percent (10%) (annualized, calculated daily) of all outstanding
portions of the Loaned Digital Currencies and Loan Fees. Lender&rsquo;s charging of the Hard Fork Fee does not constitute a waiver of
its right to declare an Event of Default for the same event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>VI.</B></TD><TD><B><U>Representations and Warranties.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The parties to this Agreement hereby make the
following representations and warranties, which shall continue during the term of this Agreement and any Loan hereunder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Each party hereto (individually, a &ldquo;<U>Party</U>&rdquo;, collectively the &ldquo;<U>Parties</U>&rdquo;)
represents and warrants that (i)&nbsp;it has the power to execute and deliver this Agreement, to enter into the Loans contemplated hereby
and to perform its obligations hereunder, (ii)&nbsp;it has taken all necessary action to authorize such execution, delivery and performance,
and (iii)&nbsp;this Agreement constitutes a legal, valid, and binding obligation enforceable against it in accordance with its terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Each Party hereto represents and warrants that it has not relied on the other for any tax or accounting
advice concerning this Agreement and that it has made its own determination as to the tax and accounting treatment of any Loan, any Digital
Currency, Collateral, or funds received or provided hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Each Party hereto represents and warrants that it is acting for its own account.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">Each Party hereto represents and warrants that it is a sophisticated party and fully familiar with the
inherent risks involved in the transactions contemplated in this Agreement, including, without limitation, risk of new financial regulatory
requirements, potential loss of money and risks due to volatility of the price of the Loaned Assets, and voluntarily takes full responsibility
for any risk to that effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">Each Party represents and warrants that it is not insolvent and is not subject to any bankruptcy or insolvency
proceedings under any applicable laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">f.</TD><TD STYLE="text-align: justify">Each Party represents and warrants there are no proceedings pending or, to its knowledge, threatened,
which could reasonably be anticipated to have any adverse effect on the transactions contemplated by this Agreement or the accuracy of
the representations and warranties hereunder or thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">g.</TD><TD STYLE="text-align: justify">Each Party represents and warrants that to its knowledge the transactions contemplated in this Agreement
are not prohibited by law or other authority in the jurisdiction of its place of incorporation, place of principal office, or residence
and that it has necessary licenses and registrations to operate in the manner contemplated in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">h.</TD><TD STYLE="text-align: justify">Lender represents and warrants that it has, or will have at the time of the loan of any Digital Currency,
the right to lend such Loaned Assets subject to the terms and conditions hereof, free and clear of all liens and encumbrances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify">Borrower represents and warrants that it has, or will have at the time of return of any Loaned Assets,
the right to transfer such Loaned Assets subject to the terms and conditions hereof, and, free and clear of all liens and encumbrances
other than those arising under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">j.</TD><TD STYLE="text-align: justify">Borrower represents and warrants that it has, or will have at the time of transfer of any Collateral,
the right to grant a first priority security interest in said Collateral subject to the terms and conditions hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>VII.</B></TD><TD><B><U>Default</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is further understood that any of the following
events shall constitute an event of default hereunder, and shall be herein referred to as an &ldquo;<U>Event of Default</U>&rdquo; or
 &ldquo;<U>Events of Default</U>&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">the failure of the Borrower to return any and all Loaned Assets and any New Tokens as defined by Section&nbsp;V
upon termination of any Loan however, Borrower shall have one (1)&nbsp;Calendar Day to cure such default;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">the failure of Borrower to pay any and all Loan Fees, Late Fees, or Early Termination Fees when due hereunder,
or to remit any New Tokens or pay any Hard Fork Fee in accordance with the terms herein; provided however, Borrower shall have five (5)&nbsp;Calendar
Days to cure such default;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">the failure of either Party to transfer Collateral or Additional Collateral, as required herein, however,
a Party shall have one (1)&nbsp;Calendar Day to cure such default with such period starting with the First Notification ; except for instances
where the Collateral Ratio falls below the Default Limit, which Borrower shall have no additional time in which to cure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">a material default by either Party in the performance of any of the other agreements, conditions, covenants,
provisions or stipulations contained in this Agreement, including without limitation a failure by Borrower to abide by its obligations
in Section&nbsp;IV or V of this Agreement and Borrower&rsquo;s failure to cure said material default within one (1)&nbsp;Calendar Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">any bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief
of debtors or dissolution proceedings that are instituted by or against the Borrower and are not be dismissed within thirty (30) days
of the initiation of said proceedings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">f.</TD><TD STYLE="text-align: justify">any representation or warranty made by either Party in any of the Loan Documents that proves to be incorrect
or untrue in any material respect as of the date of making or deemed making thereof however, a party shall have one (1)&nbsp;Calendar
Days to cure such default.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">g.</TD><TD STYLE="text-align: justify">Any material or intentional misrepresentation by the Borrower regarding the Borrower&rsquo;s financial
status, business activities, or any other material aspect affecting the Borrower&rsquo;s creditworthiness or public reputation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>VIII.</B></TD><TD><B><U>Remedies</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Upon the occurrence and during the continuation of any Event of Default by Borrower, the Lender may, at
its option: (1)&nbsp;declare the entire Loan Balance outstanding for any Loan hereunder immediately due and payable; (2)&nbsp;terminate
this Agreement and any Loan upon notice to Borrower; (3)&nbsp;transfer any Collateral from the collateral account to Lender&rsquo;s operating
account necessary for the payment of any nonpayment, liability, obligation, or indebtedness created by this Agreement or by Lender in
furtherance of its performance hereunder and/or its lending business, including but not limited to using the Collateral to purchase the
relevant Digital Currency to replenish Lender&rsquo;s supply of the relevant Digital Currency or selling any Collateral in a relevant
market for such Digital Currency; (4)&nbsp;purchase on Lender&rsquo;s own account a like amount of Loaned Assets in a relevant market
for such Digital Currency and then collect from Borrower amounts expended by Lender for such purchase; (5)&nbsp;exercise its rights under
Section&nbsp;XII herein; (6)&nbsp;require the Borrower to adjust Borrower&rsquo;s positions or unilaterally liquidate Borrower&rsquo;s
positions on held with Lender or through any services provided by any of Lender&rsquo;s affiliates (7)&nbsp;exercise all other rights
and remedies available to the Lender hereunder, under applicable law, or in equity; provided, that upon any Event of Default pursuant
to Section&nbsp;VII as to a particular Loan, the entire Loan Balance then outstanding hereunder shall automatically become and be immediately
due and payable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">On the occurrence of any Event of Default under this Agreement and any and all Loans made pursuant to
this Agreement shall be terminated immediately and become due and payable, and Lender shall have immediate right to the Collateral to
the fullest extent permitted herein and by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">In the event that the purchase price of any replacement Digital Currency pursuant to Section&nbsp;VIII
(a)(3)&nbsp;&amp; (a)(4)&nbsp;above exceeds the amount of the Collateral, Borrower shall be liable to Lender for the amount of such excess
together with interest thereon in the amount of ten percent (10%) or as modified in the Term Sheet. As security for Borrower&rsquo;s obligation
to pay such excess, Lender shall have, and Borrower hereby grants, a security interest in any property of Borrower then held by or for
Lender and a right of setoff with respect to such property and any other amount payable by Lender to Borrower. The purchase price of replacement
Digital Currency purchased under this Section&nbsp;shall include, and the proceeds of any sale of Collateral shall be determined after
deduction of, broker&rsquo;s fees and commissions and all other reasonable costs, fees and expense related to such purchase or sale (as
the case may be). In the event Lender exercises its rights under this Section, Lender may elect in its sole discretion, in lieu of purchasing
all or a portion of the replacement Digital Currencies or selling all or a portion of the Collateral, to be deemed to have made, respectively,
such purchase of replacement Digital Currencies or sale of Collateral for an amount equal to the price therefor on the date of such exercise
obtained from a generally recognized source.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">To the extent that the Loans are now or hereafter secured by property other than the Collateral, or by
the guarantee, endorsement or property of any other person, then upon an Event of Default by Borrower, Lender shall have the right in
its sole discretion to determine which rights, security, liens, security interests or remedies Lender shall at any time pursue, relinquish,
subordinate, modify or take any other action with respect thereto, without in any way modifying or affecting any of them or any of Lender&rsquo;s
rights hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">In connection with the exercise of its remedies pursuant to this Section&nbsp;VIII, Lender may (1)&nbsp;exchange,
enforce, waive or release any portion of the Collateral or Loans in favor of the Lender or relating to any other security for the Loans;
(2)&nbsp;apply such Collateral or security and direct the order or manner of sale thereof as the Lender may, from time to time, determine;
and (3)&nbsp;settle, compromise, collect or otherwise liquidate any such Collateral or security in any manner following the occurrence
of an Event of Default, without affecting or impairing the Lender's right to take any other further action with respect to any Collateral
or security or any part thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">f.</TD><TD STYLE="text-align: justify">In addition to its rights hereunder, the non-defaulting Party shall have any rights otherwise available
to it under any other agreement or applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">g.</TD><TD STYLE="text-align: justify">LIMITATION OF LIABILITY; BORROWER EXPRESSLY UNDERSTANDS AND AGREES THAT LENDER AND ITS AFFILIATES AND
SERVICE PROVIDERS, AND THEIR RESPECTIVE OFFICERS, DIRECTORS, AGENTS, JOINT VENTURERS, EMPLOYEES, AND REPRESENTATIVES WILL NOT BE LIABLE
FOR ANY INDIRECT,&nbsp;INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY DAMAGES, OR DAMAGES FOR LOSS OF PROFITS INCLUDING WITHOUT LIMITATION
DAMAGES FOR LOSS OF GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF LENDER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES),
WHETHER BASED ON CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, OR OTHERWISE, RESULTING FROM LENDER&rsquo;S ACTIONS OR INACTIONS PURSUANT
TO THIS AGREEMENT.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>IX.</B></TD><TD STYLE="text-align: justify"><B><U>Rights and Remedies Cumulative.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No delay or omission by the Lender in exercising
any right or remedy hereunder shall operate as a waiver of the future exercise of that right or remedy or of any other rights or remedies
hereunder. All rights of the Lender stated herein are cumulative and in addition to all other rights provided by law, in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>X.</B></TD><TD STYLE="text-align: justify"><B><U>Survival of Rights and Remedies.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All remedies hereunder and all obligations with
respect to any Loan shall survive the termination of the relevant Loan, return of Loaned Assets or Collateral, and termination of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XI.</B></TD><TD STYLE="text-align: justify"><B><U>Collection Costs.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event Borrower fails to pay any amounts
due or to return any Digital Currency or upon the occurrence of any Event of Default in Section&nbsp;VII hereunder, Borrower shall, upon
demand, pay to Lender all reasonable costs and expenses, including without limitation, reasonable attorneys&rsquo; fees and court costs,
broker fees, and technology costs incurred by the Lender in connection with the enforcement of its rights hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XII.</B></TD><TD STYLE="text-align: justify"><B><U>Governing Law; Dispute Resolution.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall be governed by, and construed
and enforced in accordance with, the laws of Illinois, United States, without giving effect to the principles of conflicts of law thereof.
Any controversy, claim or dispute arising out of or relating to this Agreement or the breach thereof shall be settled solely and exclusively
by binding arbitration in Chicago,&nbsp;Illinois, United States administered by JAMS. Such arbitration shall be conducted in accordance
with the then prevailing JAMS Streamlined Arbitration Rules&nbsp;&amp; Procedures, with the following exceptions to such rules&nbsp;if
in conflict: (a)&nbsp;one arbitrator, who shall be a retired judge, shall be chosen by JAMS; (b)&nbsp;each Party to the arbitration will
pay an equal share of the expenses and fees of the arbitrator, together with other expenses of the arbitration incurred or approved by
the arbitrator; and (c)&nbsp;arbitration may proceed in the absence of any Party if written notice (pursuant to the JAMS&rsquo; rules&nbsp;and
regulations) of the proceedings has been given to such Party. Each Party shall bear its own attorneys&rsquo; fees and expenses. The Parties
agree to abide by all decisions and awards rendered in such proceedings. Such decisions and awards rendered by the arbitrator shall be
final and conclusive. All such controversies, claims or disputes shall be settled in this manner in lieu of any action at law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XIII.</B></TD><TD><B><U>Confidentiality.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">Each Party to this Agreement shall hold in confidence all information obtained from the other Party in
connection with this Agreement and the transactions contemplated hereby, including without limitation any discussions preceding the execution
of this Agreement (collectively, &ldquo;<U>Confidential Information</U>&rdquo;). Confidential Information shall not include information
that the receiving Party demonstrates with competent evidence was, or becomes, (i)&nbsp;available to the public through no violation of
this Section&nbsp;XIII, (ii)&nbsp;in the possession of the receiving Party on a non-confidential basis prior to disclosure, (iii)&nbsp;available
to the receiving Party on a non-confidential basis from a source other than the other Party or its affiliates, subsidiaries, officers,
directors, employees, contractors, attorneys, accountants, bankers or consultants (the &ldquo;<U>Representatives</U>&rdquo;), or (iv)&nbsp;independently
developed by the receiving Party without reference to or use of such Confidential Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">Each Party shall (i)&nbsp;keep such Confidential Information confidential and shall not, without the prior
written consent of the other Party, disclose or allow the disclosure of such Confidential Information to any third party, except as otherwise
herein provided, and (ii)&nbsp;restrict internal access to and reproduction of the Confidential Information to a Party&rsquo;s Representatives
only on a need to know basis; provided, however, that such Representatives shall be under an obligation of confidentiality at least as
strict as set forth in this Section&nbsp;XIII.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Each Party also agrees not to use Confidential Information for any purpose other than in connection with
transactions contemplated by this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d.</TD><TD STYLE="text-align: justify">The provisions of this Section&nbsp;XIII will not restrict a Party from disclosing the other Party&rsquo;s
Confidential Information to the extent required by any law, regulation, or direction by a court of competent jurisdiction or government
agency or regulatory authority with jurisdiction over said Party; provided that the Party required to make such a disclosure uses reasonable
efforts to give the other Party reasonable advance notice of such required disclosure in order to enable the other Party to prevent or
limit such disclosure. Notwithstanding the foregoing, Lender may disclose the other Party&rsquo;s Confidential Information without notice
pursuant to a written request by a governmental agency or regulatory authority.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e.</TD><TD STYLE="text-align: justify">The obligations with respect to Confidential Information shall survive for a period of three (3)&nbsp;years
from the date of this Agreement. Notwithstanding anything in this agreement to the contrary, a Party may retain copies of Confidential
Information (the &ldquo;<U>Retained Confidential Information</U>&rdquo;) to the extent necessary (i)&nbsp;to comply with its recordkeeping
obligations, (ii)&nbsp;in the routine backup of data storage systems, and (iii)&nbsp;in order to determine the scope of, and compliance
with, its obligations under this Section&nbsp;XIII; provided, however, that such Party agrees that any Retained Confidential Information
shall be accessible only by legal or compliance personnel of such Party and the confidentiality obligations of this Section&nbsp;XIII
shall survive with respect to the Retained Confidential Information for so long as such information is retained.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XIV.</B></TD><TD><B><U>Notices.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise provided in this Agreement, all
notices or demands relating to this Agreement shall be in writing and shall be personally delivered or sent by Express or certified mail
(postage prepaid, return receipt requested), overnight courier, electronic mail (at such email addresses as a Party may designate in accordance
herewith), or to the respective address set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lender</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: FalconX Charlie,&nbsp;Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address: 1850 Gateway Dr, 6th floor - San Mateo CA 94404 US</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: Legal Team</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: <U>legal@falconx.io</U>, with a copy to <U>operations@falconx.io</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Borrower</B>:<BR>
Name: Marvel Operations Corp.<BR>
Address: 642 Newtown Yardley Road, Newtown, PA 18940.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn: _________________________________________<BR>
Email: ________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Either Party may change its address by giving the other Party written
notice of its new address as herein provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XV.</B></TD><TD><B><U>Modifications.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All modifications or amendments
to this Agreement or any Term Sheet shall be effective only when reduced to writing and signed by both parties hereto. Such modifications
or amendments may be made through additional language included in a Loan Term Sheet or through the execution of an agreement by the Borrower
with a FalconX affiliate (including, but not limited to Falcon Labs, Ltd), in which scenario the FalconX affiliate shall have the full
authorization and power of Lender to modify or revise this Agreement on behalf of Lender</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XVI.</B></TD><TD><B><U>Single Agreement</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Borrower and Lender acknowledge that, and have
entered into this Agreement in reliance on the fact that, all Loans hereunder constitute a single business and contractual relationship
and have been entered into in consideration of each other. Accordingly, Borrower and Lender hereby agree that payments, deliveries, and
other transfers made by either of them in respect of any Loan shall be deemed to have been made in consideration of payments, deliveries,
and other transfers in respect of any other Loan hereunder, and the obligations to make any such payments, deliveries and other transfers
may be applied against each other and netted. In addition, Borrower and Lender acknowledge that, and have entered into this Agreement
in reliance on the fact that, all Loans hereunder have been entered into in consideration of each other. Accordingly, Borrower and Lender
hereby agree that (a)&nbsp;each shall perform all of its obligations in respect of each Loan hereunder, and that a default in the performance
of any such obligation by Borrower or by Lender (the &ldquo;<U>Defaulting Party</U>&rdquo;) in any Loan hereunder shall constitute a default
by the Defaulting Party under all such Loans hereunder, and (b)&nbsp;the non-defaulting Party shall be entitled to set off claims and
apply property held by it in respect of any Loan hereunder against obligations owing to it in respect of any other Loan with the Defaulting
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XVII.</B></TD><TD><B><U>Entire Agreement.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Agreement, each exhibit referenced herein, and all Loan Term Sheets
constitute the entire Agreement among the parties with respect to the subject matter hereof and supersedes any prior negotiations, understandings
and agreements. Nothing in this Section&nbsp;XVII shall be construed to conflict with or negate Section&nbsp;XVI above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XVIII.</B></TD><TD><B><U>Successors and Assigns.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement shall bind and inure to the benefit
of the respective successors and assigns of each of the parties; provided, that Borrower may not assign this Agreement or any rights or
duties hereunder without the prior written consent of the Lender (such consent to not be unreasonably withheld). Lender may assign this
Agreement or any rights or duties hereunder upon notice to Borrower. Notwithstanding the foregoing, in the event of a change of control
of Lender or Borrower, prior written consent shall not be required so such Party provides the other Party with written notice prior to
the consummation of such change of control. For purposes of the foregoing, a &ldquo;change of control&rdquo; shall mean a transaction
or series of related transactions in which a person or entity, or a group of affiliated (or otherwise related) persons or entities acquires
from stockholders of the Party shares representing more than fifty percent (50%) of the outstanding voting stock of such Party. Neither
this Agreement nor any provision hereof, nor any Exhibit&nbsp;hereto or document executed or delivered herewith, or Loan Term Sheet hereunder,
shall create any rights in favor of or impose any obligation upon any person or entity other than the parties hereto and their respective
successors and permitted assigns<I>.</I> For the avoidance of doubt, any and all claims and liabilities against the Lender arising in
any way out of this Agreement are only the obligation of the Lender, and not any of its parents or affiliates. The Parties agree that
none of the Lender&rsquo;s parents or affiliates shall have any liability under this Agreement nor do such related entities guarantee
any of the Lender&rsquo;s obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XIX.</B></TD><TD><B><U>Severability of Provisions.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each provision of this Agreement shall be severable
from every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XX.</B></TD><TD><B><U>Counterpart Execution.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Agreement may be executed in any number of
counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original,
and all of which, when taken together, shall constitute but one and the same Agreement. Delivery of an executed counterpart of this Agreement
by email or other electronic method of transmission shall be equally as effective as delivery of an original executed counterpart of this
Agreement. Any Party delivering an executed counterpart of this Agreement by email or other electronic method of transmission also shall
deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect
the validity, enforceability, and binding effect of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XXI.</B></TD><TD><B><U>Relationship of Parties.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing contained in this Agreement shall be deemed
or construed by the Parties, or by any third party, to create the relationship of partnership or joint venture between the parties hereto,
it being understood and agreed that no provision contained herein shall be deemed to create any relationship between the parties hereto
other than the relationship of Borrower and Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XXII.</B></TD><TD><B><U>No Waiver.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The failure of or delay by either Party to enforce
an obligation or exercise a right or remedy under any provision of this Agreement or to exercise any election in this Agreement shall
not be construed as a waiver of such provision, and the waiver of a particular obligation in one circumstance will not prevent such Party
from subsequently requiring compliance with the obligation or exercising the right or remedy in the future. No waiver or modification
by either Party of any provision of this Agreement shall be deemed to have been made unless expressed in writing and signed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XXIII.</B></TD><TD><B><U>Indemnification.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Party shall indemnify and hold harmless the
other Party, or any of its parents or affiliates, from and against any and all third party claims, demands, losses, expenses and liabilities
of any and every nature (including attorneys&rsquo; fees of the Party choosing to defend against any such claims, demands, losses, expenses
and liabilities) that it may sustain or incur or that may be asserted against it arising out of the lending or borrowing of Digital Currency
or U.S. Dollars under this Agreement, except for any and all claims, demands, losses, expenses and liabilities arising out of or relating
to that Party&rsquo;s bad faith, gross negligence or willful misconduct in the performance of its duties under this Agreement. This indemnity
shall be a continuing obligation of each Party, its successors and assigns, notwithstanding the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XXIV.</B></TD><TD><B><U>Term and Termination.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Term of this Agreement shall commence on the
date hereof for a period of one year, and shall automatically renew for successive one-year terms annually, unless either Party provides
notice of a desire to terminate the contract no less than ten (10)&nbsp;days prior to the end of such one-year period. The foregoing notwithstanding,
this Agreement may be terminated as set forth in Section&nbsp;VII or upon thirty (30) days&rsquo; notice by either Party to the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a termination of this Agreement,
any Loaned Assets shall be redelivered immediately and any fees owed shall be payable immediately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XXV.</B></TD><TD STYLE="text-align: justify"><B><U>No Reliance.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Except as expressly set forth in this Agreement,
each party acknowledges that it is entering into this Agreement based solely upon its own investigation and evaluation, and not in reliance
upon any statement, representation, warranty, or agreement of the other party except those specifically included in this Agreement. Each
party acknowledges that no representation or warranty not specifically contained in this Agreement has been made by or on behalf of the
other party.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Each party further acknowledges that it has
had such opportunity as it deems necessary to independently verify the information contained herein, and to seek advice from its own legal,
tax, and business advisors and such other experts as it has deemed necessary in connection with its decision to enter into this Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>To the extent that, prior to the execution
of this Agreement, either party has received or may receive information from the other party, that party understands and agrees that it
is not relying on any such information in deciding to engage in this transaction, unless such information is expressly incorporated into
this Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>XXVI.</B></TD><TD><B><U>Miscellaneous.</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever used herein, the singular number shall
include the plural, the plural the singular, and the use of the masculine, feminine, or neuter gender shall include all genders where
necessary and appropriate. This Agreement is solely for the benefit of the parties hereto and their respective successors and assigns,
and no other Person shall have any right, benefit, priority or interest under, or because of the existence of, this Agreement. The section
headings are for convenience only and shall not affect the interpretation or construction of this Agreement. The Parties acknowledge that
the Agreement and any Lending Request are the result of negotiation between the Parties which are represented by sophisticated counsel
and therefore none of the Agreement&rsquo;s provisions will be construed against the drafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[signature page&nbsp;follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF</B>, the parties have caused this Agreement to be executed and delivered as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LENDER</B>:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BORROWER</B>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FalconX Charlie,&nbsp;Inc</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marvel Operations Corp.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized Agents. </B> The following are authorized to deliver
Lending Requests on behalf of Borrower in accordance with Section&nbsp;II hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Borrower may change its Authorized Agents by notice given to Lender
as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LOAN TERM SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Lender Agreement dated __________________
(the &ldquo;<U>Loan Effective Date</U>&rdquo;) between FalconX Charlie,&nbsp;Inc (&ldquo;<U>Lender</U>&rdquo;) and _______________________________________________________________
(&ldquo;<U>Borrower</U>&rdquo;) [select A or B: (A)&nbsp;supersedes the following preceding term sheet(s)&nbsp;between the parties dated
as of: [List specific term sheets by date]; (B)&nbsp;is made in addition to any prior term sheets without superseding them], and incorporates
all of the terms of the Master Lender Agreement between Lender and Borrower on _____________ as per the following specific terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lender:
    </FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FalconX
    Charlie,&nbsp;Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned Assets:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Fee:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Type:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity
    Date: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collateral:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Collateral Ratio: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Margin
    Call Limit: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Default
    Limit:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    Limit: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FalconX Charlie,&nbsp;Inc</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Robert Rutherford &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Vice President of Operations</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>tm2526455d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INDEMNIFICATION AND ADVANCEMENT AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps">This
Amended and Restated Indemnification and Advancement Agreement</FONT> (this <B><I>&ldquo;Agreement&rdquo;</I></B>) is made as of September&nbsp;[&#9679;],
2025 by and between <FONT STYLE="font-variant: small-caps">Helius Medical Technologies,&nbsp;Inc</FONT>., a Delaware corporation (the
<B><I>&ldquo;Company&rdquo;</I></B>), and [&#9679;], a member of the Board of Directors or an officer of the Company (<B><I>&ldquo;Indemnitee&rdquo;</I></B>).
This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and
advancement of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Recitals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
the Board of Directors of the Company (the <B><I>&ldquo;Board&rdquo;</I></B>) believes that highly competent persons have become more
reluctant to serve publicly-held corporations as directors, officers, or in other capacities unless they are provided with adequate protection
through insurance or adequate indemnification and advancement of expenses against inordinate risks of claims and actions against them
arising out of their service to and activities on behalf of the corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
the Board has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing
basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities.
Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other
business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in
the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations
or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters
that traditionally would have been brought only against the Company or business enterprise itself. The amended and restated bylaws and
the amended and restated certificate of incorporation of the Company (each as may be amended or amended and restated from time to time,
the <B><I>&ldquo;Bylaws&rdquo;</I></B> and the <B><I>&ldquo;Certificate of Incorporation&rdquo;</I></B>, respectively) require indemnification
of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law
of the State of Delaware (the <B><I>&ldquo;DGCL&rdquo;</I></B>). The Bylaws, the Certificate of Incorporation, and the DGCL expressly
provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered
into between the Company and its directors, officers, and other persons with respect to indemnification and advancement of expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
the uncertainties relating to such insurance, to indemnification, and to advancement of expenses may increase the difficulty of attracting
and retaining such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of
the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such
protection in the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf
of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from
undue concern that they will not be so indemnified;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,
this Agreement is a supplement to, and in furtherance of, the Bylaws, the Certificate of Incorporation, and any resolutions adopted pursuant
thereto, as well as any rights of Indemnitee under any directors&rsquo; and officers&rsquo; liability insurance policy, and is not a substitute
therefor, and does not diminish or abrogate any rights of Indemnitee thereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Whereas</B></FONT>,&nbsp;Indemnitee
does not regard the protection available under the Bylaws, the Certificate of Incorporation, and available insurance as adequate in the
present circumstances, and may not be willing to serve or continue to serve as an officer or director without adequate additional protection,
and the Company desires Indemnitee to serve or continue to serve in such capacity. Indemnitee is willing to serve, continue to serve and
to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified and be advanced expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>Now,
Therefore</B></FONT>, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant
and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Services
to the Company.</FONT></B> Indemnitee agrees to serve or continue to serve as a director and/or officer of the Company for so long as
Indemnitee is duly elected or appointed or retained or until Indemnitee tenders Indemnitee&rsquo;s resignation of until Indemnitee is
removed. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation
imposed by operation of law) or indicate that Indemnitee is unwilling to serve as a director, if nominated. This Agreement does not create
any obligation on the Company to continue Indemnitee in such position and is not an employment contract between the Company (or any of
its subsidiaries or any Enterprise) and Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Definitions.</FONT></B>
As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Agent&rdquo;</I></B>
means any person who is authorized by the Company or an Enterprise to act for or represent the interests of the Company or an Enterprise,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>A
<B><I>&ldquo;Change in Control&rdquo; </I></B>occurs upon the earliest to occur after the date of this Agreement of any of the following
events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Acquisition
of Stock by Third Party</B>. Any Person (as defined below) becomes the Beneficial Owner (as defined below), directly or indirectly, of
securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&rsquo;s then outstanding
securities, unless: (1)&nbsp;the change in relative beneficial ownership of the Company&rsquo;s securities by any Person results solely
from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors or
(2)&nbsp;such acquisition was approved in advance by the Continuing Directors (as defined below) and such acquisition would not constitute
a Change of Control under part (iii)&nbsp;of this definition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Change
in Board of Directors</B>. During any period of two (2)&nbsp;consecutive years (not including any period prior to the execution of this
Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated
by a person who has entered into an agreement with the Company to effect a transaction described in <U>Sections 2(b)(i)</U>, <U>2(b)(iii)</U>&nbsp;or
<U>2(b)(iv)</U>&nbsp;of this Agreement) whose appointment by the Board or nomination for election by the Company&rsquo;s stockholders
was approved by a vote of a majority of the directors then still in office who either were directors at the beginning of the period or
whose election or nomination for election was previously so approved (collectively, the <B><I>&ldquo;Continuing Directors&rdquo;</I></B>),
cease for any reason to constitute at least a majority of the members of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Corporate
Transactions</B>. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to
represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the
combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and
with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iv)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Liquidation</B>.
The approval by the stockholders of the Company of a complete liquidation or dissolution of the Company or an agreement or series of agreements
for the sale or disposition by the Company of all or substantially all of the Company&rsquo;s assets; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(v)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Other
Events</B>. There occurs any other event of a nature that would be required to be reported in response to Item 6(e)&nbsp;of Schedule 14A
of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below),
whether or not the Company is then subject to such reporting requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(vi)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>For
purposes of this <U>Section&nbsp;2(b)</U>, the following terms have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(1)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Beneficial
Owner&rdquo;</I></B> has the meaning given to such term in Rule&nbsp;13d-3 under the Exchange Act; provided, however, that Beneficial
Owner excludes any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger or consolidation
of the Company with another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(2)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Corporate
Status&rdquo;</I></B> describes the status of a person who is or was acting as a director, officer, employee, or Agent of the Company
or an Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(3)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Disinterested
Director&rdquo;</I></B> means a director of the Company who is not and was not a party to the Proceeding (as defined below) in respect
of which indemnification is sought by Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(4)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Enterprise&rdquo;
</I></B>means any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity
for which Indemnitee is or was serving at the request of the Company as a director, officer, employee, or Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(5)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Exchange
Act&rdquo; </I></B>means the Securities Exchange Act of 1934, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(6)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Expenses&rdquo;
</I></B>includes all reasonable attorneys&rsquo; fees, retainers, court costs, transcript costs, fees and other costs of experts and other
professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service
fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under
this Agreement, excise taxes and penalties under the Employee Retirement Income Security Act of 1974, as amended, and all other disbursements,
obligations, or expenses of the types customarily incurred in connection with preparing for or participating in a Proceeding. Expenses
also include (i)&nbsp;Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the
premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii)&nbsp;for
purposes of <U>Section&nbsp;14(d)</U>&nbsp;of this Agreement only, Expenses incurred by Indemnitee in connection with the interpretation,
enforcement or defense of Indemnitee&rsquo;s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes
of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses
included in such demand that are certified by affidavit of Indemnitee&rsquo;s counsel as being reasonable in the good faith judgment of
such counsel will be presumed conclusively to be reasonable. Expenses, however, do not include amounts paid in settlement by Indemnitee
or the amount of judgments or fines against Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(7)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>&ldquo;<B><I>Independent
Counsel</I></B>&rdquo; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently
is, nor in the five years prior to its selection or appointment has been, retained to represent: (i)&nbsp;the Company or Indemnitee in
any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees
under similar indemnification agreements) or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder.
Notwithstanding the foregoing, the term &ldquo;Independent Counsel&rdquo; does not include any person who, under the applicable standards
of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action
to determine Indemnitee&rsquo;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent
Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(8)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Person&rdquo;</I></B>
has the meaning as set forth in Sections 13(d)&nbsp;and 14(d)&nbsp;of the Exchange Act; provided, however, that Person excludes (i)&nbsp;the
Company, (ii)&nbsp;any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii)&nbsp;any
entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(9)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><I>&ldquo;Proceeding&rdquo;
</I></B>includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate
dispute resolution mechanism, investigation, inquiry, administrative hearing, or any other actual, threatened or completed proceeding,
whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, regulatory, or
investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is, or will be involved as a party,
potential party, non-party witness, or otherwise by reason of Indemnitee&rsquo;s Corporate Status or by reason of any action taken by
Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee&rsquo;s part while acting pursuant
to Indemnitee&rsquo;s Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred
for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. A Proceeding also includes
a situation Indemnitee believes in good faith may lead to, or culminate in, the institution of a Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Indemnity
in Third-Party Proceedings.</FONT></B> The Company will indemnify Indemnitee in accordance with the provisions of this <U>Section&nbsp;3</U>
if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right
of the Company to procure a judgment in its favor. Pursuant to this <U>Section&nbsp;3</U> and in accordance with <U>Section&nbsp;13(d)</U>&nbsp;below,
the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts
paid in settlement (including all interest, assessments and other charges paid or payable in connection with, or in respect of, such Expenses,
judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on Indemnitee&rsquo;s behalf in connection
with such Proceeding or any claim, issue, or matter therein, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed
to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding, had no reasonable cause to believe
that Indemnitee&rsquo;s conduct was unlawful; provided, in no event shall Indemnitee be entitled to be indemnified, held harmless or advanced
any amounts hereunder in respect of any Expenses, judgments, liabilities, fines, penalties and amounts paid in settlement (if any) that
Indemnitee may incur by reason of his or her own actual fraud, gross negligence or intentional misconduct. Indemnitee shall not be found
to have committed actual fraud, gross negligence or intentional misconduct for any purpose of this Agreement unless or until a court of
competent jurisdiction shall have made a finding to the effect and until such finding has been made,&nbsp;Indemnitee shall be entitled
to the full benefits of indemnification and advancement of Expenses pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Indemnity
in Proceedings by or in the Right of the Company.</FONT></B> The Company will indemnify Indemnitee in accordance with the provisions of
this <U>Section&nbsp;4</U> if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right
of the Company to procure a judgment in its favor. Pursuant to this <U>Section&nbsp;4</U> and in accordance with <U>Section&nbsp;13(d)</U>&nbsp;below,
the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred
by Indemnitee or on Indemnitee&rsquo;s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in good faith and in a manner Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company. The
Company will not indemnify Indemnitee for Expenses under this <U>Section&nbsp;4</U> related to any claim, issue, or matter in a Proceeding
for which Indemnitee has been finally adjudged by a court to be liable to the Company, unless, and only to the extent that, the Court
of Chancery of the State of Delaware (the <B><I>&ldquo;Delaware Court&rdquo;</I></B>) or any court in which the Proceeding was brought
determines upon application by Indemnitee that, despite the adjudication of liability but in view of all the circumstances of the case,&nbsp;Indemnitee
is fairly and reasonably entitled to indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Indemnification
for Expenses of a Party Who is Wholly or Partly Successful.</FONT></B> To the fullest extent permitted by applicable law, the Company
will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee in connection with any Proceeding to the
extent that Indemnitee is successful, on the merits or otherwise. If Indemnitee is not wholly successful in such Proceeding but is successful,
on the merits or otherwise, as to one or more but less than all claims, issues, or matters in such Proceeding, the Company will indemnify
Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&rsquo;s behalf in connection with or related
to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this <U>Section&nbsp;5</U>
and without limitation, the termination of any claim, issue, or matter in such a Proceeding by dismissal, with or without prejudice, will
be deemed to be a successful result as to such claim, issue, or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Indemnification
for Expenses of a Witness.</FONT></B> To the fullest extent permitted by applicable law, the Company will indemnify Indemnitee against
all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee&rsquo;s behalf in connection with any Proceeding to which
Indemnitee is not a party but to which Indemnitee is a witness, deponent, interviewee, or otherwise asked to participate or provide information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Partial
Indemnification.</FONT></B> If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some
or a portion of Expenses, but not, however, for the total amount thereof, the Company will indemnify Indemnitee for the portion thereof
to which Indemnitee is entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Additional
Indemnification. </FONT></B>Notwithstanding any limitation in <U>Sections 3</U>, <U>4</U>, or <U>5</U> of this Agreement, the Company
will indemnify Indemnitee to the fullest extent permitted by applicable law (including but not limited to, the DGCL and any amendments
to or replacements of the DGCL adopted after the date of this Agreement that expand the Company&rsquo;s ability to indemnify its officers,
directors, employees or Agents) if Indemnitee is a party to, or threatened to be made a party to, any Proceeding (including a Proceeding
by or in the right of the Company to procure a judgment in its favor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Exclusions</FONT>.</B>
Notwithstanding any provision in this Agreement, the Company is not obligated under this Agreement to indemnify, or advance Expenses to,&nbsp;Indemnitee
for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>any
amount actually paid to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except to the extent provided
in <U>Section&nbsp;15(d)</U>&nbsp;of this Agreement and except with respect to any excess beyond the amount paid under any insurance policy,
contract, agreement, advancement or other indemnity provision;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>an
accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning
of Section&nbsp;16(b)&nbsp;of the Exchange Act (or successor rule) or similar provisions of state statutory law or common law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>reimbursement
of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee
from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise
from an accounting restatement of the Company pursuant to Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 (the <B><I>&ldquo;Sarbanes-Oxley
Act&rdquo;</I></B>), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation
of Section&nbsp;306 of the Sarbanes-Oxley Act);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>reimbursement
of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the
compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements
implementing Section&nbsp;10D of the Exchange Act; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>any
Proceeding initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company
or its directors, officers, employees or other indemnitees, unless (i)&nbsp;the Proceeding or part of any Proceeding is to enforce Indemnitee&rsquo;s
rights to indemnification or advancement, of Expenses, including a Proceeding (or any part of any Proceeding) initiated pursuant to <U>Section&nbsp;14</U>
of this Agreement, (ii)&nbsp;the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (iii)&nbsp;the
Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Advances
of Expenses.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company will advance, to the fullest extent not prohibited by applicable law, the Expenses incurred by Indemnitee in connection with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>any
Proceeding (or any part of any Proceeding) not initiated by Indemnitee; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>any
Proceeding (or any part of any Proceeding) initiated by Indemnitee if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(1)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>the
Proceeding or part of any Proceeding is to enforce Indemnitee&rsquo;s rights to obtain indemnification or advancement of Expenses from
the Company or Enterprise, including a proceeding initiated pursuant to <U>Section&nbsp;14</U> of this Agreement, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(2)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>the
Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company will advance the Expenses within thirty (30) days after the receipt by the Company of a statement or statements requesting such
advances from time to time, whether prior to or after final disposition of any Proceeding eligible for advancement of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>Advances
will be unsecured and interest free. Indemnitee hereby undertakes to repay any amounts so advanced (without interest) to the extent that
it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company, thus Indemnitee qualifies for advances upon
the execution of this Agreement and delivery to the Company. No other form of undertaking is required other than the execution of this
Agreement. The Company will make advances without regard to Indemnitee&rsquo;s ability to repay the Expenses and without regard to Indemnitee&rsquo;s
ultimate entitlement to indemnification under the other provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Procedure
for Notification of Claim for Indemnification or Advancement.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>Indemnitee
will promptly notify the Company in writing of any Proceeding with respect to which Indemnitee intends to seek indemnification or advancement
of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. Indemnitee will
include in the written notification to the Company a description of the nature of the Proceeding and the facts underlying the Proceeding
and provide such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether
and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. Indemnitee&rsquo;s failure
to notify the Company will not relieve the Company from any obligation it may have to Indemnitee under this Agreement, and any delay in
so notifying the Company will not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company will,
promptly upon receipt of such a request for indemnification or advancement, advise the Board in writing that Indemnitee has requested
indemnification or advancement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company will be entitled to participate in the Proceeding at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>With
respect to any Proceeding for which Indemnitee requests advancement of Expenses and/or indemnification, the Company may, at its option,
assume the defense of such Proceeding with counsel reasonably acceptable to Indemnitee. Upon assumption of the defense by the Company
and the retention of such counsel by the Company,&nbsp;Indemnitee will not be entitled to advancement of Expenses or indemnification under
this Agreement for Expenses subsequently incurred by Indemnitee with respect to the Proceeding, and any such Expenses will be at Indemnitee&rsquo;s
sole cost and expense. However, if Indemnitee&rsquo;s counsel delivers a written notice to the Company stating that such counsel has reasonably
concluded that there is or may be a conflict of interest between the Company and Indemnitee with respect to the Proceeding, or if the
Company shall not, in fact, have employed counsel or otherwise actively pursued the defense of such proceeding within a reasonable time,
then Indemnitee will be eligible for indemnification and advancement of Expenses for such Proceeding consistent with the provisions of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Procedure
Upon Application for Indemnification.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>Unless
a Change in Control has occurred, the determination of Indemnitee&rsquo;s entitlement to indemnification will be made:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>by
a majority vote of the Disinterested Directors, even though less than a quorum of the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>by
a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of
the Board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>if
there are no such Disinterested Directors or, if such Disinterested Directors so direct, by written opinion provided by Independent Counsel
selected by the Board; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iv)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>if
so directed by the Board, by the stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>If
a Change in Control has occurred, the determination of Indemnitee&rsquo;s entitlement to indemnification will be made by written opinion
provided by Independent Counsel selected by Indemnitee (unless Indemnitee requests such selection be made by the Board)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
party selecting Independent Counsel pursuant to subsection (a)(iii)&nbsp;or (b)&nbsp;of this <U>Section&nbsp;12</U> will provide written
notice of the selection of Independent Counsel to the other party within ten (10)&nbsp;days of such selection. The notified party may,
within ten (10)&nbsp;days after receiving written notice of the selection of Independent Counsel, deliver to the selecting party a written
objection to such selection; <U>provided</U>, <U>however</U>, that such objection may be asserted only on the ground that the Independent
Counsel so selected does not meet the requirements of &ldquo;Independent Counsel&rdquo; as defined in <U>Section&nbsp;2</U> of this Agreement,
and the objection will set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person
so selected will act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected
may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection
is without merit. If, within thirty (30) days after the later of submission by Indemnitee of a written request for indemnification pursuant
to <U>Section&nbsp;11(a)</U>&nbsp;of this Agreement and the final disposition of the Proceeding,&nbsp;Independent Counsel has not been
selected or, if selected, any objection to such selection has not been resolved, either the Company or Indemnitee may petition the Delaware
Court for resolution of any objection made by the Company or Indemnitee to the other&rsquo;s selection of Independent Counsel and/or for
the appointment as Independent Counsel of a person selected by such court or by such other person as such court designates. Upon the due
commencement of any judicial proceeding or arbitration pursuant to <U>Section&nbsp;14(a)</U>&nbsp;of this Agreement,&nbsp;Independent
Counsel will be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional
conduct then prevailing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>Indemnitee
will cooperate with the person, persons or entity making the determination with respect to Indemnitee&rsquo;s entitlement to indemnification,
including providing to such person, persons, or entity upon reasonable advance request any documentation or information which is not privileged
or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.
The Company will advance and pay any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making the indemnification
determination irrespective of the determination as to Indemnitee&rsquo;s entitlement to indemnification and the Company hereby indemnifies
and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing of the determination that Indemnitee
is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied and
providing a copy of any written opinion provided to the Board by Independent Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>If
it is determined that Indemnitee is entitled to indemnification, the Company will make payment to Indemnitee within thirty (30) days after
such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Presumptions
and Effect of Certain Proceedings.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>In
making a determination with respect to entitlement to indemnification under this Agreement, the person, persons, or entity making such
determination will, to the fullest extent not prohibited by law, presume Indemnitee is entitled to indemnification under this Agreement
if Indemnitee has submitted a request for indemnification in accordance with <U>Section&nbsp;11(a)</U>&nbsp;of this Agreement, and the
Company will, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption. Neither the failure
of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action
pursuant to this Agreement that indemnification is proper under the circumstances because Indemnitee has met the applicable standard of
conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such
applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard
of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>If
the determination of Indemnitee&rsquo;s entitlement to indemnification has not been made pursuant to <U>Section&nbsp;12</U> of this Agreement
within sixty (60) days after the later of (i)&nbsp;receipt by the Company of Indemnitee&rsquo;s request for indemnification pursuant to
<U>Section&nbsp;11(a)</U>&nbsp;of this Agreement and (ii)&nbsp;the final disposition of the Proceeding for which Indemnitee requested
Indemnification (<B><I>the &ldquo;Determination Period&rdquo;</I></B>), the requisite determination of entitlement to indemnification
will, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee will be entitled to such indemnification
absent (y)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s
statement not materially misleading, in connection with the request for indemnification or (z)&nbsp;a prohibition of such indemnification
under applicable law. The Determination Period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if
the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional
time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, the Determination Period
will not apply (i)&nbsp;if the determination of entitlement to indemnification is to be made by the stockholders pursuant to <U>Section&nbsp;12(a)(iv)</U>&nbsp;of
this Agreement and if (A)&nbsp;within fifteen (15) days after receipt by the Company of the request for such determination the Board has
resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five
(75) days after such receipt and such determination is made thereat, or (B)&nbsp;a special meeting of stockholders is called within fifteen
(15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days
after having been so called and such determination is made thereat, or (ii)&nbsp;if the determination of entitlement to indemnification
is to be made by Independent Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
termination of any Proceeding or of any claim, issue, or matter therein by judgment, order, settlement or conviction, or upon a plea of
<U>nolo contendere</U> or its equivalent, will not (except as otherwise expressly provided in this Agreement) of itself adversely affect
the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee
had reasonable cause to believe that Indemnitee&rsquo;s conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>For
purposes of any determination of good faith in connection with <U>Section&nbsp;3</U> or <U>4</U> of this Agreement,&nbsp;Indemnitee will
be deemed to have acted in good faith if Indemnitee acted based on (i)&nbsp;the records or books of account of the Company, its subsidiaries,
or an Enterprise, including financial statements, (ii)&nbsp;information supplied to Indemnitee by the directors or officers of the Company,
its subsidiaries, or an Enterprise in the course of their duties, (iii)&nbsp;the advice of legal counsel for the Company, its subsidiaries,
or an Enterprise or (iv)&nbsp;information or records given or reports made to the Company or an Enterprise by an independent certified
public accountant or by an appraiser, financial advisor or other expert selected with reasonable care by or on behalf of the Company,
its subsidiaries, or an Enterprise. Further,&nbsp;Indemnitee will be deemed to have acted in a manner &ldquo;not opposed to the best interests
of the Company,&rdquo; as referred to in <U>Sections 3</U> and <U>4</U> of this Agreement if Indemnitee acted in good faith and in a manner
Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan. The provisions
of this <U>Section&nbsp;13(d)</U>&nbsp;are not exclusive and do not limit in any way the other circumstances in which Indemnitee may be
deemed to have met the applicable standard of conduct set forth in <U>Sections 3</U> and <U>4</U> of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
knowledge and/or actions, or failure to act, of any other person affiliated with the Company or an Enterprise (including, but not limited
to, a director, officer, trustee, partner, managing member, Agent or employee) may not be imputed to Indemnitee for purposes of determining
Indemnitee&rsquo;s right to indemnification under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Remedies
of Indemnitee.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>Indemnitee
may commence litigation against the Company in the Delaware Court to obtain indemnification or advancement of Expenses provided by this
Agreement in the event that (i)&nbsp;a determination is made pursuant to <U>Section&nbsp;12</U> of this Agreement that Indemnitee is not
entitled to indemnification under this Agreement, (ii)&nbsp;the Company does not advance Expenses pursuant to <U>Section&nbsp;10</U> of
this Agreement, (iii)&nbsp;the determination of entitlement to indemnification is not made pursuant to <U>Section&nbsp;12</U> of this
Agreement within the Determination Period, (iv)&nbsp;the Company does not indemnify Indemnitee pursuant to <U>Section&nbsp;5</U> or <U>6</U>
or the second to last sentence of <U>Section&nbsp;12(d)</U>&nbsp;of this Agreement within thirty (30) days after receipt by the Company
of a written request therefor, (v)&nbsp;the Company does not indemnify Indemnitee pursuant to <U>Section&nbsp;3</U>, <U>4</U>, <U>7</U>,
or <U>8</U> of this Agreement within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification,
or (vi)&nbsp;in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or
unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from,&nbsp;Indemnitee the benefits
provided or intended to be provided to Indemnitee hereunder. Alternatively,&nbsp;Indemnitee, at Indemnitee&rsquo;s option, may seek an
award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules&nbsp;of the American Arbitration
Association. Indemnitee A party must commence such Proceeding seeking an adjudication or an award in arbitration within one hundred and
eighty (180) days following the date on which Indemnitee first has the right to commence such Proceeding pursuant to this <U>Section&nbsp;14(a)</U>;
<U>provided</U>, <U>however</U>, that the foregoing clause does not apply in respect of a Proceeding brought by Indemnitee to enforce
Indemnitee&rsquo;s rights under <U>Section&nbsp;5</U> of this Agreement. The Company will not oppose Indemnitee&rsquo;s right to seek
any such adjudication or award in arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>If
a determination is made pursuant to <U>Section&nbsp;12</U> of this Agreement that Indemnitee is not entitled to indemnification, any judicial
proceeding or arbitration commenced pursuant to this <U>Section&nbsp;14</U> will be conducted in all respects as a <I>de novo</I> trial
or arbitration on the merits and Indemnitee may not be prejudiced by reason of that adverse determination. In any judicial proceeding
or arbitration commenced pursuant to this <U>Section&nbsp;14</U> the Company will have the burden of proving Indemnitee is not entitled
to indemnification or advancement of Expenses, as the case may be, and will not introduce evidence of the determination made pursuant
to <U>Section&nbsp;12</U> of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>If
a determination is made pursuant to <U>Section&nbsp;12</U> of this Agreement that Indemnitee is entitled to indemnification, the Company
will be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this <U>Section&nbsp;14</U> unless
(i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s statement
not materially misleading, in connection with Indemnitees&rsquo; request for indemnification, or (ii)&nbsp;the Company is prohibited from
indemnifying Indemnitee under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company is, to the fullest extent not prohibited by law, precluded from asserting in any judicial proceeding or arbitration commenced
pursuant to this <U>Section&nbsp;14</U> that the procedures and presumptions of this Agreement are not valid, binding, or enforceable
and will stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>It
is the intent of the Company that, to the fullest extent permitted by law,&nbsp;Indemnitee not be required to incur legal fees or other
Expenses associated with the interpretation, enforcement, or defense of Indemnitee&rsquo;s rights under this Agreement, by litigation
or otherwise, because the cost and expense thereof would substantially detract from the benefits intended to be extended to Indemnitee
under this Agreement. The Company, to the fullest extent permitted by law, will (within thirty (30) days after receipt by the Company
of a written request therefor) advance to Indemnitee such Expenses which are incurred by Indemnitee in connection with a Proceeding concerning
this Agreement,&nbsp;Indemnitee&rsquo;s other rights to indemnification or advancement of Expenses from the Company, or concerning any
directors&rsquo; and officers&rsquo; liability insurance policies maintained by the Company, and will indemnify Indemnitee against any
and all such Expenses unless the court determines that Indemnitee&rsquo;s claims in such action were made in bad faith or frivolous, or
that the Company is prohibited by law from indemnifying Indemnitee for such Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>15.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Non-exclusivity;
Survival of Rights; Insurance; Subrogation</FONT>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
indemnification and advancement of Expenses provided by this Agreement are not exclusive of any other rights to which Indemnitee may at
any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders, a resolution
of the board of directors, or otherwise. The indemnification and advancement of Expenses provided by this Agreement may not be limited
or restricted by any amendment, alteration or repeal of this Agreement in any way with respect to any action taken or omitted by Indemnitee
in Indemnitee&rsquo;s Corporate Status occurring prior to any amendment, alteration or repeal of this Agreement. To the extent that a
change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would
be afforded currently under the Bylaws, the Certificate of Incorporation, or this Agreement, it is the intent of the parties hereto that
Indemnitee enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to
be exclusive of any other right or remedy, and every other right and remedy is cumulative and in addition to every other right and remedy
given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder,
or otherwise, will not prevent the concurrent assertion or employment of any other right or remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company hereby acknowledges that Indemnitee may have certain rights to indemnification, advancement of Expenses and/or insurance provided
by one or more other Persons with whom or which Indemnitee may be associated. The relationship between the Company and such other Persons,
other than an Enterprise, with respect to Indemnitee&rsquo;s rights to indemnification, advancement of Expenses, and insurance is described
by this subsection, subject to the provisions of subsection (d)&nbsp;of this <U>Section&nbsp;15</U> with respect to a Proceeding concerning
Indemnitee&rsquo;s Corporate Status with an Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company hereby acknowledges and agrees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(1)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>the
Company&rsquo;s obligations to Indemnitee are primary and any obligation of any other Persons, other than an Enterprise, are secondary
(i.e., the Company is the indemnitor of first resort) with respect to any request for indemnification or advancement of Expenses made
pursuant to this Agreement concerning any Proceeding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(2)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>the
Company is primarily liable for all indemnification or advancement of Expenses obligations for any Proceeding, whether created by law,
the Bylaws, the Certificate of Incorporation, contract (including this Agreement) or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(3)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>any
obligation of any other Persons with whom or which Indemnitee may be associated to indemnify Indemnitee and/or advance Expenses to Indemnitee
in respect of any proceeding are secondary to the Company&rsquo;s obligations; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(4)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>the
Company will indemnify Indemnitee and advance Expenses to Indemnitee hereunder to the fullest extent provided herein without regard to
any rights Indemnitee may have against any other Person with whom or which Indemnitee may be associated or an insurer of any such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company irrevocably waives, relinquishes and releases (A)&nbsp;any other Person with whom or which Indemnitee may be associated from any
claim of contribution, subrogation, reimbursement, exoneration or indemnification, or any other recovery of any kind in respect of amounts
paid by the Company to Indemnitee pursuant to this Agreement and (B)&nbsp;any right to participate in any claim or remedy of Indemnitee
against any Person whether or not such claim, remedy or right arises in equity or under contract, statute or common law, including, without
limitation, the right to take or receive from any Person, directly or indirectly, in cash or other property or by set-off or in any other
manner, payment or security on account of such claim, remedy or right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>In
the event any other Person with whom or which Indemnitee may be associated or their insurers advances or extinguishes any liability or
loss for Indemnitee, the payor has a right of subrogation against the Company or its insurers for all amounts so paid which would otherwise
be payable by the Company or its insurers under this Agreement. In no event will payment by any other Person with whom or which Indemnitee
may be associated or their insurers affect the obligations of the Company hereunder or shift primary liability for the Company&rsquo;s
obligation to indemnify or advance Expenses to any other Person with whom or which Indemnitee may be associated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(iv)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>Any
indemnification or advancement of Expenses provided by any other Person with whom or which Indemnitee may be associated is specifically
in excess over the Company&rsquo;s obligation to indemnify and advance Expenses or any valid and collectible insurance (including but
not limited to any malpractice insurance or professional errors and omissions insurance) provided by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>To
the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees,
or Agents of the Company, the Company will obtain a policy or policies covering Indemnitee to the maximum extent of the coverage available
for any such director, officer, employee or Agent under such policy or policies, including coverage in the event the Company does not
or cannot, for any reason, indemnify or advance Expenses to Indemnitee as required by this Agreement. If, at the time of the receipt of
a notice of a claim pursuant to this Agreement, the Company has director and officer liability insurance in effect, the Company will give
prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures
set forth in the respective policies. The Company will thereafter take all necessary or desirable action to cause such insurers to pay,
on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Indemnitee
agrees to assist the Company&rsquo;s efforts to cause the insurers to pay such amounts and will comply with the terms of such policies,
including selection of approved panel counsel, if required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company&rsquo;s obligation to indemnify or advance Expenses hereunder to Indemnitee for any Proceeding concerning Indemnitee&rsquo;s Corporate
Status with an Enterprise will be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses
from such Enterprise. The Company and Indemnitee intend that any such Enterprise (and its insurers) be the indemnitor of first resort
with respect to indemnification and advancement of Expenses for any Proceeding related to or arising from Indemnitee&rsquo;s Corporate
Status with such Enterprise. The Company&rsquo;s obligation to indemnify and advance Expenses to Indemnitee is secondary to the obligations
the Enterprise or its insurers owe to Indemnitee. Indemnitee agrees to take all reasonably necessary and desirable action to obtain from
an Enterprise indemnification and advancement of Expenses for any Proceeding related to, or arising from,&nbsp;Indemnitee&rsquo;s Corporate
Status with such Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>In
the event of any payment made by the Company under this Agreement, the Company will be subrogated to the extent of such payment to all
of the rights of recovery of Indemnitee from any Enterprise or its insurance carrier. Indemnitee will execute all papers required and
take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring
suit to enforce such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Duration
of Agreement.</FONT></B> The indemnification and advancement of Expenses rights provided by or granted pursuant to this Agreement (a)&nbsp;are
binding upon and enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor
by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), (b)&nbsp;are continuing
as to an Indemnitee who has ceased to be a director, officer, employee or Agent of the Company or of any other Enterprise, and (c)&nbsp;inure
to the benefit of Indemnitee and Indemnitee&rsquo;s spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>17.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Severability.</FONT></B>
If any provision or provisions of this Agreement is held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the
validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any
Section&nbsp;of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid,
illegal or unenforceable) will not in any way be affected or impaired thereby and will remain enforceable to the fullest extent permitted
by law; (b)&nbsp;such provision or provisions will be deemed reformed to the extent necessary to conform to applicable law and to give
the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement
(including, without limitation, each portion of any Section&nbsp;of this Agreement containing any such provision held to be invalid, illegal
or unenforceable, that is not itself invalid, illegal or unenforceable) will be construed so as to give effect to the intent manifested
thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>18.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Interpretation.</FONT></B>
Any ambiguity in the terms of this Agreement will be resolved in favor of Indemnitee and in a manner to provide the maximum indemnification
and advancement of Expenses permitted by law. The Company and Indemnitee intend that this Agreement provide to the fullest extent permitted
by law for indemnification and advancement of Expenses in excess of that expressly provided, without limitation, by the Certificate of
Incorporation, the Bylaws, vote of the Company&rsquo;s stockholders or disinterested directors, or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>19.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Enforcement.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>The
Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee to serve as a director, officer, employee, or Agent of the Company, and the Company acknowledges that Indemnitee
is relying upon this Agreement in serving or continuing to serve as director, officer, employee, or Agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></B>This
Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and expressly supersedes
all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof,
including, without limitation, any prior indemnification agreements entered into between the Company and Indemnitee; provided, however,
that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws, any directors&rsquo; and officers&rsquo;
insurance maintained by the Company, and applicable law, is not a substitute therefor, and does not diminish or abrogate any rights of
Indemnitee thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>20.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Modification
and Waiver.</FONT></B> No supplement, modification or amendment of this Agreement is binding unless executed in writing by the parties
hereto. No waiver of any of the provisions of this Agreement will be valid unless executed in writing by the party entitled to enforce
the provision to be waived and any such waiver will not be deemed or constitutes a waiver of any other provisions of this Agreement, nor
will any waiver constitute a continuing waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>21.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Notice
by Indemnitee.</FONT></B> Indemnitee agrees to promptly notify the Company in writing upon being served with any summons, citation, subpoena,
complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement
of Expenses covered hereunder. The failure of Indemnitee to so notify the Company does not relieve the Company of any obligation which
it may have to Indemnitee under this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>22.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Notices.</FONT></B>
All notices, requests, demands and other communications under this Agreement will be in writing and will be deemed to have been duly given
if (a)&nbsp;delivered by hand to the other party, (b)&nbsp;sent by reputable overnight courier to the other party or (c)&nbsp;sent by
facsimile transmission or electronic mail, with receipt of oral confirmation that such communication has been received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If to Indemnitee,
at the address indicated on the signature page&nbsp;of this Agreement, or such other address as Indemnitee provides to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">If to the Company to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Helius Medical Technologies,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">642 Newtown Yardley Rd #100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Newtown, PA 18940</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">or to any other address as may have been furnished to Indemnitee
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>23.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Contribution.</FONT></B>
To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee
for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred by Indemnitee, whether
for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim
relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances
of such Proceeding in order to reflect (a)&nbsp;the relative benefits received by the Company and Indemnitee as a result of the event(s)&nbsp;and/or
transaction(s)&nbsp;giving cause to such Proceeding; and/or (b)&nbsp;the relative fault of the Company (and its directors, officers, employees
and Agents) and Indemnitee in connection with such event(s)&nbsp;and/or transaction(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>24.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Applicable
Law and Consent to Jurisdiction.</FONT></B> This Agreement and the legal relations among the parties are governed by, and construed and
enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any
arbitration commenced by Indemnitee pursuant to <U>Section&nbsp;14(a)</U>&nbsp;of this Agreement, the Company and Indemnitee hereby irrevocably
and unconditionally (a)&nbsp;agree that any action, claim, or proceeding between the parties arising out of or in connection with this
Agreement may be brought only in the Delaware Court and not in any other state or federal court in the United States of America or any
court in any other country, (b)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action,
claim, or proceeding arising out of or in connection with this Agreement, (c)&nbsp;waive any objection to the laying of venue of any such
action, claim, or proceeding in the Delaware Court, and (d)&nbsp;waive, and agree not to plead or to make, any claim that any such action,
claim, or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>25.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Identical
Counterparts.</FONT></B> This Agreement may be executed in one or more counterparts, each of which will for all purposes be deemed to
be an original but all of which together constitute one and the same Agreement. Only one such counterpart signed by the party against
whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>26.<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-variant: small-caps">Headings.</FONT></B>
The headings of this Agreement are inserted for convenience only and do not constitute part of this Agreement or affect the construction
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signatures
on the Following Page</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, the parties have executed this Indemnification and Advancement Agreement on and as of the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE COMPANY:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNITEE:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Helius Medical Technologies,&nbsp;Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">[Insert Name]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address: Indemnitee&rsquo;s last mailing address and email address as then contained in the records of the Company or such other address as Indemnitee may designate</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Signature
Page&nbsp;to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Amended
and Restated Indemnification and Advancement Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>tm2526455d1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXECUTIVE CHAIRMAN LETTER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS AGREEMENT</B> is made
and entered into effective as September&nbsp;18, 2025 (the &ldquo;Effective Date&rdquo;), by and between <B>Helius Medical Technologies,&nbsp;Inc.,
</B>a Delaware corporation (the &ldquo;Company&rdquo;) and Joseph Chee<B>, </B>an individual (&ldquo;Director&rdquo;) with his principal
residence at A-38A-02, Tropicana Grande Condos, Tropicana Golf&nbsp;&amp; Country Resort, 47410 Petaling Jaya, Selangor, Malaysia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Term. </U></B>This Agreement shall continue for a period of one (1)&nbsp;year from the Effective Date. It may be renewed for a successive one-year term upon termination.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Position and Responsibilities.</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Position</U>. The Board of Directors hereby appoints Mr.&nbsp;Chee to serve as Executive Chairman effective as the closing of the private placement of public equity announced on September&nbsp;15, 2025 (the &ldquo;PIPE&rdquo;). The Board of Directors hereby appoints the Director to also serve as a Board Member until the next annual meeting of the Company&rsquo;s shareholders or until his earlier resignation, removal, or death. Mr.&nbsp;Chee shall perform such duties and responsibilities as are customarily related to such positions in accordance with Company&rsquo;s bylaws and applicable law, including, but not limited to, the implementation of the digital asset treasury authorized by the Board of Directors (the &ldquo;Services&rdquo;). Director hereby agrees to use his best efforts to provide the Services. Director shall not allow any other person or entity to perform any of the Services for or instead of Director. Director shall comply with the statutes, rules, regulations, and orders of any governmental or quasi-governmental authority, which are applicable to the Company and the performance of the Services, and Company&rsquo;s rules, regulations, and practices as they may from time-to-time be adopted or modified.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other Activities</U>. Director may be employed by another company, may serve on other Boards of Directors or Advisory Boards, and may engage in any other business activity (whether or not pursued for pecuniary advantage), as long as such outside activities do not violate Director&rsquo;s fiduciary obligations under applicable laws. Director represents that Director has no outstanding agreement or obligation that is in conflict with any of the provisions of this Agreement, and Director agrees to use his best efforts to avoid or minimize any such conflict and agrees not to enter into any agreement or obligation that could create such a conflict without the approval of a majority of the Board of Directors. If, at any time, Director is required to make any disclosure or take any action that may conflict with any of the provisions of this Agreement, Director will promptly notify the Board of such obligation, prior to making such disclosure or taking such action.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Conflict</U>. Director will not engage in any activity that creates an actual or perceived conflict of interest with Company, regardless of whether such activity is prohibited by Company&rsquo;s conflict of interest guidelines or this Agreement, and Director agrees to notify the Board of Directors before engaging in any activity that could reasonably be assumed to create a potential conflict of interest with Company. Notwithstanding the provisions of Section&nbsp;2(b)&nbsp;hereof, Director shall not engage in any activity that is in direct competition with the Company or serve in any capacity (including, but not limited to, as an employee, consultant, advisor or director) in any company or entity that competes directly or indirectly with the Company, as reasonably determined by a majority of Company&rsquo;s disinterested board members, without the approval of the Board of Directors.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Compensation and Benefits.</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Executive Chairman&rsquo;s Fee</U>. The Company shall, on or around the Effective Date, grant Director an equity award of RSUs (as defined in the Helius Medical Technologies,&nbsp;Inc. 2022 Equity Incentive Plan (as may be amended from time to time (the &ldquo;Plan&rdquo;)) equal to (i)&nbsp;1% of the aggregate number of common stock and pre-funded warrants issued in the PIPE (the &ldquo;Pre-Funded Warrant&rdquo;), plus (ii)&nbsp;0.5% of the aggregate number of common stock underlying the stapled warrants issued in connection with the PIPE (collectively, the &ldquo;Equity Award&rdquo;) for his services related to the implementation of the digital asset treasury for the Company. Following the closing of the PIPE and within 10 business days of the exercise of a stapled warrant issued to PIPE investors (&ldquo;Stapled Warrants&rdquo;), the Company shall issue to Mr.&nbsp;Chee an additional RSU award equal to 0.5% of the number of shares of the Company&rsquo;s common stock issuable upon the exercise of the Stapled Warrants that are exercised for cash (the &ldquo;Additional Equity Award&rdquo;). The Equity Award and the Additional Equity Award shall only be subject to the same (but not any further) restrictions or conditions as the pre-funded warrant or the Stapled Warrant issued in connection with the PIPE, to the extent applicable.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If there are not sufficient shares available under the Plan, the Equity Award or the Additional Equity Award (as applicable) will be subject to shareholder approval increasing the shares available under the Plan. The parties acknowledge that this equity award is not exclusive and is in addition to, not in lieu of, any other compensation and benefits that shall be paid to Director for rendering the Services under this Letter, which shall be set forth in separate agreement mutually agreed by the Company and Director.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses</U>. The Company shall reimburse Director for all reasonable business expenses incurred in the performance of the Services in accordance with Company&rsquo;s expense reimbursement guidelines.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification. </U>Company will indemnify and defend Director against any liability incurred in the performance of the Services to the fullest extent authorized in Company&rsquo;s amended and restated certificate of incorporation, amended and restated bylaws, and applicable law. Company will purchase Director&rsquo;s and Officer&rsquo;s liability insurance when a policy is purchased by the Company and Director shall be entitled to the protection of any insurance policies the Company maintains for the benefit of its Directors and Officers against all costs, charges and expenses in connection with any action, suit or proceeding to which he may be made a party by reason of his affiliation with Company, its subsidiaries, or affiliates.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Records</U>. So long as the Director shall serve as a member of the Company&rsquo;s Board of Directors and/or Executive Chairman, the Director shall have full access to books and records of Company and access to management of the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Termination.</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Right to Terminate</U>. At any time, Director may be removed as Board Member as provided in Company&rsquo;s amended and restated certificate of incorporation, amended and restated bylaws, and applicable law and in accordance with the Strategic Advisory Agreement, entered into in connection with the PIPE. Director may resign as Board Member or Director as provided in Company&rsquo;s amended and restated certificate of incorporation, amended and restated bylaws, and applicable law. Notwithstanding anything to the contrary contained in or arising from this Agreement or any statements, policies, or practices of Company, neither Director nor Company shall be required to provide any advance notice or any reason or cause for termination of Director&rsquo;s status as Board Member, except as provided in Company&rsquo;s amended and restated certificate of incorporation, Company&rsquo;s amended and restated bylaws, and applicable law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effect of Termination as Director</U>. Upon Director&rsquo;s termination this Agreement will terminate; Company shall pay to Director all compensation and expenses to which Director is entitled up through the date of termination; and Director shall be entitled to his rights under any other applicable law. Thereafter, all of Company&rsquo;s obligations under this Agreement shall cease.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Termination Obligations.</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director agrees that all property, including, without limitation, all equipment, tangible proprietary information, documents, records, notes, contracts, and computer-generated materials provided to or prepared by Director incident to the Services and his membership on the Company&rsquo;s Board of Directors or any committee therefore the sole and exclusive property of the Company and shall be promptly returned to the Company at such time as the Director is no longer a member of the Company&rsquo;s Board of Directors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon termination of this Agreement, Director shall be deemed to have resigned from all offices then held with Company by virtue of his position as Board Member. Director agrees that following any termination of this Agreement, he shall cooperate with Company in the winding up or transferring to other directors of any pending work and shall also cooperate with Company (to the extent allowed by law, and at Company&rsquo;s expense) in the defense of any action brought by any third party against Company that relates to the Services.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Nondisclosure Obligations.</U></B> Director shall maintain in confidence and shall not, directly or indirectly, disclose or use, either during or after the term of this Agreement, any Proprietary Information (as defined below), confidential information, or trade secrets belonging to Company, whether or not it is in written or permanent form, except to the extent necessary to perform the Services, as required by a lawful government order or subpoena, or as authorized in writing by Company. These nondisclosure obligations also apply to Proprietary Information belonging to customers and suppliers of Company, and other third parties, learned by Director as a result of performing the Services. &ldquo;<B>Proprietary Information</B>&rdquo; means all information pertaining in any manner to the business of Company, unless (i)&nbsp;the information is or becomes publicly known through lawful means; (ii)&nbsp;the information was part of Director&rsquo;s general knowledge prior to his relationship with Company; or (iii)&nbsp;the information is disclosed to Director without restriction by a third party who rightfully possesses the information and did not learn of it from Company.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Dispute Resolution.</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Jurisdiction and Venue</U>. The parties agree that any suit, action, or proceeding between Director and Company (and its affiliates, shareholders, directors, officers, employees, members, agents, successors, attorneys, and assigns) relating to this Agreement shall be brought in either the Delaware Chancery Court (the &ldquo;Chancery Court&rdquo;) or the courts of the United States of America located in the State of Delaware (the &ldquo;Delaware Courts&rdquo;) and that the parties shall submit to the jurisdiction of such court. The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court. If any one or more provisions of this Section&nbsp;shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Attorneys&rsquo; Fees</U>. Should any litigation, arbitration or other proceeding be commenced between the parties concerning the rights or obligations of the parties under this Agreement, the party prevailing in such proceeding shall be entitled, in addition to such other relief as may be granted, to a reasonable sum as and for its attorneys&rsquo; fees in such proceeding. This amount shall be determined by the court in such proceeding or in a separate action brought for that purpose. In addition to any amount received as attorneys&rsquo; fees, the prevailing party also shall be entitled to receive from the party held to be liable, an amount equal to the attorneys&rsquo; fees and costs incurred in enforcing any judgment against such party. This Section&nbsp;is severable from the other provisions of this Agreement and survives any judgment and is not deemed merged into any judgment.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Entire Agreement.</U></B> This Agreement constitutes the entire understanding between the parties hereto superseding all prior and contemporaneous agreements or understandings among the parties hereto concerning the Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendments; Waivers.</U></B> This Agreement may be amended, modified, superseded, or canceled, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by the parties or, in the case of a waiver, by the party to be charged. Any amendment or waiver by the Company must be approved by the Company&rsquo;s Board of Directors and executed on behalf of the Company by its Chief Executive Officer or Chief Financial Officer. If the Director shall also serve as Chief Executive Officer or Chief Financial Officer, such amendment or waiver must be executed on behalf of the Company by an officer designed by the Company&rsquo;s Board of Directors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Assignment. </U></B>This Agreement shall not be assignable by either party.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Severability. </U></B>If any provision of this Agreement shall be held by a court to be invalid, unenforceable, or void, such provision shall be enforced to fullest extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period or scope of any provision is declared by a court of competent jurisdiction to exceed the maximum time period or scope that such court deems enforceable, then such court shall reduce the time period or scope to the maximum time period or scope permitted by law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Governing Law.</U></B> This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Interpretation. </U></B>This Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Captions are used for reference purposes only and should be ignored in the interpretation of the Agreement.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Binding Agreement.</U></B> Each party represents and warrants to the other that the person(s)&nbsp;signing this Agreement below has authority to bind the party to this Agreement and that this Agreement will legally bind both Company and Director. To the extent that the practices, policies, or procedures of Company, now or in the future, are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent change in Director&rsquo;s duties or compensation as Board Member will not affect the validity or scope of the remainder of this Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Director Acknowledgment.</U></B> Director acknowledges Director has had the opportunity to consult legal counsel concerning this Agreement, that Director has read and understands the Agreement, that Director is fully aware of its legal effect, and that Director has entered into it freely based on his own judgment and not on any representations or promises other than those contained in this Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Counterparts. </U></B>This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Date of Agreement.</U></B> The parties have duly executed this Agreement as of the date first written above.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helius Medical Technologies,&nbsp;Inc. </FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Chee</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Delaware Corporation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jeffrey S. Mathiesen</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph Chee</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey S. Mathiesen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Chee</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer, Secretary and Treasurer</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Executive Chairman</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>tm2526455d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right; background-color: white; color: Black"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right; background-color: white; color: Black"><FONT STYLE="color: Black"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: right; background-color: white; color: Black"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white; color: Black"><FONT STYLE="color: Black"><B>Helius
(NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital</B></FONT>&nbsp;</P>

<P STYLE="color: Black; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="color: Black"><B>Closes
Over $500 Million Private Placement to Launch SOL Treasury Company</B></FONT></P>

<P STYLE="color: Black; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="color: Black"><B><I>Preeminent
SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to accelerate
Solana&rsquo;s growth</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>The financing drew
participation from leading investors across traditional finance and crypto, including <I>Big Brain Holdings, Avenir, SinoHope, FalconX,
Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, HashKey Capital, and Republic Digital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">Newtown, Pa.
 &ndash; September&nbsp;18, 2025 Helius Medical Technologies,&nbsp;Inc. (Nasdaq: HSDT) (&ldquo;Helius&rdquo; or the &ldquo;Company&rdquo;)
today announced that it has closed its previously announced private placement offering (the &ldquo;Offering&rdquo;) of common stock and
stapled warrants to purchase common stock (and/or pre-funded warrants to purchase shares of common stock in lieu thereof) at a purchase
price of $6.881 and stapled warrants to purchase shares of common stock with an exercise price equal to $10.134 per stapled warrant. The
stapled warrants will be exercisable for a period of three years from the date of the Offering. The transaction generated gross proceeds
of over $500 million, with an additional $750 million available to be raised upon exercise of all the stapled warrants issued in the Offering,
increasing the total potential proceeds to over $1.25 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">The Offering
was led by Pantera Capital, the first U.S. institutional asset manager focused exclusively on blockchain and a pioneer in DATs, as well
as Summer Capital, one of the earliest licensed fund managers in Asia to invest in crypto, with participation from a high-quality group
of investors including <I>Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless,
Laser Digital, HashKey Capital, and Republic Digital</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">The Company
intends to use the net proceeds of the Offering to implement a digital asset treasury strategy and acquire SOL, the native cryptocurrency
of the Solana blockchain. SOL will serve as the Company&rsquo;s primary treasury reserve asset. Solana has historically been the fastest
growing blockchain, leading the industry in transaction revenue and processing more than 3,500 transactions per second. The network is
also the most widely adopted, averaging about 3.7 million daily active wallets and surpassing 23 billion transactions year to date. SOL
is financially productive by design, offering a ~7% native staking yield, whereas assets like BTC are non-yield-bearing. The Company intends
to leverage the native yield-generating properties of Solana&rsquo;s architecture &ndash; and capture opportunities in DeFi and broader
onchain activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">In addition,
upon the closing, the Company appointed Joseph Chee (Founder and Chairman of Summer Capital and Former Head of Investment Banking, Asia
at UBS) as its Executive Chairman and Director. The Company has also appointed Cosmo Jiang (General Partner at Pantera Capital) as a board
observer and Dan Morehead (Founder and Managing Partner of Pantera Capital) as a Strategic Advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">&ldquo;We&rsquo;re
offering investors public-market exposure to Solana, which we view as the most commercially viable blockchain today. Its adoption journey
is still in its early stages. Pantera pioneered the crypto fund industry in the U.S. by launching the first bitcoin fund in 2013, which
has since delivered 1,500x returns. But at $2.3 trillion, Bitcoin&rsquo;s scale is significant. Solana, with a market cap just 6% of Bitcoin&rsquo;s,
offers compelling potential for asymmetric growth.&rdquo; said Dan Morehead, Founder and Managing Partner of Pantera Capital.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">&ldquo;HSDT
has had over $500 million of cumulative trading volume since announcement of its digital asset treasury strategy, which is the highest
trading liquidity of any Solana treasury company, &quot; said Cosmo Jiang, General Partner at Pantera Capital. Just as Michael Saylor
has done for Bitcoin with Strategy (MSTR) and Tom Lee and Mozayyx have done for Ethereum with Bitmine (BMNR), we aim to do the same with
Solana and accelerate global adoption. We're excited to embark on the next leg of our journey in maximizing shareholder value by growing
our Solana-per-share.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">&ldquo;We
are thrilled to join forces with a leadership team laser-focused on maximizing SOL per share by leveraging the most commercially viable
blockchain for decentralized finance and consumer applications,&rdquo; said Joseph Chee, Founder and Chairman of Summer Capital. &ldquo;Our
thesis is that all capital markets transactions, from tokenization to payments, are moving onto blockchain rails, and Helius aims to bridge
public markets with the Solana network, where we expect the majority of that activity to take place.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B>SOL Treasury
Strategy and Institutional Roadmap</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">In the coming
months, the Company expects to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #242424">&#9679;</FONT></TD><TD STYLE="text-align: justify">Build an initial SOL position with plans to significantly scale holdings over the next 12&ndash;24 months via a best-in-class capital
markets program, incorporating ATM sales and other proven strategies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: #242424">&#9679;</FONT></TD><TD STYLE="text-align: justify">Evaluate staking, lending and other opportunities throughout the ecosystem to generate revenue from the SOL Treasury, while maintaining
a conservative risk profile.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">The Company&rsquo;s
common stock will continue to trade on the Nasdaq Capital Market under the ticker &ldquo;<FONT STYLE="color: #242424">HSDT</FONT>&rdquo;,
with the updated treasury strategy effective immediately following the closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">The Company
will emphasize transparency and verification of holdings, strong engagement with the SOL ecosystem and community. Additional updates on
the Offering, SOL acquisitions, treasury growth, relevant stockholder approvals and governance measures are expected in the coming weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B>Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">Clear Street
served as the exclusive financial advisor and lead placement agent to the Company, and Maxim Group LLC and Tiger Securities acted as co-placement
agents to the Company. Honigman LLP served as counsel to the Company. Reed Smith LLP served as counsel to Pantera Capital. Cooley LLP
served as counsel to Summer Capital. Winston&nbsp;&amp; Strawn LLP served as counsel to Clear Street.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B><I>Securities
Disclaimers</I></B><I>:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">The information
provided in this press release is intended for informational purposes only and does not constitute investment advice, endorsement, analysis,
or recommendations with respect to any financial instruments, investments, or issuers. Investment in cryptocurrency and DeFi projects
involves substantial risk, including the risk of complete loss. This press release does not take into account the investment objectives,
financial situation, or specific needs of any particular person and each individual is urged to consult their legal and financial advisors
before making any investment decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">The offer
and sale of the securities in the Offering, including the shares of common stock underlying the pre-funded warrants, was made to institutional
accredited investors in a transaction not involving a public offering pursuant to Section&nbsp;4(a)(2)&nbsp;of the Securities Act of 1933,
as amended (the &quot;Securities Act&quot;) and/or Rule&nbsp;506(b)&nbsp;of Regulation D promulgated thereunder, and have not been registered
under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the Offering and shares of common
stock underlying the pre-funded warrants may not be offered or sold in the United States except pursuant to an effective registration
statement with the Securities and Exchange Commission (&quot;SEC&quot;) or an applicable exemption from the registration requirements
of the Securities Act and such other applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">This press
release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there
be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">The private
placement was conducted in accordance with applicable Nasdaq rules&nbsp;and was priced to satisfy the &quot;Minimum Price&quot; requirement
(as defined in the Nasdaq rules).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B>About Helius
Medical Technologies,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">Helius
Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology
platform that amplifies the brain&rsquo;s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving
the lives of people dealing with neurologic diseases. The Company&rsquo;s first commercial product is the Portable Neuromodulation Stimulator.
For more information about the PoNS&reg; or Helius Medical Technologies, visit <U>www.heliusmedical.com</U>.</P>

<P STYLE="color: Black; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B>About Pantera
Capital Management LP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">Pantera Capital
is the first institutional investment firm focused exclusively on bitcoin, other digital currencies, and companies in the blockchain tech
ecosystem. Pantera launched the first cryptocurrency fund in the United States when bitcoin was at $65 /BTC in 2013. The firm subsequently
launched the first exclusively-blockchain venture fund. In 2017, Pantera was the first firm to offer an early-stage token fund. Pantera
Bitcoin Fund has returned 153,159% in twelve years and has returned billions to its investors. Pantera manages $5.2bn across three strategies
 &ndash; passive, hedge, and venture &ndash; exclusively focused on bitcoin, other digital currencies, and companies in the blockchain
tech ecosystem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">Demonstrating
leadership in the Digital Asset Token (DAT) space, Pantera has invested in the first U.S. DATs (DFDV, CEP) and committed over $300 million
to DAT investments, making it one of the most active investors in this area. The firm&rsquo;s early and exclusive focus on blockchain
has established significant credibility on Wall Street and among mainstream investors, bridging traditional finance with the emerging
digital asset sector. Pantera&rsquo;s largest active investment is in Solana, underscoring its strong, long-term conviction in the potential
of this blockchain ecosystem.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B>About Summer
Capital Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">Summer Capital
is a prominent investment management and advisory firm with operations spanning Hong Kong, mainland China, and Southeast Asia. The firm
specializes in early-stage and growth-stage investments across &ldquo;new economy&rdquo; sectors such as fintech, blockchain infrastructure
and applications, consumer technology, and healthcare. As a crypto pioneer in Asia, Summer Capital has been one of the earliest licensed
fund managers in Asia and actively invests in crypto/blockchain sector since 2018. Most of the investment professionals at Summer Capital
have extensive investment banking and/or capital markets experience which is relevant to building out DATs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">Summer Capital
leverages longstanding relationships to access historically under-allocated institutional capital in Asia, enhancing its capital distribution
capabilities. In addition, the firm maintains a strong conviction in Solana, and will continue to strengthen the partnerships with the
Solana Foundation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B>Cautionary
Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">This press
release contains statements that constitute &ldquo;forward-looking statements&rdquo; within the meaning of the U.S. federal securities
laws. Forward-looking statements are statements other than historical facts and include, without limitation, statements regarding the
potential for and amount of additional cash proceeds from warrant exercises, the anticipated use of proceeds from the announced Offering,
<FONT STYLE="color: #242424">future stockholder approvals, </FONT>future announcements and priorities, expectations regarding management,
<FONT STYLE="color: #242424">corporate governance, </FONT>market position, business strategies, future financial and operating performance,
and other projections or statements of plans and objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; background-color: white">These
forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown
risks, uncertainties, and other factors&mdash;many of which are beyond the Company&rsquo;s control&mdash;that may cause actual results,
performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect
actual results include, among others, the Company&rsquo;s ability to execute its growth strategy; its ability to raise and deploy capital
effectively; developments in technology and the competitive landscape; the market performance of SOL; and other risks and uncertainties
described under &ldquo;Risk Factors&rdquo; in the Company&rsquo;s Annual Report on Form&nbsp;10-K filed with the SEC on March&nbsp;25,
2025, and in other subsequent filings with the SEC. These filings are available at <FONT STYLE="color: Black"><U>www.sec.gov.</U></FONT>
The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future
events, or otherwise, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><B>Twitter/X:
</B>@HeliusHSDT&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="color: #242424"><B>Website:
</B></FONT><U>https://www.helius.company/&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="color: #242424"><B>Linkedin:
</B></FONT><U>https://www.linkedin.com/company/helius-solana-company/</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media Contacts:</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helius Medical Technologies,&nbsp;Inc.</FONT></TD>
    <TD STYLE="width: 25%">Philip Trip Taylor <BR>
Gilmartin Group</TD>
    <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>investorrelations@heliusmedical.com</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pantera Capital Management LP</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>ir@panteracapital.com <BR>
press@panteracapital.com</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>hsdt-20250915.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaGLabOdzZR+mYkxtmB7bRm6fygtINL7nyh2kWz2Aa0B -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:hsdt="http://heliusmedical.com/20250915" elementFormDefault="qualified" targetNamespace="http://heliusmedical.com/20250915">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://heliusmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="hsdt-20250915_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="hsdt-20250915_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>hsdt-20250915_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>hsdt-20250915_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="hsdt-20250915.xsd#Cover" roleURI="http://heliusmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://heliusmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2526455d1_8kimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2526455d1_8kimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !_ /H# 2(  A$! Q$!_\0
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M5U4LK<LDW[OW:DM%%)D>_P"((_F*#46BBB@ HI"P'4T @\B@!:*** "BBB@
MHI"P'!-&X=.<^F#_ (4 +13=P'4X_ _X4NY<9S_GZ=: %HI 0>AI: "BBB@
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M0222SV\4D@B2\ 07&POA&<@??5J_F1(^'!8'(DZY 7D>@YY[$@8YS7\5'_!
MN>=/VP_$;--(@/PIU4&+>_ES2V]]!Y9E2,JLAB@9!$)PY1.,_+Q_:S"-J*N<
MY)!/&>$0_3OCIT]Z_J7@G.\3G^2QQV)ES2]JZ,7R\NE.G%2T?]]/79[H_P E
M_&;@W!<"\=YIDN7\RPL(TJT(2ES.GS)Q5-2^THI:/HM&W:Y%=7]G90SW%Y<P
M6MM;*S7-U<S16]M;(L?F%YYYWCBB0)@EG=5&>2!DURD?Q*^'DS(L7C?P<S.R
M*BQ^+-!G=GD*K'&L<>HNY=RXVA5.<$ X()^?_P!ND2P_LD?M!W4;R));?#/7
M;RVEB9HI8+J".)%>*2)E=2RLV222!]W'-?P>_##6=>/Q"\!+_;6NAI_&/@Z"
M20:UJ89HY-302 JLX0AP^&!4K\J@CBOLH0E4ORV=KWNTMM]_0_*D[I-;-)KY
MG^CK'*LQ<1_-L;:2> <@$,IY#*000PR#V-)),D8R^0-I<X!.%4%F)Q_= )/H
M!FLKPZSG1],<]3IFEJJDDA5&GVS8#'+-EW9B6)8DG)K0G3*QD$D,/+)P" '7
M!X((/!"Y.1@]">L/1N/5;_?;<&TMS,U3Q/H.AF$:OK>CZ0UT9EMEU74[#36N
MC;L%D^R_;KBW$X4MR4) &"<"ETKQ-X>UV2XBT?7=&U>>VVFYBTO5+'4&@SD+
MYBVD\Q3(7'S@?-\IP3BOYQ/^#@*\OXK/]GL6^HW]HEQ>>*TN$M+N:UCD\B(K
M;,RPLHW))LP0!G/.2!CC_P#@W\OKZ_\ ''QT^W:EJ-^5T#198UO[RYO5@E-P
ML<K0_:)9/++^7SQT+ 8)R-51@Z?.][.6R^S>VMO(7/'O^!_4/13'<( 6(4$X
MR03S@D# Y[$YZ<>]1&X3L6;U*K@?3!4G..I_2LBBQ29[=\$^V!UR>W%,+L!G
M:O;I(">3Z 9^OIUIHE^8H1M9U(5Q]T%<G![\Y!/3(SCG% &/XA\1Z3X5T34M
M?UNY-EI6DV5SJ%_=^6T@AMK6-99I"%#;B$8,JG[^"!TK\]M-_P""M/[">IZY
M;^'+#XRI/K-Y??V;;6">'==99[TW#6P@6Z^P?9O-$\;(8Q,7!&2""#7V#\<$
M,?P9^*DC$AT\ ^)DD4$^6_\ Q*,993N&4Y"LHR1U)Z'_ #\? K#_ (6OX1BA
M>6.*#XF0%(8Y&6-B->O)<NHR#\\8)P.0S ]JWH4Z=2E4J2OST[\BMU4N7T6C
M?_ ,'N_5_P!?U^)_HL7OB+3-+T2?Q#>W26.B6VGR:M=7]TKP0VMC':F]DGN#
M,%,*+""5W@!CA5Y(%?*$?_!0C]BZ:6WC3]H?X;O=7,BPP6_]NP+-),\@A6$(
M6&)2[A1&2&!;&.>?5/BK8:EK'P&\=:=8VTU_J&H?##4K6ST^WA,\EU<7&BA(
M84MXPC/)(\Q555@Q 1AT8'^&CP_^Q=^U2?$VC74W[-OQ/%C#K<5]/<CP)?1V
M[1OKD4DDJ7-S' L"HF5_>N?E0X0D "91O:R7F_N$?W_Z9J5EK-A9ZKIL\5UI
M^H6MO>6-W XD@NK6YB6:"XAD4D/')'(K*1VJ_7G'PGM+S2_AC\/M-OK22QOK
M#P;X;M+RRN$6*XM+B'2+19+>>.,;%FB(*N .HY).:]!\^,?>."."/0YQC\^*
MR:L[=C:/PKT_S)J*8K!BP!Y0[6]G'4#U&,8[YS[4C2!7"$_,PRHP>G3G\0<G
M/ ['.0%$E%(>_(7"ELGOC''XY[<^E1LX7;\P;*AFQCY0<\#WP&/.3\O(&: )
M:*A$T1VYF559BJL5P"1N."6('08[<^F<4>?'DC<"!T8=&]<4 3=U_P!Y?_0A
M5BJ)G7( YXW!OX=PY5#[L0 !G.3QFKH.0#Z@'CIS0!^;G_!4W_DT#Q=_V.7P
MW_\ 4SLZ_F"7H/H/Y5_3[_P5-_Y- \7?]CE\-_\ U,[.OY@EZ#Z#^5?YE?2Z
M_P"3I8#_ +(K(O\ U8<0G^IOT*O^319K_P!E_G__ *J>'!1]]?Q_FM?L1_P3
M9_Y(I^T-_NZS_P"H[#7X[C[Z_C_-:_8C_@FS_P D4_:&_P!W6?\ U'8:^4^C
MU_R6\_\ L6U__3B/LOI,?\F_K?\ 8PX:_P#5],_CVO/^/_4/^O\ U'_TYWU5
M3P2>0<CG'; _P)]."#UJU>?\?^H?]?\ J/\ Z<[ZJK=3]/Z/7[U7GR9Q*5D_
M?BK.]M825].JZ'[3PU%3R#!Q>W+-_=%6/V\_X(&*T?[8?BGNK?##6L$@D O-
M8DA3VSWQU[]!G^V&/[JGL&;/M\D8&?J>GK7\4G_! \;OVO\ Q-MQQ\,=8R>P
MQ-IXY_'BO[78QM&.N3G\E3_&OZ=\*JGM.%*3<5&V,Q"]V]GL[ZZWUL?Y4?2K
MBH>+F;4X[/!X63?6[E47H?)W[=9_XP\_:,Y.#\,/$1'7'*0<X_3\Q7\%WPRD
M1/B'\/V9@,>./"S ]PJ:E"5(P,A5Q\IZ+CC%?WI_MW?\F>?M%_\ 9+O$/_H$
M-?P+^"=1M-&\9^%=7U":2WTG1->T#5=1O([::[865O=K/.%M;=))G90%&!Z@
M^Q_5<)!-2=W]KMVO^I_-OPQ[V27W)(_T@]"95T?2QT)TW3W&%/*FRA"G@'C"
MD#_=QV%:,C*L7/ 78QX. JLI9N!T Y)K\C]+_P""R_[!5K:VEK-X_P#%4<UM
MIVGV\J+\.?%CJ)(K.&*0*YLE$BAE*"1 5.T@$E35T?\ !9W]@R1E2'XB^*26
M1X3(WPX\5JD6\G<[AK3!6-22Q)SWZX%83IVJ2U>NKVZMZ&3E?IM^I\%?\'!'
M_'E^SN<$ :AXF9L@@8:-W!.0,Y(5OJ%)YQ7#_P#!ONX7Q]\=6+81?#VE-(2>
M /M1*EL]><D$Y.<]Z\"_X*X?MJ? ?]KFV^#H^#&OZ]K<WA>]UAM475?"^M:'
M%%!<0-&+E9+VU2/RF))B);$FP@LFY<^]?\&_6]O'?Q[<84MX:T1E+8" _:F8
M%CEE"^I+8VC)(Y ZH4T\-4=W[J:6WVF[M]K7=K>1/F?U#ZC>6MO8W%U/=16]
MM:P27=S<23FWB@M8(GFFGEG S%%%$K2.P*$(K?,!D'\5/V@?^"W?[/?PI\2Z
MCX1^''AOQ!\8-8T:]O-+U:_TV0Z+X9M=1LW\IX+?4YTF>\ <,/-6%XY" 8V(
MR:\#_P""VW[9.N^$H-%_9;^'&MS:?J/BNR?5_B?-IMPL6HQ:)=#R(-)AN()G
MEMWO8KZ.0J0/-B5W4?(%;\LO^">W_!.+Q+^VGJMUKVLZ[>^#?@[X5NVTG5M0
MM;.:+4M=N_+DN;>PT6Y:TN?.ODAW27EP'5U9?G+,P(Y/9KN_N1?.^R_$_3+P
M[_P<$^'6O[4>+_V=]:T_37EG$D^D>*X)+JWA654,L@ETR(2NF2%B9PSY,:!B
MP!_:G]F?]K?X+_M5>$I/%/PH\2OJQM&1-:T'4(A9:SX>N'<QB'4HY%B?8'*J
MLJ(826"D@D5^)/Q\_P""#WAC1/A_KFO_  "\>^*;[X@:5:F_MO#/BS['<:7K
MJQ0&X>$.MM+(M[<['A#J.)0APA&1^)G[+7QZ\>?L>_M >&_&>DM=Z==:=KTG
MACQUX=NKF6WM+S1#=I%JEEK-A)(HG:WEAD-E.")%RLG"C8=J>'C.+?-).]M$
MO(/:/LOQ/[L?CDRO\%OBOL<2$^ _$I!7&6!TC(8 ?WNH[5_GV?#T8^+WA@L.
M!\283R..-;O_ %K^^WQ]XIT[Q_\ LV^+?%NB,)M)\4?#+5M8L74A0J7&B&:-
M#("ZR*74(I7(((PV>#_ GX!W'XL>&"R[2WQ&MF*YSC?K5^0-W'(Y!XY_#DPL
M?<JT];-SUZJSE+TWC8EO5^=_Q/\ 0]NM5BT?P4=<NXIVMM(\-)J=PEJ2ER]O
M8Z5%.Z6[*=RR2*KG@@E%P>%K\2H?^"\_P!778O#[_"3XE/*^K2:0\ZKIS6PF
M_M4Z<D3(3),1DFY=0"I*M(W)R?V?\8G'PB\0'T^'M\?_ "VIJ_SQ(SCXAQKU
M_P"+A2#/_<Q2'I]#BBE'VD9R>G*VDEY7[Z].@,_T*]<^)NF:#\([CXMR65^V
MAVG@Z/QG)IT,4*WIL9[)+U+?"*"9TCE5&"D=!C&./QX\(_\ !=?X&^+?%7A[
MPK;_  H^(4-YXAURS\/6]S(UJ+;S;B]B@@NBC,3^\:5=S,F\@JK9 P/T?^(I
MQ^Q'K(');X#V@QG!&/#MJ<_C7\+OP4S_ ,+E^%+8^]\0_#+$>F[6M.&/?&?Q
M]JF%)5.>3;7*IM)6^RFUOKJTA3JRAR))/F<5K?K))[>3/]%VS<2Q),$9!<HE
MT5?!D4W*B38Y7Y2T:D)@$XP>W-?//[5?[17AO]E?X/ZY\9O%&BZKKVF^'IK>
M)].T?9]LG:[FCMTC'F<,,R%U7*C/.0<D_0FG?\>EK_UYVG_HE:_+_P#X+(?\
MF,_$+_L):%_Z7PUC"/-*,;VNTKFTGRQ;73_)_P"1YK^S_P#\%E?@O^T-\6/"
M7PA\,_#;XA:;K'C&[^S6]_JXL4LK=UA,D_S+<SM^Y&"R!0H0.=P(PW[%RM"D
M<IE*P(B-)),L@CC6"%3()&=B%6(KOW<A!@GC#9_@]_X)CL$_;:^!9).(_$=X
MQP2-PET^5=N1TQG/?.,5_4I_P5G^-OBOX)?L=^.=5\)7$MEJ_B:^B\$IJ%O'
MNDL[+5[::*YF0K(CQ2^66V2AOD8Y/0YNM!4Y**;:Y8RN[=;WVZ:&-.M*<6W%
M*TFM+[*UM^]V>4?M0_\ !9']G?X >(=1\%>%]+U?XM^+-*NY=.U/3=$+6^@Z
M?=VXCDN([C4[BU*Q20QNX8QPS NJHI"LL@^1=,_X."O"OVF(:[^SQK]AIOG&
M&[GT_P 5VEQ+:PN5W36UO+8VXO;A%*MY"2C"GJH.#^,G[!_[(>H_MF?':/X:
MR>*)O#VEVFE7/B?Q;KS2Q3ZW=Z5,\:W+Q?:ED6YO9)C'$%8EA"99!A@I7]T/
M%G_! 7X07>@W!^'_ ,9OB!H?B-HX_P"SK_7;>RO]*E.U#NN;6**/RXYRZQL-
MOF@JK(P/%74HQ@TE)N^][:75UL7SOLOQ/TB_9?\ ^"AW[-/[4Z&P\$>,(M%\
M4(HN+GP?XI:+2M51%6+][&9V^SW1WLH'V65U=_EZ[L??>]>Q_0_X5_-Q^P+_
M ,$BO'OP<_:!UCQS^T1IWA37-!\%VT\7@&\TR]GN(]>GFN(5:XN;<I&]OL5'
MF1"SM&^"K)PU?T=F"Y8EA.@#$D#RSP"<@?>["L914;:W+C)RO?H?G1_P5.W?
M\,@>+\#/_%9_#<GOA?\ A,K('U  ZDXXZYK^8!1PIYR1UQC*XX('3!ROJ/R-
M?U5?\%'/ /BOXD?LK^-?#?@W2I-9UM-:\):PFG1,PFN+30O$,&JWX@5"IDF%
MG#(8HBP#R;4;"DFOY8[ZTO-.N;O3-4L+S3M6LKJ6*ZL+H+'J-D\<K1B"YM%*
M^7;EU*(Z94J,[0#Q_FM]+;+<9/Q$P6/>&Q$<'3X/R:C/%^RG["-:ECL]G4HR
MJI-*=.&(H3G&WNQJTVW[VG^G/T*\YR]>&N9Y3+&86&.?'.=XF&%E6IQQ-2C7
MRW(J5&HJ4FI.G4GAZZA+:3I5+6<=:JY+ X[9&#SZ_CC /UXYS7[#_P#!-LY^
M"?[0V,#*ZL#TYW>'K<$ _P# CGIW]*_'55)('&1SC()'0^G X['\?7]B?^";
M8Q\$?VA,G)\K5Q_WUX?AQ@8[D@9]!QSS7Q7T>J*?'34:EU_9=:6DKJSDVFU?
MKOW\NA^C?2;K0CP-[&*BV\QX;4HI;O\ MZ6^B3MMOIWU/X];_P#X_P#43SQJ
M&H@9]&U*\_H3_3BH.,#C/ [^Q&/SX^I'?%3WHS?:G_V$+P_]\WUU&?QW=/4<
MTP_>;V>4?G*Q_7BOW?$P<LUFFFO^%'%1OL^2%)\L;[\L7\*V3>B1^U\*R3R2
MDKWLI66]M4M.VG;0_<#_ (($@?\ #8/BA2>&^&NL;AGUGL"W/7D\\=.W%?VN
M+U]@#^>]U_\ 040?AGJ23_$S_P $$?\ D\+Q/_V3#6?_ $;95_;)#]T_4?\
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MB.7Q1'X-\"^,;9?$$NG+I[Z@;B*XE>-],6>81!Y)$Q&9Y53<Z^80"Q_AW\
MK\5_"ZL,,OQ&M5.%"#Y=9U '"@D!<YP>_/ %5A7?G??VC^_G?Z@S_0G\8_\
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MV"^-7P#^'WQO\,ZEX?\ ''AZWUFWDCS:7A8V^HZ;.K J]M,@5_-A<;U =D8
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M;)O3W+7D[6:VMN?MU_P00_Y/"\3_ /9,-9_]&V/^(K^V2'[I^H_] 6OXI_\
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MB,*I%!X@%M%;R/\ 9XEMHK62:21S'%-,^]%&U?@[_@GA_P %)-;_ &+KF_\
M"?B?2KWQ9\'_ !'>_:]6T>T2:ZUSPQJRM.B3:)$)HH;N /L=K95RH)#2=Z_M
M/\0Z+I6OZ#JFA:M90WND:I8SZ;J-A+"KPW5A=QF.YLWC<!?+GA9U.1A6(? 8
M C\"/VD_^"$OPZ\<:[<^*_@3X_?X4/?SWE]/X0UJSEUCPR)[F3S5-K.YDGM&
M1BY\F"1(F8A6  K;V\9TZ=*4'[BWYDT[/32UU^(I0:5UJ[[;'N&H?\%P?V*8
M?#L>KVU_\1=0U::"0R^&;#P-JUKJ,#%,>4;V8);;WZ!U*A>6VR<QO^?.@?\
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MSG! P3C/(QQ6=9:?:1VL4?E1;/)3]R -BLP#L25"([%V+&4 %B688#5KJL:
M!0BA5"C 484=%X . 23SDY)).:_IK)LEP60X"CEV AR4:48MQYJD_?Y(I^]4
ME*;VZL_S,XNXSSGCS/,5Q#GD(4\;B)2@J=.-*,:=&,Y.G!*E&,7RII-N[;N[
MZZ8NLZK::+9W^JZI=VNG:5I\:3WNH7UW%9V5I; #SKBYN9PL<"0@J226#;U^
M937/-XS\*6_AJ/QFWBC08?"8M1=KXHN=1M(M!>RN;A8 W]LO*+0K)*%\IRP,
MIP,)DUX#^W-)_P 8F_M$ O\ NU^&&N2%F\Y3&R-:%A&R%#M =)!)&Q=9 5#
MA@/YY_B;X)_:@\/?L8O^SAJ,NHM\#O!/PE\+?M'6'Q16[9_^$B\$^+-)\/3V
MWPWOTN;E;@:AH/B.]N;]_-57\F:W11Y)$=>J?,G].FN?&7X7>$+BVLO$_P 1
M/ OAJZU/3K75]/LM=\7Z)I5W=Z=>1HT5W;QW]S LML[RQQ07$<AAFW,RN"K1
MTNH?&CX466E:3K%[\2_!UCI.NQW+:+JEYXBTF/3-56Q98[MK"_DN?L%\+9BO
MF+;W4Q5B.05!/X2_&[P-X@\<?M:^ ;7P]^RYX&_:AE@_9"^'^H3>#/'6IVFD
MZ=X=L_/TE[?5+66\CFL;QU>2",V0B;;),=Y+3JK^M_$3X%^ ?$?[1/[ OPN\
M?? /P+X0\+/X-^)U[JGP6$6F>(/"VBZEY&E3_9UBCLVLIF\]VO(Y!;9M< A]
M\2"K@D[W[?UU1$ZBIVOUT7]?,_:%O$_AE/#T7B,^)=#?0)HH+F/7GO[+^Q);
M:66(07$E]#-+;)#)(T<5O*TK;FFVB/Y<-7\2_$'P5X,LK75/%?C+PWX3L+UE
M>TO=:U_3=/M[M9/WD;13W,D<<\4G5&3+.N"JDD"OP/\ %EI;?#>S_P""@/P,
M\%ZC?6OPE\&'X5:UX<\,"\O+JQ\*Z[JOB6)M:TC1[BY_>65H%4LNE*(;6(VZ
M16EJ%4JOTSI'PP\"?M)?MJ>-_!/QPT&T\<>%OA5\"/ %Q\.O 6O,FH>$H(=:
MLK%;SQ"^@2+<)-J$;3O'#<BVE\F25I=JL%(F22;2'&2G%26SV^3L?K19^*M!
MU;0CXHT[7]-O/#DMK/J2:[;7UM>:-/I]BI2ZN([R&3R8XX6S)+*W^K1')4X(
M$%IXP\*3^'1XHB\3Z%/X46!KYO$B:C9S:";<$!V34G8VY6-FC#-D%?,&0,?-
M^:7[:E[\*OV8?V6K7X+?#VU7X>Z3\6O&=A\,M&M]$_M"3^QO#GBG4TMO&^KV
MPT^WGO[5-'T9]3N8K4*76?R0(\^7M^.?A1\0O"]I^QG^VM^S;X9\2R^*-#^!
M=C./ VK7-IJMK>7_ (%UBVMKJPO FL00W[W2W"P)]JE9RX?=)MP?,<-^FSWM
M^HW)Q5UOMJKZ?,_H)L;ZTU;3X-0L+NWFL+^SAO+#4;=H+NTN;6[!^RW,#Y"2
MK(N9%! 4* 0_1AYYKGQ@^%OA349-$\3?$GP5X8U>W5#J6DZ_XLT'2M6M8F'[
MBY?3+F]6?;<KM:)8U,6P[C,K?*<K]G2U%M\!/@LI1PI^%G@,%S!*S/YGAS3I
M&$K,_P IDEN+G.64LTA!XV*/SC_X*A_L^?!?4]*^&?Q N_AEX0N_&OB/X[_#
MGP[KOB.71;.35=0T.ZU:TLIM,N;J*V,SVT]JSQF)VP>7+;P&76Z[K7S1/M:G
M=?\ @$?\C]*]1^.?P@TFRM;W4_BC\/K*SU>Q-SHCZCXJT6.SU*TM)1;3W-I>
M?;3#>*)"HF2(DJ& 5I <C?C^)'@8^&HO&;^-O"DOA&.5XO\ A(UU_3!H/FQL
MJ&*VU>XN+6TD;>0NR,R'..N0:_"7]I+X*V>F?MH^#/ 7PA_9&^&WQWT?0?V?
M#<6/PP\0ZKHOA+0M(34M4"W>IQ1WMHUK(P903)L:4F,! 22M>N>(OAMX=\3?
M&W]D3]GOXK_"7PQ\)?AI/\/_ !-XHNO@QI>H+>^$]0^)%M<32:?X4O)X(DTS
M6%N-AD11&Q"PJ4POR5B]WZO\V7OJ]WK]Y^OEG\3O 6J:3'X@TWQQX4OM&EOX
M--35(O$FE36!OKPO]AL3=P3S1M=W.-L5NHW,JL5)"XK>O_%7AK1[NST?4_$&
MD:7J%];SW-I97M[##=W-O:+&T]S#"Y65K*-"2UV8Q$%7<P4-\OY"?\%"O@M\
M-/@/^S;H=O\  KX:^'="U)OC?\.M3@\,:0L&D:?J.N?:9AIUA>S2P16FC17\
MDI24Q1PJY99>'?<WD7Q'^(W[2GC3]J#X>?\ "^/@AI7P5NK#X+?&%?#D6B>,
MK7Q.-9,7AZWW&\>VN),1Z:US)/%%*BB=]J2"08%(#]T/^$Q\*+HEKXED\3>'
MO^$>O/*CAUV?4[7^QF>X?RXH[;4=XMI9Y)2(U*/]_$8.]2M9OB7XB>!/!0M'
M\6^,/#?AR&_\G[!+K/B+2M)M]02=MD!BDO+A!-YK]!$7+M\PZU_+;!\0/B#\
M(/V3-+^!WQ+U2ZU'P+\9M=\->-?@KXT"WKQ>'M8TSQQ9:GK/@B6X^T2%+>.U
MM)+2S\T[9C=.HWR1D#]-_@M\&_AG^TQ^T_\ M.2_'KPII7CA_AX/"OACX>^%
M_%DD.LZ;X5\*/HT$SZAI^FW<-U;:;>?;)&GM=02"*YMV)C6=%4Q4 ?KE+XN\
M,QQ:7=OXCT1;77+A+'1)9+^S\K4[YFQ%::=*)6^TF4D!9(!DD#((85KZIJ=E
MH^G2W^IZC;:99V41FN;Z\NH+2Q@7>R[9M0OY;>WC&3@"20-D;57@5_/9X+BO
M-"\3> _AOI>N7NM?#CX>_MS>%M ^'=_<RWMT9-%NHXKG4])L[N24F2SL-4,T
M C!9 5V$E45%^\/V^HX?%OQ&_99^#WBZYU.P^$7Q'\?:U_PL1DGFM=-U*+38
MK"XLM'UB6-MHM;V5G5+60;)P\J F/>J[)13NK?>G^I,FTE;N?H!X5^(/@OQQ
MY]QX,\5^'?%26,WV:Y&@ZYIVLC3[P$*8[M;":<P,V_#&38$D9%(;<&%'5/BA
M\-M$UQ/"VI>//!VG>(992J^'KWQ3H%MK>^0*(@UC=723ES*>(T#,0PVAF)4?
MD]\5O 7A+]E;]J?X73_LS^%].\%7'C+X;>/#XI^'7A!H]$\.:Q:Z3IUR^C^)
MAH=I;VVF3:G!+:V+L9(UO;DR!T9T63/@OP[\-_!_PW^RGX?_ &H/'_[-%Q^T
M]XJNM7UOQ7\3?']QKVGQ^(?"-YH.KRWL-I;-KGF:@EI;1VUOC3=+E5"]Z0L3
M^?@YSW^2,^:7?\/^ ?O?+XP\+VDNK6M_XGT2QNM%MX-6UJUN-;T_S]-TEHC)
M!>:B$E(L+*XV,T4\KA74C"DN!7)^'?C'\+_%6H0:)X6^)_@CQ#J4UNZP:=H_
MB?2=2O;N4.[N(X+6YEE_=(R[W90%5&<X53C\8_'^K6.O^/\ ]N;Q%IUA+IEE
MK'[)GPK\16&D;IY?L]MKVBQ7UC93IIL<BA<NMM)+% 50K)+*5@AFV==^P;\"
M];FT'P9J>K_L1?#'X)V.J_">66P_:#T/Q/H>J^*M2U#6= 6UCU2\TBVTRSU:
M&:>.Z-XES<W,HMUDF<,@#EM%&*L]+^O_  2G4F].G^%?Y'Z_Z9\4?ASK&N2^
M'=*\>^$=6UL+,9=&L/$.DW>L0O:2K;SQBSM[V2X:)'RKLD17<"C$$YKUH.X
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MBYNY97+2,SB$J<) G.?HM]+AE5%)E")C&),,0"/E.%4%<9PQ.[)Q@8K6P!T
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MJ!#?VY/'O]% 'P/^T'_P3\\!?M!_$[2_B]>_&']H#X5^-M*\))X,CO\ X/\
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KU&.\BC!M()-4UG51%:,8L/P1]^FP@8EG16=B6=@O!8\L>O<DFKM% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 15, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 15,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HELIUS MEDICAL TECHNOLOGIES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4787690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">642 Newtown Yardley Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newtown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">944-6100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;A
    Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HSDT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2526455d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://heliusmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>hsdt-20250915.xsd</File>
    <File>hsdt-20250915_lab.xml</File>
    <File>hsdt-20250915_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2526455d1_8k.htm">tm2526455d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tm2526455d1_8kimg01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2526455d1_8k.htm": {
   "nsprefix": "hsdt",
   "nsuri": "http://heliusmedical.com/20250915",
   "dts": {
    "schema": {
     "local": [
      "hsdt-20250915.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "hsdt-20250915_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hsdt-20250915_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2526455d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://heliusmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526455d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2526455d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://heliusmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-25-091281-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-091281-xbrl.zip
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M37(1N^#^O0C9^?GQLA-\9=G%R.3MN-AD ?,*<V92P@&>N@?1+;#^+Y,(,.R
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MO24[M%VC66,6GP?:?S E@>H_(RR^+IJXI3"CDL/:,\J7]:#W#3"YO@+]D#F
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M IL;/&1W[[K &55VALJM4:O5</E&K;Z=77,HZ/J4?(<6O4)-0X=R04^S*-%
MHF!DD+,3#P4$2A1+H$="5\N1^T%9:]Z*@KYW+J#$#]"!Q$T(5SQP5/4)A:EB
M.O#U.U5=QHZLD>W&OH-:YQ:3C,,)3TQ:CB.0B>>-_.<)*)3SGSW_/@D9R2_
MN@FX\?PH'AMO;R3PXB0UE!$N: ,A&9TF[(9H.8 3J=B)C(VH[<S\=2FRV\A@
M&5)G0[00J+DAI5W31('Q/@/C?<E7*V'&=8R&&U*!";X4]B/"2Q!H>U"-( U3
MW29]<.%46QCE3N-\2C?%4^EP&]DOR>@Z25J\^^?&IM;K0GA.R6,*RQ$Q)HQ!
M0Z5,:+LY%R0I?";C\VB2ZPYSU&.0T5N7+3%RXW<*1YE&PF_:\O64^Y8#&CCB
M /N8&'LA %L49,T)R#:JZ\=2LDDJBA5K=Z5P7VD<82E++XX"E;%T$"W=4#;_
M5'>OO6BZ>8;N^U3X@L9XE!]*O(,P!-2Y8AZH@Z-L4AG.VQJH]!DV"PU4>Z7H
M:I"L7B0,(+[()QC2(<JR%U.;QRJM1MK!MV75Q80<$ARN+(\4@;PZ?HC-C"A6
MIMH/9%59U*8AKQ^-C$<I'6-J4Y+GUI'G>&\+^:@"XE-NGK%LB@6U;Z?K7(6,
ML&*6CG0]FCZ^37Y4H&H(D9%U+?E-]RXN+HYJ.*/*F?IOFB'B7BNQME_H))77
M>D55N683L5A=- D2U3*U:EPPF[.8D2F$3-49+313B1==VA>!^(^<3VUF1U<%
MY;'8F&\:Z<"J;EJ0LO3C]&K4%$3G:,\F/@J"<N9*5%%_@:B4'\"NUYBNCT_U
M)M %J 9EI/.*9/3>(R_.RTF#IZ68+.*-FO]D&2-9.PWTHFB+B 6E0_+@8MJ(
M:S1S:T&R== 4.$T69Z;[%N1VQ:(R1^6GTI5]=)$0P$&F-GE5;P.J85L,]JAZ
MT@=N.Q*\.!"5V0XX# V5VP#G!G-.R(W7#O^):TU6)NM:_R3K?N%D75X!WWQI
M3MW(*SCK3S 0&16;B;S@94)WY5AYV2*TR)9K%MA]A@PXK##O?DZ^*TX/=#(&
M9UPE]2LD"5JK+^JIB^9XN+X.T1=:X<J'T!> D$SS?8WEEE9V >/9S'R"3(.4
MA&BIR<^R)K_Q=).?M&$$ ?ZG 'B$'Y":([JX%\\5*4!E/V5*/V5.)DJ,2H6=
M4P-4[$2NDD>Y(FBE;YI3Y)/K3!8ZGHLNIO'Z95"<\FW*A)ED-,#!$;X:155P
MI))N2 HRC;:/XA[;@0$.SNP HUN?!?=?7Z8VU2BZG.D4?<%UC+FI!!J&2\E8
M3'>06LAUI2Y9JK$7<FSD?F4SD7F69CJ!%J4J#7S!N1=([XU$:;[9O22!*N67
M,H'3MCR?A$//IVS!4K,^[:-A$>\8?^[4:N6:_+]ZOBS%-XD7M8PL\$M$"15B
MHQRQ#*/"<0#O [BOB[ER5&)C,6^NS]/(\48>?QHL>QJ+YY F2[JBV5'K1J$*
M8]U[]]F:?8$GI:I^Z297?!--_1%5$_,L94;R1]<")+XW%B@WU5VR8*)D*;#,
M?,?U3=&FM6+(9LA1.^04 *M&\55V%)FU.64*\5Z6Z9MF<3'INA'-5\416MUL
M5VOU:K+,ZNSD]2F-564QZ>8!!C9/QL".+QPAKYR[8+^9.CZD(I3*%#8%&$M(
M1YDVJ)A,G&'%!'[WK[;D:\G@ZH(9D%/<!#6O]2EY4M*(76R FB'J-,3+*'EW
MMY"47Q>)WI)I*M^FA)1)DEB7>"+=9G=IR%V654H\!RW]B>_:P5 Q,,K*L@I3
MJ0NQ%EJHEM*&2J218"U*6Z5?ZK.C0Y0K7NM5V"PQ.3BNS$K=_$Q$T_!!?0,D
MNOT'BCN00)4-U].M&%154HS->+/%][64JX(7-H$T"V_T>NF7WM/E;'T)%+/-
M,R)>9V[$N4-TD- , S&=7D_66:@E?U)Z72=ZU_XG>O<+1^\.[,,SS\<X?.7<
M\ZC HZN[P+V^@-%MCM&#+[CCMDLI&MJGH_89=;L+#)4K0=X?">XF<BK7ZN4$
M"4%Q'K='O!$4(HCDX6X[&8.)%UC5P@@DBZVR#_'5+UUZNI ZRMX@5-V3,$]4
MN$6J/TH(7-\.[G7AI&KB)B\^HM0UO8EC&2;'JY/<##&7)YNIDQ-OV:CBV4B]
MU@F=6VE@(+J%%0T-ACB-UD>Z[;W4\^276#J> EOJ3ZAH;QRWJJFRS@AGQ$+_
M/I<!.8(.8VA<&MX9X%"[3$+3&XGHVD29]28A;1[AT)<-0V]/VB)>B$$@K%&#
M\Y"GJ%J5QA:-ODLI2Q)MTXAO@.W+)*.ZN)@I4*;7CU I*@:6YBKQ*\@+B5)R
M>+TR23/Y!TZJ*N_(R? "Z\D6#T)%P-3[ 'L =1^7"F77D/U<NNMSVT&\T\U%
MK.O3U9F1Q^+,5SY)VS, - >KF@DC@%33'DL]K ')S5).9&XN,D8)6BQAVD^<
M0!&Q+E3P9,,(1[)N..\N7;U6^1 E6JGP6.+M!.SDV/INULGZ;A7<([_@/KY8
M.Q7(T39;'CQX@Y44:ZCL@B U9980@LE84X)#2&":$3+@K+HT*(<7OZ&, JJ!
M6"(BT<CA]ZIM;W26U(9<TE=<*J_IGR)>W*9KD\ </4=+38KGT*-AWJI&O&HY
M>O\M%;U*/L?%\266"1NPK.4'5KWA8TD[,VG!)6]9.7SZDYIE:[1_!N&LRR-U
M:E[U7B'_+'[+"+8'C^Y$J:SXDF-6VE+762PZ7JHDE-(CB' PN2<^M?I#K2)X
M?KQ04;N1IO8X(PYB?3J=5L'<KPZ\A[*Z$X 4-)%OA) $%XC54D$F!Y9LT7:-
MO.!(,8'KNW:69TY4]C%#ZN10A/Q>R%O:>:1.MPCPE:OZ16&TG02MIYI)1XB+
M%$7<#XRI]UJA9K258,C!0UJ88/..R#T!E='S'D3B+,M&0A7&Y=H1LB-M/J#"
M)3AY$/J95]E$E<5%!_.JF T,XTM/*BL\NRZX-:8M-?*K,XLO/3>FX@S9NTH%
M"MVY)7M;'0]9UA 'T5NIXAY/Q*=! CFJ!B8:UIO,%QJ7$P>$LC8P[@(=N_AD
M!*#1B-T\]"72=2;1?OY7^#L \U)'6V0PECQR JR< =F75U6G1.(]+- !Y8 4
MKN-?% K)]@U3"45EQ,9!A<R%S:BS%2Z?A.PG98@XI+J+H:FSZ 71W80W02_N
MD13S<D'6D'2#"806@'4.@NQMJ5:BO\=82:;^?O22B;<R1R];-O&-C>- [#']
M6PG=^X/0U_,_8##>Y([FKM ;EU0$(+0*PB*];%A$+;WS6]ZKP_4+L5> O_BN
M>7D0!SU_\]"X]*K1^[-#:P% A;@XWH$Q$ 55X[<8_SF/KMI;CNB)IMZM/>N.
M3^+4?W*S\,-_S*GE[789!G*%:V+\H]<_X&P(JA1F'C7:C:U6NVW5OXA9LU*O
M#L/1<V(,LT(1JOCA]VWYQX&]+)NW- <-'ZSYTN4L5GX5(@(']]F/@SK5O#09
MO03@L3L,A%'0K\>B<$5^@G:G'-W:+.C1%/D$YZJE%%U5ZJM[2I1D??,+DUKC
M!4BM\0,H[=GA3E%:82WF+TP)S1>@A.8/H(1GAWMY ;.4-@7)_OB*>"+(@ (F
MT>"A^JO2T.ZNDO]ZE@HX5!58'-\MM:<=U><\*<RHOS2%_?A=75.AQ8TLM%A!
M<*^?EIY1W+3R'*C'T\'S&<'XUEO*RVNS%5MNRWJR$QYR<-'!3=[ 8[4L$=W\
M0MG1<1VP0-BG=S?G4?CR3:[+M$G.]N&+Q:">.43QP\L@MOXI@_CURB DBBG@
MU>W\?GET>W=S^LIJ!M6'-K4DV,,[E+:[V#<Y^1(*?1%W9657,N8)4U'S!6RG
M1(4!EHPFRZR_*C/#GDDRST@Y;C'D3E\W4*7PJ!H@.]Z%GD'3Q67(+Q00?3UA
MQ.<,D8&ZWUNI[I/*#"#&3]^6&L^IO("UWI^>=^ZZ[.+TI'-\=,YN3X_?7UZ=
M7_W>.>WJ0,SEL:K5?7HP3P]2Q]*N+8]FZF%KC6IEACV+>?1\.'XWWUL6\UT>
MN'W6P[8/-X--]H?H]WTQ9]TJN^ @)K"C*)-9LV<.UCX?Z)=\)'*Q^(QKY.'E
M)T;)K1TZ+XZ38T!#/Y%D4JTYR_JEOZI!77P)Y/5;KT49YY4VZ/8^NY+O5MUC
MYSP(7Y=)^D(&XCHGEEBZ*P!<8G8VLV;[K'-"OWRI[;P#+ST4;D Q782-'A-_
MS,Z^6J<?IE^/+FYZNX/-V<G6^;GWGW?6Z.OGEM?ZZ^/TYM/6Y/PNG//[__2L
MZV"T&5X&'S_6!IW==MOL=/^R/S9"JV->MO_SY\UT=OYM[)Q>>#L=?M$&B_S^
MSUGSHC^T6F?UWFSG6ZO5G[\[_G3_^W7OZG/7=6?3T;M=_CET3J[.[#.[[9J#
M]LW9]>2O[=JGCUO3T5^C^?;-U8?:M[L/_-3]X R_WK5GE\U6Z]OX\T7=JGVT
M[CXT1O?3B]KM1[/]<;-S\<<?4^\/:^OTOSO!7V?W]B!P/@ZLP?3ZYN&AZTS>
MCVUSZ/=.&N8G?K\YJ^\<?11W7:_U5F)DL^=9<_QW&(Z<P_\/4$L#!!0    (
M *6#,EOJ(%;)?D0  'M&   7    =&TR-3(V-#4U9#%?.&MI;6<P,2YJ<&?,
MN7=44]'_+1@$I#?I-4B5+KT31.D"T@4$E")-.@A(B=*E%P'I2N^A(S7T(DU
M0#JA=Q)J@)"\?-^;^<U:,_/6>FO>/W.SLI*;>^XYV>?S^>S/W@GF'V8=0*FE
MIJD&P,'! ;S%/@"8)<#S_YS];QW_F>1_=PX<3#> BA  !MSBXG  'E#AX%+A
M8/H!0   !_]_# #\'P?. UP\_(<$A$3$)-@!392 !SBXN _P</'Q\?"P5X.Q
MUP%X5/B/'HL^>TBM_XZ PY-&[$OR3T).E;H>6H,I.)>XC5<H$3$=/0,C$S</
M[Q,^?@E)*6D96;GG+U35U#4TM0R-C$U,7YN9V]K9OW=P='+V]O']Z.<?\"DL
M/"(R*OIK3$KJM[3TC.^9606%1<4EI67E%?4-C4W-+;]:VWK[^@<&AX9'?D_/
M_)V=F_^WL C;V-S:WMG=VS] G)U?7%Y=(V]N_X,+!X#[7]#_7W%187$]P,/#
MQ2/X#RZ<!W[_&4"%A_]8].&C9_H$[SRI.<2^$-*H)/^LZR'B%#> T]IX31'3
M<4G N!'_@?;?D?VO 0O]_X3LOX#]7[@6 :2X.-C@X5(!0 #TC:0L3R090B.Y
MUC%RAQ$WL()-\7R(0!$N9Q0X8D+KWECBS_S1@7>)6'.R#&\W04V<IY2#N['J
MB/BK4 ^Y\DW<[PIZ7D!=;]P#;5+2/!<8:#'Q:AGI>:?DU")G/NZ^ 6*==!+;
MSZ.M;8VQ0 J3RMODO\(ILO G/2HZ5<UWE,?]U0W_%?55+(^QUVAPY_N8)+%/
MN5'5_FP.IS3#3*I!N -74_K7QIG]YKQ\<OA$0/_-*I ?MDS[(<0S-E?&L.>O
M#LR8;U;?M]3@=Y:IJYF.KI1.I3D&H!IDBMQ=SP]#,[<B@ D=FJ6.S<V5/2F.
MLSO)7U\7-#5G%J8$L+RE!22?LP$>=KG?IX!=A/2N?OSMXG">,VF1LX[P(?/6
MF_(1D,\6P,L[6-40DCX .R;PM(JNM(_(5;60EB7$9!M_3-P5V-0;RH\&LRFH
M8P!$>OVL!E=JU!,^%!2#(_<9L';)W%4&KE#.V-'P^&AQ!>T&Q6>0>2B22V%X
MD6" $/UB,OJBW^8S1VVB=J/7#P] /'Q)G?"W>"C-_#F0"+F#/.UW9J0S%GSY
ME(9OX^EY2JZ 39I62@ZW]L+22DF&8&>A&P9 4@\J\U_;VS?L@Y!Z!AEG&X4C
M0V7&N"K><?)-Y!+]+:7G-UK.^3E*R].X4&WP4>]J8E53@[GH/5[>TX=J1&RH
MS>2A2VG:?VX \E;920* ;>);BLW7",8D(F6@ V"[8>3#.E7"@@P7&W(+-_?U
MB/URA09OB^PP'IOG7ZK#2T6]RS3FLK+Q<J.U3->=E$\'8$[#\N/YIJTT2;\3
MW>7%:B56)G.?NV;N<^ 46!Q-$Y"X!\W$ (C=.5.J  <>,L!<VM:R4]%[^G,0
M3/T[.O8F'UXRI4S^?QOM2@/X__^81U)J*NM),KRMN-,E%??S]]L8P)^(US\H
M(D'K/Z#40?;P[*OW"(<X!8IR]6+_2*' 7B8%IEAE8:[FQOF.Y^Y%!X\L*L7"
MVRPTMZ5FJ._*0W_ATJ+*#SXU5]8X2YL/M@;[5AU<GVD*_ZQV]F9>,4#I[FBF
M'&SX^KVM&K.Q]QC3?1/JC\[& -;+H6>.;,(80-TH#(HN^>B+ZB&/S5,?39)+
M'@2_Q "T,  I=$9 EP,&0(5+]$V=.;HXPQ@F6$AK2*96M:]F?+CI'>/[?IDK
MMYB4&W_41=C4_6O^?N*?H<AZ!;W(A03?Z%&/RP;G-R[9;\O?T[(7QQ9']&ZW
M"IG3.,VYY%%%O+0,D-?TEBV9W<@4_.,:,4,8^L*>XA'_L'ACF:"NS*#HQ"?O
M.:@7:#WIS+8OG]KAV^>P_O0?[92%O.IQX5SYWRJ>==1M[C .$D+Z,C+M%@EE
MMX35%;\.Z7J V/*:;C$ # !OLSUE?CUJ*(RF_IDO[6#9U#BUA#M+6)_VUN]B
M0G[$5]%?0=U4"<I#(\',HGFC_6]H*E12$NAQS(OIB5^%WQ=+;10;>%Y7M%NA
M[CJM2I>"^1V-^OT#]43Z9O*E1,3[2D6<A,W,U/CWFR%^-&LF\YEW>PT*7[?Y
M11->F!CNJ/5R#7/5F?(??DF:HB=@ZY0P>:]J;-GM^HI008KV5<X#"N-!.41>
M)#0^_Q\(32*^Z1YFWIG8N[;(?VZ(@/0V0].'GB'R;U4Q@!@%3@6_>E7)DE*%
M^J)/)>'IVVXVH4LA-<FXNUK_?-T/76"0 ?<'0>;PO+1-=P R5@LA'>6[9-<V
M?4G&CV;^[A"CL9G$QR]*.OQ&L'EZQS'?:SQC C2CD*TXVB!IDM]LA#"R%MSO
MQ #ZTZJ+9R?/G\>B%#<2B%_[[YKYE"NH\DU(&C92ARZ4[>7.3!55-4+U=.^>
M7PNJ ^+R=O$_7=Z#1$W26IY\L.64D?P>7I_RC"Q)A3I%/*[RHZ"<P\D6[F=R
M%Q6A)2,QFNYNO-3DGM/\-DW6@,T9WM5MS_E%_ACS@;*R!5=7Z7G(,))?DM,@
MRSGHS-18L'J4:ZW]VEE;E2:3#0.(YKR)(5,MB'D"*$BJ9=4!A W_P/_O9__C
M$Q9J-=A,SNU;#" "($2STNTK@Z) &IR\<0#M[L]]IHM1?K;GY CXKQNPSQ/H
MJ0@ZG'_ ]/]\ PAQQ0!Z#,%;?Q0L,0#;C#[P_<NCPYM0J[ ]4!I8#PHW6KN1
MH* '_]N&KV$ AO)RZ+<9/VXIMJUW3*</T;KIN.CAJE@,P(1%!5P.58'<2)A!
M[C-N, !TA;_'*_)+^[O1%/$9 F+US1SRICL@-B^7I$K7$X>.?P^JNAI/<#[/
M0;[G4'Z_&Y:$LWYU"1G"N8Z" C]SHL#/5J'OL$6:_1PM6'I,M$1412XZH2!+
MN)N(_K6?=2-2N @^'%N[UQ: H#(A\\\/NU+K?!7D-:WS*;+L9T([,^[>\\LX
MFWX$T_K+C-Z\.U5D1 5:;ON2Z7/ZQ9M?Z_<NI;V0]Y5O-K9+W?:=)$UXJG8T
MOPBMPP".UQ"E5U((X_3R]6 #5],>:LLAWJ\AK-;+C7FLLZY%-C.:[UPX:*<A
M\^-^B<,"@"SN)&].AXW*'G1^&>7#D+6R._"8U@6%5=B72X[*UM]/NY<U =X)
M1D#(*CONH+CUU+^@><:,G?'G5#PP[B>!U7?[O#174PN'UZ<.M^3RX?5L(NL'
MK]\< NHJS%P5:"7YGM2$!$CSY,4NE)32S=4OCEN"?V  1^_N@H+H[^N#F!83
M^\9MW6,E1IDM\A\A>0XTLONM&-,V(]P*VYYQI4RZTZ00IL#QZ)E)8(S#P&!S
M:.8C)18Z @[=5IP MK"\P$</9<?!M$"X<NNNWA)%_X<9C<\HOMEGL8$WWMKN
MP03I]AJ_JR*?,.*I>&Q3QZ$ZP"Y/X\LJ<[:2]!AAE/?RFZ5ZG]#%ZSFGU/E;
M=4,V]N,BSGL#9V?[NCE&C> U/<N\/0R &_5^?9G^ 6+5*64;-4I".%U-J/5F
M(E_,T^AOUW2,N5*LVDJ-JB_8P9[TFC[CJ?F2A8#D^.S8E,62!<?0#GU>P*I,
M@?)W[MQ9M0!VNWD^8#\D*E5,T$H:[BU>SR\8(OC'X6, <95GE>>!\/;RKT5:
M70]E&?;\? S +5D05*]^3.#+/)QB$20^[RY4_#6+[VU;J$RR%1^'O:]@U0)7
M"L'*D"2*#?5TSG<30=*M?=]4$YD_J$0>JOFPJ3S2<>OO'PWB*ABA!_*M$>3W
MCP2!HY]$1E"A7$A@8_,:^/E9T4FJA4363?[>(4NEJ"=PO*XYQ9^ G?)W &D1
MY7/2L'_3FF)J8C>X3MZ?=6F?O><%K@!2]QZZ"/15[:K/L%S*O4^O*$JA5<O_
M\(\4RTD?;5ZG<^5D_<D5JTO2)%6H]R#$F2<()52@;)5E4"0ZI%#;G'6_7O)P
M%1H;-^R_)8]\Q]354KA/YO/>PG[65YY,LB:^'3_U".KVJX4Z0FA$19F!]T'&
M?ZBP:4&88^IRA=DT;\FI-59[5M#W89@LR8Y0T3G-\)N@]: UOAX9R"XUFOQ!
M!S1F\BJ0[C;^ON"-E7^U\*/I$Y?76V<< A_&:NOC1WC&*!]Z3V@P;&(K<FWT
M\! #8 GRN?M87+:6]D?"S-;B;C1[-M30H^[WG_L",X5ZM+6"C^!#HN%9_;#2
MB>N&]-&CU<6EX3>(4R3PKR+-D,=GNL?/9$;PSD.5NW?K9/>'.E^X4=>]O^3_
M!7Q)RRMS -8:+AC@"?3K4?K'ZA7H^5*XV\'Y:I^=%[N#(5VY3@76WW\RF_V-
M\+Q^]B:'#;5%/<,ILTN#D[@!I-I7HIV2% );M$J9FZ3:>Y=9K]RXLD<NSDFF
M.Q&^6HI6(ZT(01.R"IPOZ6  H8WHWD]YK>ZP48JX<J6&@.#[;->W>:SS9@Z=
MTF0?V"T@M<'9X]2#P[;4]'AVH8225Q1#>*(H1F0YYR-6!=P-N^1G2A;8SE'(
M:"\?:9A45<CER_L3 P !']1BV1@"8_@98!M#\36))E*6T=9&\G#$ZT",8I*!
M%S=IC,)Y-4+.E\^H7.!\!LK18BQLK5H(AI.RG<YB -;S&^""@=/HQG&1%_G]
MTBV:M@463F?.\Z;76O#G+K:LY9TI@6%/#8D%V=-6 ;815AJT9^%@^*O$?VU.
MKIMZBT!8^\J;X=H>]_OV!^-<D^P1[PA?VQB<T*AIO+5@V,TW0E:^*W<!XG3X
MEKY>T@&7.0-))04L%)56J14R3.F9GFB\T_;O%1_A'#,V?BV*P^#S%AR92($>
M6&O21$C%^TH?+2$47O=5#P0K#L.Y+SX>,Q\F:W*5>WNSD#PHL =_VMU^'LX%
MX-'OK,K(O@L'@V_?%]M7_3,[:/N L'2ZC:CNW(Y?)N<*/9C;X<XBB;8S>#[$
MY27 QUIQ'S#4&Z@]+@)+[#N6NIW69CZD>(ATFS[[#:,3B-6.]HE535GUWV2F
M<XSF7R<O3-%U^1.$'%J5X0Q5)/=,G(P9J93_*)78VPD:RXJQJ;7I9GMU[.[
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M(FT^#NP*3#0O7BW!)K@25].?ZES"Y(+&*1\7M03!G8?"B>)/_NVH,!32&>.
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M>L;G+K I]3JYT7!YA,5[@-?(;E1NO2)%&8(U>'3F%D'26*8(_8PBA5L5!KO
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MW:F^F=]+QO-[[MH060B__3UI6B<MQWF@Q#]EV_"W6HB;;F9YT2JXL<^_0*7
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M)BCP%B\B0_HV0+WNC_;0](BN0MB2MJ.K[9_+:FT#>!?4-J#D6UQ##ULFSNI
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M'EJQ?']C-E"FU/KC\.K<3%-*IW=QT6RUOHQR;2EU"#JE#,1%_P'#]29Q0OZ
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M8_AGVZCA(,WJ2:7PZS%<X#R/<OA*M)N=9 W<WYVVJE0QN0"A%[W;.MJ*=N%
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M\K<Z*E2C=XFP842>!"<@PQ=S7#HQ%?_PW!,LQ2^K"R_>>\</-1ZW_N-,QY5
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MZ:X_4PS42 M#TY@)*^F<O@OF86!=D YP'R0V!#7; *L"+6JLXKL .6'V0P<
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M8OMBZX%0L)I/&JV;79$M9QCA":$$?,!Z)66$^$]8_'FN4@3^XZ3Q^UC%0[
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M\@N>2*S!!Q966=KG6H-+I\APB-PR&(V!DJ.D#C$0$[FZM/53BS_"U&!2H*=
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MU;RL1&&;WX,Z+?"X8T_+*=%N$@DBAIX)N1XZ(];/!DFIBEJBLJ#JP3:I$M.
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MZ@0LL<H^N$098<,@Y_W"C,70[M[W:TZH0E?+\0FT3H(P;ZN/B"3U.#;,,_7
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M;B0UBV$D[".ZP+':)!8_>X-EF;6O4W=\/V_!8B>R$RGR/(6TL2X]ND:,!B#
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MIR37E'7VZEYZB'3>PFD4'VO.O,3!UG"R+RN<*E[IOVG*HT$69H27I\[=1!"
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M)%8Z5/Z?JAQ1ZIP+IG 7**J]CQBGX>@L;B]1B\R2#$:R ?YX@X<</C$'9\4
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MEL79"*$JH@@1R8*<D]I<D43?9$%(TT?O!G77C'[Q.ZV0:R21[$-A DXJ#2#
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M9Z?OW]&J3M[\U\F[UV]AG6?1R3\_OJ5_O7CP^\M=6N;GKFGSZ5(^S,M,X:!
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M75GL& O9A(/ #OQQH6J5N!L ]W:,W@,*QS\\*J??]-C%!*ZR6L RVXNDC2Y
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M?1Z] YV93^1=A3M^Y/[H@?X5?C/V]D?!VRD4XT_YP=E'_!_<<_@OG.; P4Z
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M74+0Z[J$Z2)#C;S2.I^1BNOW^0Z"7Q=)YFH7;#?3?#08Q&#QK;8(H\L$P1=
MI^'&\-MZD=>+01P]O M"W$00XNCA711B6V[*+J7'_(P)8J(+-5JT]704AST/
MF'RA OY(RRG=<G<@Q700:&%_KV]3)ZET1G#GX$DA?D*ZHI5^<PSL'T-95S7P
MENI/7B'W%^NU-Z.&#=T$U.H\J7.%G6[9F'X[B(B,SH^2M%R+N.KVI7!-K*9#
MXU4%H(S:F/#<G;H92#@]C)X'\XO"Z6G %4S#:W16"A@+6=?2\WXO"TK\X,SJ
M0ITGA8$RT&KV)CO#NNYB8.V4 ,FG<)YCX27W,:YJW5 Q;*(6CHP%G@QKK;7>
M%)DRII8CZ4Z*/-5GFI0Z1Q'-H?F\3F  ;"-NSHJ277";=7\5Q+RH6S?%F/0
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M]WTZ7&3'&TX:<CS>'G)DMRG26EXLR8$L?;,3QQV\QJ&ZU#R5G&H7&D+;Y8R
M86(%TDUT;2,9 3\HSN$@(_;@.AP[Z[90S*.;I1@.S:QF09OJ5ZYRX\<;I&8P
M+%<) E9!1C%C]VMUP^-Y01GU$ >F>,HMH97'6\1=5D25K']TY(@=Q\U(Y%&[
M4<4GI;L^U>H</;;HC#(^F6;0"G%"6QXQ;TS+G =$VK<R,$B<>D\#WB+E=9NT
M5^PTLJA2*IJ_3/(%KA%;%)4(=GDAJBQ\H!*D+@-H]Y>/F]-KD"E2%%.*T%LP
MMCIC6^F8%<XHGTT0=H*]NNH+V*C6\SV4H^5X^+B^Q[3K^#-G)ZC+^F:([X#U
M/4D>QG:#&[5"Z2((TU?.!IGB!X,P8#-O9-7&S>FE0<"M<ZZ5WF&1_X)!Q5YF
MA@G38Q@/+JJMC>^%93:@I7_L^O8Q8PE>0-Y_IQ)<F,'^'H51G)"061?5<U6Z
MKZ(RARI3CB7>4RSEE.0OSL-+F@M;L<6 T3Q3=*&K]EXUG8HKV9PE5KF65&FN
MNW)@_%FE';4(K$H7?67%_MPF5G+#O 2![&UIX'4( 0:5$3G0: ''6*A?,,Q@
M^-+2R=; ?(:B:EAS=HOJ.-BSQ( %U8$8I#F'OPS62 L2GIF(UNB%5V#0A[@%
MKXH3BHS23#$<>"W9 OT&?-[ PVE#I]B;5+:5FZX*Q4OP<OUMYM+P*_>9&T 0
MU(ACB 3995X@J+G(IZTQL^U9! @_%O7747\]S75$5?VKU+3%UWS-6,ZCNUC.
MC<1R'MW%<K;EIFPJ$!<W*P]/4*/]2OB,ORP],3J!V,CXXJ*@B1 ".8A%JG!?
M;<'[/'G0N!2]FO+-Z0ED AC'0#%G R=NSXU."C(D%4?S]5E2S%$/18@X^\.J
M]MJ71JJN$;B.$C6E0*2QCQ\&64!F<5O,^'>ITNFL$MW.R1MRE0&=#ML8P]VF
MRY)0-XFSMG/B4'XMZ@MN8IBDY,8&-$H@ 0E,J@==V*]]%1";9&@F9 H&2:SB
M&IDE7_)9-]/+E=?0#Y!#FOZC^WO:.\NU5GU@+(,5IR<M.AY#@_<FY>(^FM<%
MD!M]Y!':DA3,H0J,.3TC+D6.K]:M7#=28_/]>PE/W/E;#I[R"@TH/6>?5U0.
M!Y,0L,=$+-MQ.]D_,6I'+EOH9F0/4@KR,])3!T[]G.#FN?FH,Q]K!@JZ-A]J
MT.W(<[0/534+C1AU>:#CE%^_@_W"'2P]WC+3TE4?_0">0FL3JQ@N!9.<3 4<
M%4XT><V]>0V*"I<\2(,+F2+Y'1 ^TD.6] !'''-&&RML)*FF*ZP5[02A1]:-
MJ>J->=ZNSG=IZ(ZR(+)RW]JR?7(PCX[#]K:,(UB29+O+Q$WF/1SJO%A>-2>O
M,[+7Z!P1/2N$C(0)*8-72JW>]?VX+8)EBTKTKE1$AAB8Y]8.RA$"2'TG$KHJ
M:6)_;S1KPB!,  %TJ9L^3*XFU]N.EX=ZDA5+[1/+\$:MKQ""<$$?&M=4./"N
M+IL(<"DX=532>K54<L$=*:O%\3@<XF)61ZNYDY0;K=XD.7O@&"@)B-4_*I?,
M&T(YQK6N?RRK=N7K%%J??%!_#B->CC.$M2$?E=CSY%2705F5!XAD^9_AZX-]
MRPD)=H#'BUK#A<4A,O,U'4X<GLYXN=::9W1+..9-EWUZ;E8=K!6/H-O'2/.(
M\;:@GK(Q4<8/:N&>K0+,DM,VP$X015TK@!P3K*9>@,5EQCH8,')CZ":F25WG
M"([F_)!FIKZH%,,3";D^$57.:JD$]V4ND=P0#R6 8@*B$/%$726;Q\Z=KF"Z
MC16#!6$1CCN:DLY>?E!H4E,J7M/EK0.UY;YSQXG?*89[NKW%<&\ZC40'A^F6
MFYO+LW%QD9"VZUT PCT'BFV'H#%L!/ @T=$_;. J]?C2>@<+-6Q1OKZO01V*
M]*#-:]=8 (I"8M2>$-2>S\'H=KPL9!>2$>4&VNP/*7L5YIV"A@)Z_TS5YVBG
M8ILO] 4;I<2V]>'+3EY^KTB:/I2BKJ[!ZE3V"C5@[82F^6$<'4SLAE#L,2\[
MNC6)>/B]>W]1D0J5JJ0QQ=:#R--] [O7<\=/L/&2^3!,FQID2^JU:X#N&=O=
M9V2^OF411^951^/Q><01GAO\)U,+> ]>/.8SYMPR!+%N&%!!G%HT.:ZMKQ6B
M/2AJI;?8ZD+:-8,7C^^"%S<2O'A\%[S8EINRH93]87NE["<L$Q2'G"M;]_=.
M3>8@USZ($W\4",8T2]2=.02]!I0^XH.4JN)*2M^W"5(B:9L*I_/,REO*F*.!
M8'XQ<U1T'7I25S(%M/]R)CU-5T[6$;(Z-\[-AE$)N99J)Z43S"&WLJ,_)(I!
M>;4QU^WN;;(U AXK*([28$__:G]O[&>'+CZC*6CF,EQN4X-*! A2AH#1]0W:
MS\8[YRDS5\":D/I1))?/K3X0K-JGF:!E#0&7S'KVB:>B8S$M/$1*A5?FSBI5
M)>YAS\\O&0_:LSM>'OS<UQE&5EN!'B"'LAH*"0L(>EE65Y%5]'=1%<41UB>K
M46(\=)%80<OIX,"P,+K1NS^\X<!"\ZETZQ92VV+59T.&_N/V,O13#Y[)9^DG
MY-V<Y.<=AU]\=WH/E5Y[1Z7O,/JHD@5KX($6[;:;0E\^&UA>]"VPTP0N9RQZ
M'@ GK>TG#=9@)K(>'QLLUUDU3R<.+R#!_;:IPYQ NW6\D@ZL_QO%Z="P'$/1
M%:]-,D5=&]T-"_;0!^>X5>"$SIW\:7OOY%L+D7;7*^=OS7JWUP\5AQPYFRW9
M%/''+0'($B.N-ISP#=9_-V,UR4N<!/VIDIZ1.!+K4-1!.,,\9@Y-(#"VGXC0
MJ'HA0=@5?H]XS/$1:P^298(K:LD)2K!6Q=)XJ?IX-S@A ;FT_AMOIE\SSQUG
M)]L#'N"W]2'-2WJCD*8,!U8K"]ODE=\'KL<PX(>/Z/IV:3XNX(D"J"@7J.G0
M.:\RC%V2LY[ BLPK^6)1.((:#@+UD'Q)BMB %))J,*,>IO&U3-$-\@_+5399
M\R$Y;F?NW?TQY )[G9X[LEQ:?,0&92\T@1-NVVIZ/(EZ-.4VGHF#E+\91-<Z
M*(>X.SH <P6F88@9)D9!PFYA(C6V$*E5$C>QE*XE64[^3BKR2"3&9!%^&M%C
MW$8[NE/.;C,'JVL</]Q>7>.W*@N4[#^P^JOV B?O*H=*XVCF_(9.54.1#7MY
M3/R#H2TEHD=DCC>?TD.]*,C^'E]T0LVB8C3KQI]>:58;2X334]=[Z]+#6C?M
M<KQWB>%,$\H,G !9V#))XT^Q3@N6E[935;@>7?4TNIP8!JP%X)U]-/1[.RBF
MVEF)?*E/[]M3^LV$%Y[<A1=N)+SPY"Z\L*/2Z&A[I=$[RM<E_XJ3/>6*HL%$
M*L[V+0CO$W.\/$06R^_)M)DHSOBL%QJEG+DXEK["_J9&-03-9EZI,@'=C5)*
M44&BC.H\;054TF] S[Q<IY (WA4;24&B%:)JL9[*U1Q2PN' 2*W.%*0<!^-5
MHJP;J=V7%H/H_M+=H7WW&UILU= ^&7VMYI;I?AQ]&D+GT,2Q);V% /"3Z(8R
MCWP4R%NCWAUO^X5J K\N:RGX1:RAARAA ?8E<S,2,#^^*X4&ARM4C;;EW#,3
M(K)J4"O]YZD3:=;!525$42"@J8W>94!Y3,H3)*G21'I$2T(]S<DE::0,ME;S
MKB73!"]"286]B)V>6[@+9P!JW)+Z0^SO39.T 3L%8UA@#S6F"TT=46IX7<$N
MH(U4&,PY7?9 -JQV'TF^*9IZTE+#V4#;BE7G!&\Q*!C_+]+X!I?A=.HS 6"=
M4C*29!GZ"9A]<NDQF]"8,Y.TR*=0DH]$M>)(X\M+7U<9+?&P2,3J;@*0FNWG
M,YX[B??0SS'<=CJAB?\"M[=KHM\4GG 1G:GTHJR*ZAR++73V<'I]AV%?_/3Q
M,?ZFK2[+Z%])G15J&7W,HO\ 9?MO>)N\*8X^G$1'/_[T^.]XQPFZPY!E/(M>
M7^0*93UEJ@(#?<\NG%T@"(M5WKNU1F<@=CCM:G00]3NIW*IR3D=A>+2]"L-K
M!WS'UQK.QH.BG/$PTEX@G[I%)D:C-5FU'$0=\!MUI:FU# EC-!<H]EV7,"XH
MLQV*Z9'6);$N&I-EF^"OE/4,-[XQ*'P\E<]==DZNXCB:8BXL8N*72='FG/V9
M4B9M\H6@94V=79Y)XW&"",DSCK*T;6&"2HC=AL-;8-JA?CL:1&A_S[<X[([3
M#G+)P' ]@.X<@^@[DFV"U4J-UM[ E*@% $H*511OK6"H.-G :5Z#_8,N_A0=
M><.E@^0GX9[K4U2OO 0N,9P63N,E4T,55#<$D?V@9M$42APT!HP)]W1_CW0\
MKA<PWX$^2G5B7&U8A=-^K@_$J)_>5*>)\U(]/5-QM;JJF=VN7-5\V,]6Z)TX
MS6QH89&_KMO#+Q]O+[\\,=QN?^]723,#'MI(..?_@AG2H,<@8*?163^$C*2C
M<\ %*AO9A;2MUS$PS* _)T.'[D,L^ LZU8IJ8L1_G0V4Z3*#Q#B1IE:LVB(O
M@6[_82-E!OZ/J!AM'%@KD3D-4'<%%O>^_9*J>3N$:PN4/=A5U&\BMK);ZF/,
M%WCP^\M1RV %/]#1=@MMQU>M*[&XCSI?4#&#+=? 86T%92+PWH(>QLF)FHT-
MQ2=UQ1SN7:51R\+KVP;!6G'^3.JJ(W9:%B;7RC1D>4VMP'#N3K8F:U4-'Q](
M"@5,E4Q1?%9&^+TDM TZ8SKQ$VQJGB8"X8&N+7G:CDC0:;5K::>6H)MN,LM-
MU-6V)_GL$+JFK&#Z*,K@K#$?HM$>)=EB0?\+]WCM_70)PACW% H1O]5G9>HG
MF?Y)#8 Q@8UVIKD*<E8@D57'/G@R4DR2N2^.;28)'1JZ*;'_K A][%\;.PB
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M1/1-,LIY7L*<8#1@"OPGV*LSD'=1ES)G%0)?U.VTU+E0?[:Z04M<@?W)00,
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MRG=I,$<I7;_43KI0B75-7@%'<.L.+^,,&";-==X5I"0YS5YOPB78PZ!*AJL
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MZY&_=X.VTTLKN".K%/@5>T (2W'(%TI9V+N9,5*.$/("C&4/_$09.=.V:56
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M*S2Y3CGG4Z[I-)0TUP6W6" C<+J5K?LE::-OA3_\=(<_W.$/5S6E_[@A]OQ
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M''N:\XX&K<+18(3GH?\?!;[&4:#UI$>!I^O+&_1_..8?<^C_=_X'4$L#!!0
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M:^)E@^=QX?A@B(UC^H5)DFX'/ZRBYAX&J/D4' PYQ4I@0$Q&,Y&P5]-[&N_
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M4P!D-;?83X );#O)NR2GB<W7W+)CU4+;[,D/U"D923*O9!/?N#+/S)*-'W8
M]($'29L0N":(@Z/R@UI& U3G,$"%;01UKZ %W&/O '8SX1APA2G$<QC9(H+2
MJ5Y4.UO;C\.^NAW23%"K<(0!!*#-:+)M0A1O@3Q@LS(LYQ!  !KIFYW!8UCU
MRML\E&%KX^>!? !C:+A)9L< 0ED-D"K?-,0OR1[R&:JGWY).6ANJ%X[*$XEG
M<$W8\-;>)'O8?@GB8S%1"'8.JOB*UW95)<(=^#"56 WU&6K WT5F*'HEC#$E
MF[@>9^# 2IF6B2 D#HF"GG.7E*D)O%3%I$(0BEG\'EA?29H5"2.WD'%S-7YB
M@?AC<A(I0@&;&J!W/5 DMK:G'F(316"$EI7MJ?NM[$#]G;@26S_'6K1)U)5>
M@D1"CIB\8>*^P*_"U%>57[)Q?C6\?,1<-H1K>V8$M)^[7_5R^1;$!+7J(4XX
MW%6F,@8&I*R"VC@\?WGYJ$?J1MN4 ;. =:]!6WJTBO4'+ZA* :A)XD9$W*!I
M!NJU^>^<(E.1);2!D4PZ@O"I@*8R< 80[X2H":54:2;2#ZE^:U/[*Q&=0VE3
M>-J@UEPG)6/SX,E 2/&>K*8/3-SGA[]VX7D-.Z/9-2-%*91_P]K7Y?#=*CU(
MGE_(8!9&I]#; '3]*H3C5@Z!/%7VZ(B^K.1-[:7=98RZG98U(IZ+#>5(( 'V
M5XK>M/,7\-%*@L' I["''*#QO165VL+7JQKUW?AZ4$><2T@0ENJM%_FF$"^,
MWXVL5LME[(5HJ;LVF?U50D84Y=5+4BH4MLIIZW.B AC!M4UO#D_52W@FA.XA
M31R/&.4VGE!066(VU<1\*JU 07"8@VM)X@AH %PO]-9OX.>+(I*M!%>-)H!G
M&@+P7Z@D)&;\[BH%3K*U$]!05^VPS>E*_/(2+F^J9U]@!NH>(IT&C]:EK$=3
MK&SJ5QU;X3?BV=U/1YOAP>'9B3HZ.3N[.#@^/GWYTU\?;#W@WZ\N#HZJWU^?
M'@]?_/7!]M;6MP\^21X77#.\K$:>4W0%4+(B)5ZDNJ>]X7'UQ,+&Q70WU-"0
M,S@\WK_C]BVYZK_L?$?_!3W^\N/3[W]LTM6K(]UB ![L'Y8VB2G+8BF* RYF
M]>P\QRM"G!LZA+5-"PD3NF> / UQ:P%6M2G>W@GQHIWOE/ #:7'R^(&"^J!7
M!!-1UP& 9X+FFN5NDNN44\\NG[D0ICH8GD-M)T8"=([ !CTZ-UD%N"P<#=GP
MYO"2_B%>^)///AL^.R&\1<@N!#LI6IPQ$FY.=#6<",CARLF4PK:<KXF<7_K"
M,(RL4HEU.+E.1;:U-6/PA"R<S0K\C[639G1@\KG@_=SZ:V*E,1[\W1CH,\5\
MPYL9@VYG+>E,, >+MD1TP@=P9TP%PJ5>H Y'GHMS+-"*\Z@VNL:/ 47=R6'D
MM%4%;H([X$77L*:<Q9Q'OIE,,7"T)>IN =UBBZM056.7))*N:$5>/\>0X.^8
MU>*C-.D,GB#PLV#5F>8\$XODG-85L#-!PVF=H 2Q'4AILHF>B$O<X$U(7R.H
M L73E"1Z.5 '31Y?#A!&(V,@W>3>>03.AHD%(AA1';)$1GJ0>7@,L$'"D\&=
M ]*'/=")6(@)62/Q!U)^FRQ'7L'>)N<OD 6 V%S[SY$?/BA$O/-GB/C+#1'?
M[Z>$3(?_ OV/^U7;44(963AGQA3=#F>3XBJZ75>0- E:I858K"PH>-$J,@/O
M2 %RRW_IA6#K6YNJGZBH0YV='4EHS%*QRI6)REQ@BV;]0N5MKE\/"MA!H_JU
M80?JA<OLA*(-P)*J67:$+7J3W'C\TN#^54KJ]ITOW(@!'CF7F"6]T*9,ZXWU
M,,=KJLMQF9S\0YW.GG%4<'''*MOT_QP5Z:<5O;W3_88#NIUCZ^'>8!4DC*$D
M]71_5W[^HDCS?IC#9E#^*2,)JG]T<QM7)MAR[2<\03+J5.U((34N8J"0GLO;
M[U+E70F?T#-P2 2FQ Z_9:Y@5,_!&!/R82+,D//(] !68JA&ED6299TLO>7$
M3(Z9.=@(=U5J.QC,8$T2(',<G&\4!XE&7H:873,1?J'%4D%A[@?MM'M=-595
M\4B2FPHE0(HW%!6A$J.Y2_"*\N4(#I(DAL@U:==@DR9@=T5*06>)P5Z!93TE
MYV\0LB8,A_!L)B7V.*$BU.?4*W2C-X*9B2#-3@' 2B8);XW(07@0[GVH>2*Z
M2 E<F4#V9]BXDZ(!HRGQ >\.!TW5J%A;F4\D>,RAV8378'.*V(>ZA1NJ&501
MT  FO!8_<=E>=8SU>#JP+TW=O)],<4819H7JE2@.$RK#?&.(ULM:USCI'67%
M[*TER^JI6XJ@X55#]Z?D]W%M9"L$BO5$40ZW2R!V4_*H]$H1&+&EL+S40H7P
M=9W0AIC[4HL5OC+\CIS,=QOZT<;.(_FE*H9KMGP0<7IN^\?'CWM<_ZE3T212
M+\Z)M-7'Y1IGN:CF^[),C S^9.OIQJB9Z-),.$.(Q1^3W*9E,A$7E/->1#3!
M")P6H_UQR5QN)A:N$$C2[31^\/J*ZSP%I=PA_L7*.29Z 0D_@.SF='C)LG?C
MI&^M8Y9:MK53IJKO]SMFG/ R;$0.AA(Y.;D#]4P_9WS05P7[<H!9!O+1/CLJ
M3Z\=<J%%'LP ;W/->6R!*"S]Y&TTU=F$T4^*+1+M-\(9GAQ5!\<8KDT_\Q9.
M;5.1RTJS-3-^X5)+5MI-0>7JB4@5()28Q*7N/9VO4 -5]J;;J0P.6"U)UDTQ
MY]'&AHLE 143/B_V*2-@S2JVT'YJ5"Y9U=]4:+'Q46Y'X#B2.2HXS5P>IF4Q
M)(O![[8THE_7B7R?3Q$OR_F^P6T?6]%-E ?GS+TP "VKM[;@7"98N!*R@"G+
M#%PP+JDQP%(_C).@Q@K;X3I7A=<AE48=K'%395MY_CM6^C5RG:F:@H C:X=M
MP:Y(1N6VH@4UZTJ._DA^NI'?$*+,H>>];)IDG4;@]AF&*!X'Y,=+U=B,<YO9
MM$RI3S4RH1ZCI4>ZG0TJIS# ,(T:;L_TZ$L[J_>(1G"]==7T?$^KV5<9LKB+
M-@29=5U/GYDR=P5N5T5!%8^EX=78D)<##&V26+6J+OA%&C%B[HRH;JGDPG:7
M<V4%2P9Q?37WD@6K()\K% / SX#2,A)*&5&O2E,?/K))J!.08+":3>%7A1FY
MV V0#Q!PB962,;<^]57E?XH=R0(QH:=&F@+(QJ;L'U*BAN:C$CY6B#.#QZBH
M3W/U'(MU>W?6DPWR*V7*]3JE;K I*:F*\ZOBK N7%Z(=:,04]P+4NRHL%X:Y
M?-#M/(<6YC:%EDL:V@IDD)=7#Z'RN27RK@Y+-:?8MMK[>7^Q6 RF_&0XR '6
MN+?Y\VT--Q^IJ_T_$IA^_&=@^JL.3+.,A+!DM].D![,J?W1V\55:@+5(+9=1
M-W7.J\V1K<@';J?O;(^44LY>P(M5D6J(/;'Z"5DY:,A6E*!=Z&VHD+K.XC7E
MVU*,':JW@TY=C6Q5)=DWG</%U-2+8[A%!=A/GZA-:FP*1=RBO'EW% 9C]5$D
ML$BW3-S:=K^U]CG>H()W6@A%X6C<[WOU#A:Z36">B5IXV?4@7Y6JUOM<M2Z%
M>F&<FG6K0MGG)7OZ/M244XWYD\>][2<_?LN[7YAD7O5(Z_4G0S\9IP+('M=A
MDH;0TH/JU3=/!CNCK/Y8 W=>-^4NK49_;E>;FQX<HWAB>B%_FZWT;;49I041
M?CO#P%(3-&D8YJN3XV.3DL<KM4I@UZ88-A K]-*J ZX5'S)K;1P?#!\I/],4
MGJY.GCA%&*)Q)%K]TM3@C!>?'_^SIXY.+A[5&79;T M2V_ZXJ6WG/D"\M!JH
M#O%48)!6.S17W89FR)7('<?H-6QE(YXUL)(V#P[Y-CDVXJW53FTI-\>0 %G6
MDR"W*LD4!PP#DL1KK\F=ET22%(6G5&Q )3R>*@'29G4]*7_E&-8M'S*IXTJP
M,73".)G5FGT?.ML"\>M=)6 (LTX-B>4S1:H>$/;@/5Q-H:8/A1$]E>#?/H9,
MR2V=-W$%CK15?1\A]H0A6_KKBQ6B]T4)DHIL0,*93<F,?)7P8#4MR^A L^?$
M'VQJ\V7:0"D6&<F@+,7"L1Q0EV_(;T'E9%0*1[GGB?H'<RR)5R+5[Y98F[\X
MAO.8PJLJN&&TD?YNAW-!7';/\M VFUQ\PW4ZX4)+\U2&+-1_9: M-76[=%E7
MYK-$>@E]:6ZH)MO2:XL(O*]<4PZ.VY(E [)2YM]4_S=>;8C-PWLLIA&U=6!/
M(&9H06M]0H*VVEOOJR7MQ>'\NSX?T>W<_OT(:6PIQ/ *-7R3%-QL[4QV'UJ.
M %Q^&*ASTLIAQM9Y4[VBX8@X%SP5:IU5. L!9L/*UE382+J JX3'>LL"%4CE
MUK#^K/J7ZGHKCLY:+@-3)*QDCKXT1?7A8EGUV7O6^Y2]90*!:L*0P 'U!\[\
MVG<5V(1@:C"!%I/?QOS5X=1\:;)I^-87F9OJ=DQ19CLJ);&"JQ*7H8IHU6X^
MK]!$6A?$D@R$:KY52U69. Z.KM=\DAW.)L4T?!)BUGR^L.D\J?NZN+5&?XGQ
MZOM-VI&6DZ2^D9<4[KHT$\U)/&K37^#'_IES+(Y753KLZRS?NBV?1"S'/%JG
M"D.K52N]%$S).% S"=1LWJ@L"_%E'335;/Z"6F5@/38QMU+Z5A6/Y%V?OW-H
M+BAM_2H.%'_#I)%Q-=91^*R(I-^-] Z3^DP(VX0*B]8X><TD+$=KC<*"B$OI
M0VU]&2N"D]=\DH93GR&36W\+*[3D4'4)?[6(OI4E7\A:?4\>JK["UOHLUIT5
MV^.2W<U;:W)[*M1RAX?:_;150-@Z(7PO%.D&M-)0HP$Y]RVEZAPQK3K@>@FA
M9;MJ<0&VH(@X:>;&M>ZIL-!650IU*<SJSZ:8G&/ -+! D+HGY8T)WXAQ^0IW
MC$,?#3]<5]Q\CDKQ@V*[W_T9V_UR8[OOE9*ECQJ^6P&SEASI$&V2L%*Q(N(]
MB@S8E,*$]/$V0/=9N!XR195$]8(:Y5(Y=9VYA92;E1G_#,MA_;4GOSPR.9F.
MH@Y?B722+H9[\3#EB%@:J@P$Y_(RS=)E\:T?SB)CE+LDO,IFB.IC(DT:%,-2
MF1O,5YD45$375@]<\1!-+5!B6I4 QY9#CK3G7%J<@^)UGGL4R!!*N0U]2,S*
MQ_2:>@ >!]@NI78ITO!A8ZI>E^:J&RK':J^L,4$25&&JK#9JWIK;XT\#&<:<
MXMO5_3;/^&+K6?DH,!=FFEGBEDV'7UT(E."M&-1(W$P($F+.XJGQNZ$U8V9@
MYLE_(=?48R1(L70LBPIOJ,S-VJ_.GK4.FYDA\$>+'[J=IHQ$2C "AKBDRLKG
M@4,":@B(89TV!UE&5+TT1']B:_KH4OC&ZE;_'XIZR>)67=/)$3UT3I_3DJ=V
MGH!)Z%.L%4N'-3=A;QJ#VRK;H[ /[DU]CWBV^0@FCOZN[SU+NA$ 9P"C.* L
M8S"(W4[[TTY,$RH9I>)1&"HH ETUJTO7CN*:V;F<,\62WR7ZW&XN!53D: @3
MTDF1Y]]*HE;6%CPRKTMIF2 +3-*K"LLXB,XU%[%\&F;Q.1K/3^M1#!<4Z<TW
M_[5+?WSA</]ODFBF;KD_P@;N FW8W6LS B@S86]5=^G/^].BF/G=S<TF7SX(
MA1";U:Y__B0?Y_[==GYFLVL#E'OGUI/P$&U^LR* T*/OY;LEU=7/GB#O[*AN
M=U"O=UA_\#9"3S.U8-=@$^M(],P#%E8_/6 T=W\OM?P)E./V,OK4.REK63MD
MOCO6J4V6N_<M\^9(A_M4.J*AE>$#PX'<7?GP_?#X/5934?A#'^;VYX]#D']W
M"?^9]=;L\GCKVX]YF._WM?4[#S<L;.<)%G8QA?6?J6%.__#7G-3>(5'@)YND
MU(Z128?:>U&RWO-W3S[JGJ&YJC1='0?]VZVE3BO?$/AXK/?QMK+^QUC6RE9^
MJTCNV_QO,YDB0&6B3#A2=@1NN;U&K<_S6P4?%$9X\DR]$K=OE_[T0_'Y1!5^
M/Q=_D_Z(UC[_52WZXUO_#U!+ 0(4 Q0    ( *6#,EO[F6X1*0,  /$+   1
M              "  0    !H<V1T+3(P,C4P.3$U+GAS9%!+ 0(4 Q0    (
M *6#,EL@^]8D_0H  '^&   5              "  5@#  !H<V1T+3(P,C4P
M.3$U7VQA8BYX;6Q02P$"% ,4    " "E@S);Y?E(4UP'  #>5P  %0
M        @ &(#@  :'-D="TR,#(U,#DQ-5]P<F4N>&UL4$L! A0#%     @
MI8,R6UPY:KZ;*P  0N(  !(              ( !%Q8  '1M,C4R-C0U-60Q
M7SAK+FAT;5!+ 0(4 Q0    ( *6#,EOJ(%;)?D0  'M&   7
M  "  >)!  !T;3(U,C8T-35D,5\X:VEM9S Q+FIP9U!+ 0(4 Q0    ( *6#
M,ENSATYZV5H  (1= @ 6              "  96&  !T;3(U,C8T-35D,5]E
M>#$P+3$N:'1M4$L! A0#%     @ I8,R6R?.CG[)1P  :+,! !8
M     ( !HN$  '1M,C4R-C0U-60Q7V5X,3 M,BYH=&U02P$"% ,4    " "E
M@S);DA854+ 8  "^@   %@              @ &?*0$ =&TR-3(V-#4U9#%?
M97@Q,"TS+FAT;5!+ 0(4 Q0    ( *6#,EL$?P8<-0<  ,8C   5
M      "  8-" 0!T;3(U,C8T-35D,5]E>#,M,2YH=&U02P$"% ,4    " "E
M@S);5-V [8P9  "#:P  %@              @ 'K20$ =&TR-3(V-#4U9#%?
@97@Y.2TQ+FAT;5!+!08     "@ * )T"  "K8P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2526455d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hsdt-20250915.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610853</identifier>
        </entity>
        <period>
            <startDate>2025-09-15</startDate>
            <endDate>2025-09-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-15" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2025-09-15" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-15" id="Fact000005">0001610853</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-15" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-15" id="Fact000011">2025-09-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-15" id="Fact000012">HELIUS MEDICAL TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-15" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-15" id="Fact000014">001-38445</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-15" id="Fact000015">36-4787690</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-15" id="Fact000016">642 Newtown Yardley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-15" id="Fact000017">Suite     100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-15" id="Fact000018">Newtown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-15" id="Fact000019">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-15" id="Fact000020">18940</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-15" id="Fact000021">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-15" id="Fact000022">944-6100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-15" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-15" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-15" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-15" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-15" id="Fact000027">Class&#160;A     Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-15" id="Fact000028">HSDT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-15" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-15" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
